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ABSTRACT
Gammaherpesviruses are associated with a number of diseases including 
lymphomas and other malignancies. Murine gammaherpesvirus 68 (MHV-68) 
constitutes the most amenable animal model for this family of pathogens. However 
experimental characterisation of gammaherpesvirus gene expression, at either the 
protein or RNA level, lags behind that of other, better-studied alpha and beta 
herpesviruses.
A differential display system and 2 independent array systems have been 
developed, with the aim of characterising MHV-68 gene expression profiles and 
providing experimental supplement to a genome that is chiefly annotated by 
homology. Furthermore, the 3 technologies are compared in terms of their strengths 
and weaknesses, with respect to these goals. The MHV-68 transcriptome is 
presented through a lytic infection in vitro, both as quantitative measures of 
transcript abundance, and as part of a hierarchical cluster analysis. Functional 
predictions have been made for various genes based on co-expression with better 
characterised genes. Each gene has also been categorised as being expressed 
with a-, (3- or y-kinetics by blocking de novo protein synthesis and viral DNA 
replication. This fundamental characterisation furthers the development of this 
model and provides an experimental basis for continued investigation of 
gammaherpesvirus pathology.
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RNA Ribonucleic acid
RPM Rotations per minute
rRNA Ribosomal RNA
RT Reverse transcriptase
RT-PCR Reverse transcription and PCR
RTase Reverse transcriptase
SCID Severe combined immune deficient
SDS Sodium dodecyl sulphate
SSC Saline-sodium citrate buffer
ssDNA Single-stranded DNA
SSPE Saline-Sodium Phosphate-EDTA Buffer
TAE Tris-acetate-EDTA
TBE Tris-borate-EDTA
TCA Trichloroacetic acid
TCID50 Tissue culture infective dose 50
TE buffer Tris-EDTA buffer
tk Thymidine kinase
TMV Tobacco mosaic virus
TPA 12-0-tetradecanoylphorbol-13-acetate
Tris Tris-(hydroxymethyl)aminomethane
tRNA Transfer RNA
uL Unique long region
Us Unique short region
UV Ultra-violet light
VEGF Vascular endothelial growth factor
VHS Virion-associated host shutoff
VP Viral protein
VZV Varicella zoster virus
w t Wild type
w/v Weight to volume
w/w Weight to weight
X-gal 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside
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1 Introduction
1.1 Family Herpesviridae
1.1.1 History of the Herpesviridae Family
The ancient Greeks first coined the term ‘herpes’, deriving it from their word 
herepein, which means ‘to creep’. There are numerous references to herpes-like 
diseases dating from ancient Sumeria (tablet dated 3rd millennium BC) and ancient 
Egypt (Ebers papyrus dated 1552 BC; reviewed in Roizman, 2001b) In 1873 AD, 
herpes disease was first demonstrated to be transmissible between two humans by 
Vidal, and in 1924, Grunter showed conclusively that herpes disease was the result 
of an infectious agent via an extensive series of animal to animal propagation 
experiments (reviewed in Whitley, 1998). In 1939, Burnet and Williams pronounced 
that herpes simplex virus (HSV) infections were lifelong, and that the virus 
remained latent until certain stimuli recalled the virus into activity, resulting in a 
lesion (Burnet, 1939). This was the first suggestion that herpesvirus infections 
become latent in their host, and can reactivate.
There have since been huge advances both in our knowledge of herpesviruses and 
in the experimental tools available to virologists. Indeed, the development of 
herpesvirus biology has often been punctuated by the development of new 
technologies. The discovery that HSV could be cultivated in the chorioallantoic 
membrane of chicken eggs gave scientists the option to move away from the 
animal models that had been the primary experimental system before (Andrews, 
1930). In particular, this method of cultivating the virus made possible various 
immunological studies of herpesviruses, through neutralisation and complement 
fixation reactions (Burnet, 1937).
The development of in vitro tissue culture technology in the 1950’s led to the 
discovery of varicella zoster virus (VZV; Weller, 1952) and human cytomegalovirus 
(HCMV; Smith, 1956; Rowe, 1956). Advancement of this technique, to allow 
cultivation of B lymphocytes and lymphoblastoid tumour cells, led to the observation 
of virus particles in lymphoblastic tumour cells (Epstein, 1957). This virus was 
characterised as Epstein-Barr virus (EBV) and was the first human 
gammaherpesvirus to be discovered (Epstein, 1965). The introduction of electron 
microscopy to virology, around this same period, was instrumental for developing 
the field as viruses could be visualised for the first time (Brenner, 1959; Wildy, 
1963).
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Further development of tissue culture techniques, to allow cultivation of T  
lymphocytes, led to the discovery of yet more human herpesviruses by the 1990’s: 
herpesvirus-6 (HHV-6) and -7 (HHV-7; Salahuddin, 1986; Frenkel, 1990). 
Herpesvirus-8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus (KSHV) was 
discovered by representational differential analysis (Chang, 1994) and was the 
second human gammaherpesvirus.
Degenerate polymerase chain reaction (PCR) has been used to detect novel 
gammaherpesviruses in pigs (Chmielewicz, 2003) and baboons (Whitby, 2003). 
Chimpanzees are known to harbour 3 distinct lineages of gammaherpesviruses 
and there are 2 distinct lineages in macaques (Rose, 1997; Lacoste, 2000; Lacoste, 
2001), and so one could predict that a third human gammaherpesvirus awaits 
discovery.
Recently, array technologies for the efficient analysis of gene expression at the 
genome level have been developed. Coupled with the whole genome sequence 
data that is available for many viruses, these technologies could provide very useful 
for the study of herpesviruses. Also, as the regulation of gene expression has been 
suggested as the key factor in determining an organism’s behaviour, rather than its 
genomic sequence (Levine, 2003), arrays present a powerful tool with which to 
examine this hypothesis. It remains to be seen how much this particular 
technological advance will influence herpesvirus biology.
1.1.2 Structural Definition of Herpesviruses
Viruses were initially characterised by their small size as assessed by filterability, 
but as the structure and composition of viruses became more apparent, viruses 
were grouped according to shared virion properties (Andrewes, 1954). The 
herpesviruses were among the first taxonomic groups to be constructed, based 
chiefly on the formation of Cowdry type-A intranuclear inclusion bodies following 
infection by these viruses (Andrewes, 1954; Andrewes, 1961). The chemical 
composition of viruses was also used to characterise them. However, the 
development of electron microscopy, and in particular negative staining, allowed 
structural definitions of viruses to become commonplace (Brenner, 1959; Wildy, 
1963). Illustrations of herpesvirus structure are shown in Figure 1.1.
Herpesviruses are enveloped viruses with a double-stranded deoxyribose nucleic 
acid (dsDNA) genome. The envelope is derived from host lipids, from which extend 
glycoprotein spikes encoded by the viral genome. While the combination of 
glycoproteins making up these spikes varies greatly between members of the 
Herpesviridae, their function is generally conserved. The glycoprotein spikes
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mediate attachment and entry of the virus into cells, cell-to-cell spread of infection, 
and also influence tissue tropism and host range (reviewed in Cole, 2003).
HSV-1’s tegument consists of four major structural proteins (Spear, 1972; Honess, 
1973) and four other gene products. These tegument proteins are the first to be 
exposed to the intracellular environment of a host cell and are thought to provide 
critical viral functions in the time between viral penetration of the cell and the 
synthesis of viral immediate-early (IE) proteins, such as shutoffof host cell protein 
synthesis (Fenwick, 1978; Smibert, 1992) and immediate-early gene transactivation 
(Campbell, 1984).
Figure 1.1. Herpesvirus structure.
A. Electron micrograph of HSV-1 virion (taken from Sander, 2003). B. 3-D computer 
reconstruction of HSV-1 outer capsid from cryo-electron micrographs, bar =100 A (adapted 
from Cheng, 2002). C. 3-D computer representation of herpesvirus structure (Reschke, 
1995). Glycoproteins in the envelope are shown in red, the envelope itself and tegument are 
shown as transparent, and the capsid is shown in blue. D. Electron micrograph of mature 
isocahedral HSV capsid (adapted from Newcomb, 1999).
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The HSV-1 capsid is isocahedral (T=16), 100-110nm in diameter, consisting of 150 
hexons and 12 pentons, each with a channel down the long axis (Wildy, 1963; Wu, 
2000a). Inside the capsid lies the nucleoprotein core, which contains the linear, 
dsDNA genome in the form of a torus. Herpesvirus genomes range from about 1 GO- 
235 kilobases pairs (kbp). The HSV-1 genome consists of 2 regions known as the 
unique long (UL) and unique short (Us) regions. These are bound by repeat regions, 
which form the internal and terminal repeats. Genome sizes can vary within a 
species as these repeat regions contain varying numbers of repeats. As a result 
genomes can range in size by more than 10kilobases (kb) within a species. The 
family can be divided into 6 groups based on their sequence arrangements 
(Roizman, 1996). Between species, gene order is generally maintained within large 
sections of the genome, with varying degrees of homology between the genes 
themselves. Homologous gene sequences between members of the herpesvirus 
family can be used to construct evolutionary trees (Gompels, 1988; Montague,
2000).
1.1.3 Herpesvirus Taxonomy
The Herpesviridae  are divided into three subfamilies: alphaherpesvirinae, 
betaherpesvirinae and gammaherpesvirinae, and there are also 61 unclassified 
herpesviruses currently listed in the ICTV database (as of 11/2003; Buchen- 
Osmond, 2002). The taxonomic structure of the herpesvirus family and examples of 
human herpesviruses are listed in Table 1.1. Currently, viral taxonomy considers 
several factors including morphology, physicochemical and physical properties, 
protein, lipid and carbohydrate composition, antigenic properties and biological 
properties (Regenmortel, 2000). In particular, sequence homology-based 
classifications of herpesviruses are gaining prominence (McGeoch, 1995; 
McGeoch, 2000).
Genetic methods of classification have the advantage that they are inherently more 
indicative of evolutionary relationships. These methods (in particular the sequence 
comparison algorithms) are becoming more sophisticated, and multiple gene 
sequence comparisons are now commonplace (Karlin, 1994; Montague, 2000; 
Alba, 2001). A recent attempt at classifying the family using the sequence of the 
conserved glycoprotein B gene is shown in Figure 1.2 (Sharp, 2002).
1.1.3.a Subfamily Gammaherpesvirinae
The 22 members of the gammaherpesvirinae  subfamily are usually associated with 
a latent infection of lymphoblastoid cells, and usually with a lytic infection of 
epithelial or fibroblast cells. A further 6 herpesviruses have been tentatively
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classified as gammaherpesviruses, pending further characterisation of these 
species (as of 11/2003; Buchen-Osmond, 2002). The subfamily is divided into two 
genera, which are known as the gamma-1 (y1) subgroup or lymphocryptoviruses, 
and gamma-2 (y2) subgroup or rhadinoviruses (Roizman, 1996). There are 2 known 
human gammaherpesviruses, EBV and HHV-8, which are part of the y1 and y2 
subgroups, respectively. The two gammaherpesvirus genera are well defined by 
genome organisation and gene content. For example, the rhadinoviruses have a 
central unique segment of 110-141 kb with a low G+C ratio (known as the L- 
deoxyribose nucleic acid (L-DNA)) that is flanked by repeated regions of high G+C  
content.
Some gammaherpesviruses viruses are difficult to assign to either one of the two 
genera. For example, equine herpesvirus 2 (EHV-2) is clearly a y2 herpesvirus 
based on gene content, but possesses an atypical genomic structure and G+C  
distribution (Telford, 1995). As 4 genera exist for alphaherpesviruses, and 3 for 
betaherpesviruses, it remains to be seen whether further genera will be assigned to 
the gammaherpesviruses.
Table 1.1. Taxonomic Structure of the Herpesviridae Family.
Taxonomic
Level Group Name Human herpesviruses
Subfamily Alphaherpesvirinae
Genus Simplexvirus Herpes simplex virus-1 (HHV-1) Herpes simples virus-2 (HHV-2)
Genus Varicellovirus Varicella zoster virus (HHV-3)
Genus "Marek's disease-like viruses"
Genus "Infectious laryngo-tracheitis-like viruses"
Subfamily Betaherpesvirinae
Genus Cytomegalovirus Human cytomegalovirus (HHV- 5)
Genus Muromegalovirus
Genus Roseolovirus Human herpesvirus-6 (HHV-6) Human herpesvirus-7 (HHV-7)
Subfamily Gammaherpesvirinae
Genus Lymphocryptovirus Epstein-Barr virus (HHV-4)
Genus Rhadinovirus Human herpesvirus-8 (HHV-8)
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Figure 1.2. Phylogeny of herpesviruses, derived from comparisons of glycoprotein B 
sequences of mammalian-host herpesviruses.
Branching patterns consistent with virus-host co-speciation are highlighted for viruses from 
primates (red) and from carnivores, artiodactyls, and rodents (blue). The scale bar indicates 
20% sequence divergence. The eight human viruses are labelled HHV; for other viruses, the 
species of origin is indicated. MHV-68 is denoted as Murine-4 (from Sharp, 2002).
1.1.3.b Genus Rhadinovirus
The only human rhadinovirus known to date is HHV-8, but rhadinoviruses have 
been isolated from a variety of organisms. Murine gammaherpesvirus-68 (MHV-68) 
is a recently discovered rhadinovirus that appears to be slightly divergent from other 
gammaherpesviruses. This is demonstrated in its glycoprotein B sequence 
homology to other gammaherpesviruses as shown in Figure 1.2, its major capsid 
protein sequence (Trus, 2001), and perhaps most clearly in its biological properties.
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Although sequence analysis of the MHV-68 genome shows it to be a y2-herpesvirus 
(Virgin, 1997), it possesses some biological properties that are more typical of 
alphaherpesviruses: It has a rapid replication cycle and can infect a broad range of 
cell lines in vitro (Svobodova, 1982a; Mistrikova, 1985). However MHV-68 also has 
a latent phase of infection in lymphoblastoid cells (B cells) (Sunil-Chandra, 1992b) 
and has been associated with tumours (Sunil-Chandra, 1994), which are properties 
characteristic of gammaherpesviruses.
MHV-68 has sparked interest as a model system for the gammaherpesviruses due 
to the practical advantages of working with this virus (detailed in 1.2.2.C). It has also 
proved to be an interesting subject for study in its own right. For example, MHV-68 
is the only virus that has been shown to encode an abundantly secreted chemokine 
binding protein (van Berkel, 1999; Parry, 2000; Alexander, 2002).
1.1.4 Disease and Pathogenesis of Herpesviruses
The main diseases associated with primary infection and reactivation of the human 
herpesviruses are shown in Table 1.2. Herpesviruses are associated with a wide 
range of diseases and are generally widely prevalent in their host population: HSV- 
1, and HCMV can show seroprevalences above 90% in the Western world (de 
Jong, 1998; Smith, 2002). HHV-8 is an exception as its seroprevalence is far lower 
at 2-4% in Europe, Southeast Asia and the Caribbean. However in areas of sub- 
Saharan Africa where it is endemic, seroprevalence reaches over 50% (Olsen, 
1998; Ablashi, 1999; DeSantis, 2002). While many herpesviruses are widespread in 
their host populations, herpesvirus infections are generally asymptomatic. However, 
these viruses do have the potential to cause life-threatening infections under a 
certain conditions.
Most of the historical references to herpesviruses relate to herpes labialis (cold 
sores). Herpes labialis is generally a result of HSV reactivating from the ganglia of 
peripheral neurones and migrating down axons to release progeny virus, usually in 
the region of the lips. Occasionally, primary HSV infection of newborn children can 
cause congenital herpes disease, which can be life threatening when it results in an 
encephalitis or a disseminated herpes infection. HCMV is the leading cause of 
congenital viral infections now that rubella is controlled by vaccination, and this type 
of HCMV infection can lead to mental retardation and deafness (Revello, 2002).
Many human herpesviruses have gained prominence due to their association with 
transplant immunosuppression and acquired immuno-deficiency syndrome (AIDS): 
HCMV and HHV-6 with solid organ transplants (Rubin, 2001), bone marrow 
transplants and stem cell transplants (Boutolleau, 2003), and HSV-1, HHV-6, and
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HCMV with AIDS (Griffiths, 2002). The immunocompromised nature of these 
patients allows reactivating herpesvirus infections to progress relatively unchecked. 
The same occurs in cancer patients undergoing therapies that also result in an 
immunocompromised state. Other diseases that may have a herpesvirus 
component include atherosclerosis and multiple sclerosis (Alber, 2000; Simmons,
2001).
Gammaherpesviruses are associated with various malignancies. EBV is associated 
with Burkitt’s lymphoma (BL), Hodgkin's disease, nasopharyngeal carcinoma, and 
other lymphoproliferative diseases. Burkitt’s lymphoma is an aggressive B cell 
tumour, the endemic form of which accounts for more than half of all childhood 
cancers in equatorial Africa (Magrath, 1991). There is a morphologically identical 
sporadic form that is more common in the USA and Europe, and BL is also 
common among HIV-positive patients, which represents a third form. All forms of 
BL show a chromosomal translocation of c-myc, resulting in increased levels of this 
transcription factor (Taub, 1982; Dalla-Favera, 1982).
Although EBV was first isolated from a BL cell line, and there is a clear 
epidemiological link between EBV and BL, it has not been possible to prove 
causation or to elucidate the mechanisms by which the virus initiates 
transformation. In particular while over 90% of endemic BL cases are associated 
with EBV infection, sporadic and HIV-related forms show 10-85% and 30-80%  
association, respectively (Gutierrez, 1992; Davi, 1998), and this has been a source 
of uncertainty in determining the aetiological role of EBV.
HHV-8 is associated with Kaposi’s sarcoma (KS), multicentric Castleman’s disease 
and primary effusion lymphoma. KS is the most common cancer in AIDS patients, 
and at the onset of the AIDS epidemic, homosexual men in the USA had a 50%  
lifetime chance of developing KS (Katz, 1994). The development and introduction of 
highly active antiretroviral therapy (HAART) in Western countries has successfully 
reduced this figure, but less than 1% of AIDS patients receive HAART in sub- 
Saharan Africa, where 70% of all global cases occur (Harries, 2002).
There are various other forms of KS such as classic KS, which occurs 
predominantly in elderly male patients of Southern European ancestry. A high 
frequency is also seen in Israel and other Middle Eastern countries (Ablashi, 2002). 
Endemic KS occurs in some parts of sub-Saharan Africa, where it is usually a 
childhood cancer, increasing in incidence since the onset of the AIDS epidemic. It is 
generally a more aggressive disease than classic KS, and children infected with it 
tend to develop lymphadenopathic tumours, which are often fatal (Ziegler, 1996).
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Table 1.2. Examples of the more common diseases associated with the human 
herpesviruses.
Virus
Some common diseases 
associated with primary 
infection
Some common diseases 
associated with reactivation
HSV-1 Herpes labialis Herpes labialis
HSV-2
Herpes genitalis 
Various localised and 
disseminated diseases resulting 
from
Congenital infection
Herpes genitalis
VZV Varicella Herpes zoster
HCMV
Various CNS and systemtic 
diseases resulting from 
Congenital infection
Usually subclinical except in 
immunocompromised patients
HHV-6 Febrile illnesses including exanthem subitum
Usually subclinical except in 
immunocompromised patients
HHV-7 Febrile illnesses including exanthem subitum
Usually subclinical except in 
immunocompromised patients
EBV Infectious mononucleosis Burkitt’s lymphoma Hodgkin’s disease
HHV-8 Usually subclinical
Kaposi’s sarcoma 
Primary effusion lymphoma 
Multicentric Castlemans disease
1.2 Murine Gammaherpesvirus -  68
1.2.1 Isolation and Initial Characterisation of MHV-68
In November 1976, Blaskovic, Stancekova, Svobodova and Mistrikova of the J. A. 
Komensky University in Bratislava performed a field study on the ecology of 
arboviruses in Slovakia (then Czechoslovakia). A number of small rodents were 
trapped and as part of the survey, were examined for the presence of viruses. From 
the 19 samples collected from bank voles (Clethrionomys glariolus) and wood mice 
{Apodemus flavicollis), 5 infectious viral strains were isolated and designated 
isolates 60, 68, 72, 76 and 78 (Blaskovic, 1980).
Baby hamster kidney cells (BHK) infected with the viral isolates became rounded up 
with swollen nuclei, which showed hourglass shaped intranuclear inclusions with 
marginalisation of host chromatin (Blaskovic, 1980; Ciampor, 1981). These features 
suggested that the infectious pathogens were part of the herpesvirus family.
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These putative herpesviruses successfully infected 16 cell lines in vitro, including 
those of mouse, rabbit and human origin. Rabbit embryo fibroblast and BHK cell 
lines produced the highest titres of infective virus at 107 and 106 tissue culture 
infective dose 50 (TCID50), respectively, while the human epithelial cell lines 
produced titres of 102-103TCID5O. Based on this broad range of host cell lines being 
permissive for infection, and the observation of rapid growth curves, the isolates 
were classified as alphaherpesviruses (Svobodova, 1982a).
The murine herpesvirus isolates were found to be antigenically related by 
complement fixation and virus neutralisation assays (Svobodova, 1982b), and 
therefore a representative murine herpesvirus was selected for further study. 
Murine herpesvirus isolate 68 was chosen, as it was the most practical to work with, 
as discussed later.
A series of experiments were performed to confirm this putative classification, 
culminating with the sequencing of the virus’ genome (Blaskovic, 1984; Rajcani, 
1986; Efstathiou, 1990; Virgin, 1997). While the virus was confirmed to be a 
herpesvirus, it was found from its deoxyribose nucleic acid (DNA) sequence to be 
part of the gammaherpesvirus subfamily, albeit an atypical member compared to 
the human herpesviruses.
1.2.2 MHV-68 as a Model System for the Gammaherpesviruses
1.2.2.a In Vitro Model Systems for Gammaherpesviruses
Much of the knowledge on gammaherpesviruses stems from work on EBV, which is 
the most extensively studied gammaherpesvirus to date. There is also a rapidly 
growing base of knowledge for HHV-8, which has received a lot of attention since 
its discovery (Chang, 1994). While some facets of gammaherpesvirus biology are 
relatively well researched, such as latency, there is still much that remains 
unknown. Even the site of EBV primary productive infection is unclear. Currently 
there is evidence for epithelial cells and B cells being the site of primary infection 
(Allday, 1988; Faulkner, 1999).
Gammaherpesvirus research has been hindered by the absence of a well- 
established model system for lytic infection. EBV and HHV-8 have narrow cell 
tropisms, which is typical for gammaherpesviruses, and there is a lack of 
permissive cell lines for studying these viruses (Blackbourn, 2000; Bornkamm, 
2001). Lytic gammaherpesviruses infections have instead been studied by inducing 
reactivation of latently infected cell lines, usually with 12-O-tetradecanoylphorbol- 
13-acetate (TPA) or sodium butyrate. These cell lines are derived from
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gammaherpesvirus-associated tumours and therefore may not be an accurate 
model of latency (Cen, 1993). Furthermore, induced reactivation does not 
necessarily show the same mechanisms as natural reactivation in vivo, especially 
considering that the induction agents induce some viral promoters directly (Farrell, 
1983; Faulkner, 1999). Therefore, studies using these cell lines may not be 
accurate representations of primary productive infection or reactivation in vivo. 
However these tumour-derived cell lines have proved useful as BCBL-1 cells (body 
cavity based lymphoma; derived from HHV-8 infected primary effusion lymphoma 
cells) are one of the only readily available sources of HHV-8 (Renne, 1996). Also, 
Burkitt’s and Hodgkin’s lymphoma-derived cell lines, which harbour latent EBV, 
have helped characterise the various latency programmes of EBV (Crawford, 
2001). Attempts to study EBV by infecting primary human cells have has limited 
success (Robinson, 1975; Savard, 2000). Cultivating HHV-8 in vitro has also 
proved problematical as those cell lines that can be infected tend only to be partially 
permissive for HHV-8 lytic infection (Renne, 1998). HVS subgroup C can transform 
human lymphocytes in vitro (as well as rabbit, rhesus monkey and it’s natural host 
the spider monkey), and there have also been many studies of HVS transformed 
cells (Hall, 2000; Whitehouse, 2003).
However, the latent life cycle of EBV is probably the best-understood example of 
herpesvirus latency. These studies have been aided by the fact the EBV will infect 
B cells in vitro, and will efficiently activate and transform them. This has served as a 
powerful model for EBV latency and initiation of lymphoproliferative disease 
(Sugden, 1994). However, at the same time, this property is also the weakness in 
the model, as in vivo, EBV infection of B cells rarely leads to lymphoproliferative 
disease.
1.2.2.b In Vivo Model Systems for Gammaherpesviruses
Attempts have been made to model EBV in non-human primates, but have had 
limited success due to cross-reacting antibodies against simian herpesviruses. 
Some New World monkeys have proved susceptible to EBV infection, such as the 
cotton marmoset (Callithrix jacchus) and the cottontop tamarin (Saguinus oedipus 
oedipus) (Epstein, 1985; Cox, 1996). However these model systems are limited by 
differing outcomes of disease, and the practical limitations of working with 
endangered species.
Severe combined immune deficient (SCID) mice can also be used to model the 
human immune system by inoculating them with human peripheral blood 
mononuclear cells (PBMC). When EBV seropositive blood donors are the source of
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PBMC, 45% of SCID mice are observed to develop lymphoma (Rochford, 1995). 
This system has been used to define the tumour types that can arise following EBV 
infection. There have also been efforts to model HHV-6 infection in this system 
(Dittmer, 1999; Aoki, 1999; Lane, 2002). However there is a relatively high degree 
of variability in this system as 3-9 month old SCID mice can develop a limited 
number of B and T cells, and up to 15% of SCID mice may spontaneously develop 
T cell lymphomas (Johannessen, 1999). Furthermore, differing methods are used to 
pre-condition mice to accept human cells, which introduces further variability. This 
system has yet to be standardised and therefore cross-comparison of data can be 
difficult.
1.2.2.C MHV-68 as a Model System for Gammaherpesviruses
Unlike other gammaherpesviruses, MHV-68 readily infects a broad range of cell 
lines, including primate and rodent-derived lines (Mistrikova, 2000). Therefore, 
MHV-68 can be used to infect well-defined tissue culture systems without a need 
for specialised conditions. Combined with its rapid replication cycle, it represents a 
very practical in vitro model system for the gammaherpesviruses. Furthermore, 
being a natural pathogen of rodents, the virus can be used to infect laboratory mice, 
which presents a natural small animal system in which to model
gammaherpesviruses in vivo.
Recently, a bacterial artificial chromosome (BAC) based mutagenesis system for 
MHV-68 has been introduced, allowing relatively simple creation of mutant strains 
(Adler, 2000). This provides a reliable method for manipulating the virus. As there 
are a wide variety of cell lines and mouse strains are available, defined changes to 
the virus’ environment can also be made. Therefore, both the pathogen and its 
environment can be controlled and modified. Such a model system has many 
advantages for gammaherpesvirus research, and in particular, human
gammaherpesvirus research can benefit greatly as many of the restrictions 
imposed on experiments with HHV-8 and EBV are obviated. However it remains to 
be seen exactly how similar the biology of MHV-68 and the human 
gammaherpesviruses are.
1.2.3 General Life Cycle of Herpesviruses
The life cycle of MHV-68 is typical of a herpesvirus in that it consists of attachment 
and penetration of the virus into the host cell, translocation of the viral genome into
the host nucleus, transcription of viral genes, replication of viral DNA, and the
assembly and release of progeny virus. A generalised herpesvirus lytic life cycle is 
shown in Figure 1.3.
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Figure 1.3. Generalised representation of a herpesvirus lytic life cycle.
Numbers represent the various stages as follows: 1 - attachment, 2 - entry into cell, 3 - entry 
into nucleus, 4 - transcription, replication and assembly of new virus particles, 5 - exit from 
nucleus, 6 - assembly of glycoproteins to cell surface, 7 - de-envelopment/re-envelopment, 
8 - release of progeny virus. Abbreviations: N - nucleus, NM - nuclear membrane, ER - 
endoplasmic reticulum, G - golgi apparatus (Adapted from Reschke, 1995)
1.2.3.a Attachment and Penetration
Much of the knowledge of the herpesvirus life cycle is derived from work on HSV-1. 
Attachment and penetration of HSV-1 relies on sequential interactions between 
specific viral glycoproteins and host cell surface receptors, initially between viral 
glycoprotein B or C and cell surface heparin sulphate (Johnson, 1984; Addison, 
1984; Epstein, 1984; WuDunn, 1989; Shukla, 2001). Heparin sulphate is also 
involved in the attachment of HMCV, HHV-7 and HHV-8 as well, but EBV 
attachment appears to be independent of heparin sulphate (Compton, 1993; 
Secchiero, 1997; Speck, 2000; Akula, 2001). After this initial step, viral glycoprotein 
D interacts with further cell surface molecules, which is thought to instigate virus­
cell fusion (Ligas, 1988). The action of other viral glycoproteins is required to 
complete adsorption of the virus (Sarmiento, 1979; Campadelli-Fiume, 1990; 
Hutchinson, 1992; Forrester, 1992; Dingwell, 1994).
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Following entry, the nucleocapsid is transported to the nuclear pore complexes 
(Miyamoto, 1971). Studies with HSV-1 have shown that around 70% of bound virus 
penetrates with a half-time of around 8min (Sodeik, 1997). Over 60% of these 
capsids are delivered to the nuclear pore complexes within 4h of entry, with the 
majority of the tegument being left behind. The capsids travel along the microtubule 
network and the viral genome is released into the nucleus (Sodeik, 2000; 
Ploubidou, 2001).
The viral DNA is accompanied by a tegument protein VP16 (also known as a-TIF, 
ICP25; the product of gene UL48), which enhances immediate early viral 
transcription via cellular transcription factors (Campbell, 1984; Flint, 1997). Another 
tegument protein, the virion-associated host shutoff protein (vhs; product of gene 
UL41) remains in the cytoplasm where it causes the disaggregation of 
polyribosomes and degradation of cellular and viral RNA (Schek, 1985; Smibert, 
1992).
1.2.3.b Transcription
Transcription of the viral genome then occurs in the nucleus in 3 distinct stages, 
known as immediate-early (IE), early (E) and late (L) (Jones, 1979). These 
designations refer back to studies of bacteriophage gene expression, and a modern 
terminology of alpha (a), beta (p) and gamma (y) kinetic classes of transcription has 
been suggested to help avoid confusion between 2 different transcription systems. 
Much of the work on herpesvirus transcription has centred on HSV-1, as it has been 
the most practical virus to work with.
a genes are transcribed without the need for any viral protein synthesis and are 
involved in priming the cell for further viral gene expression. Of the close to 100 
transcripts encoded by HSV-1, only 5 are expressed as a genes. The HSV-1 
tegument protein, a-TIF, also enters the nucleus with the viral DNA and interacts 
with the host’s transcription factors (Batterson, 1983; Xiao, 1990). The resulting 
complex binds to a-gene promoters in the viral genome and initiates transcription of 
a genes by the host’s RNA polymerase II (Campbell, 1984; Preston, 1988).
Three of the proteins encoded by HSV-Ts a genes then form further nuclear 
complexes and are involved in initiating p transcription (genes a0, a4 and UL54 
encoding proteins ICP0, ICP4 and ICP27, respectively). The a  gene a22 (encoding 
ICP22) is essential in most but not all cell lines and is involved in initiation of y gene 
transcription (Post, 1981; Long, 1999). The last a gene, Us12 (encoding ICP47), is
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involved in modulating the host’s immune response by blocking antigen 
presentation (York, 1994).
(3 gene transcription is defined by it’s requirement for viral protein synthesis, as their 
transcription requires redirection of the host’s transcriptional machinery by the a 
gene products (Honess, 1974). The p gene products are primarily involved in viral 
DNA replication and as soon as sufficient levels of p proteins are produced, viral 
DNA replication commences, p gene promoters are unlike a  gene promoters in that 
they are diverse and do not share common elements (Roizman, 2001a). Therefore, 
the expression of p genes cannot be predicted from their promoter sequences and 
their expression profiles can vary greatly. In HSV-1, UL39, UL40 and UL29 
(ribonucleotide reductase, large and small subunits, and major DNA binding protein, 
respectively) are amongst the first p genes to be expressed (Conley, 1981; Huszar, 
1981), while others such as UL23 and UL30 (thymidine kinase and DNA 
polymerase, respectively) are expressed later (Klemperer, 1967; Purifoy, 1977).
The y genes tend to encode structural components of virus particles. They are 
further divided into y1 and y2 classes, which are also referred to as early or leaky 
late and true late classes, respectively (Jones, 1979). Transcription of y1 genes 
commences around the same time as the p genes but their expression levels only 
peak after DNA replication has been initiated (e.g. HSV-1 UL27 and Us6, 
glycoproteins B and D, respectively). y2 genes are only expressed following the 
onset of viral DNA replication (e.g. HSV-1 UL44, glycoprotein C). Similar to p genes, 
the promoter sequences of y genes do not share any common elements, which 
explains the diversity of their expression patterns (Roizman, 2001a).
Herpesvirus transcription therefore occurs as a 3 stage cascade. A small number of 
a genes are expressed via the host transcriptional machinery, and the products of 
these genes are principally involved in starting the subsequent rounds of 
transcription. Following the synthesis of a proteins, p and y1 proteins are then 
produced. Following synthesis of p proteins, viral DNA replication commences, 
which triggers the production of y2 proteins. y1 protein levels only reach their peak 
following the onset of viral DNA replication.
1.2.3.C Assembly and Release of Progeny Virus
Once viral DNA has been replicated and the structural proteins synthesised, they 
are incorporated into new virus particles inside the nucleus (reviewed in Roizman, 
2001a). New viral genomes are packaged into preformed capsids, the exact
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mechanisms for which are not fully elucidated, but this process starts with the 
procapsid structure (Sheaffer, 2001).
There follows a complex process of envelopment that appears at first glance to be 
rather inefficient (Whiteley, 1999; Skepper, 2001; Mettenleiter, 2002). Mature 
capsids bud through the inner nuclear membrane, which contains viral 
glycoproteins. These primarily enveloped capsids then bud through the outer 
nuclear membrane where the primary envelope is lost. The cytoplasmic capsids 
then associate with the various tegument proteins, including VP16 and vhs. These 
2 proteins appear to interact with the capsids and help the final envelopment 
process. Final envelopment involves the mature capsids, with their associated 
tegument proteins, budding into exocytotic vesicles, which contain all the 
glycoproteins associated with the mature virions on their membranes. These now 
infectious virions either remain cell associated within these vesicles and spread to 
uninfected cells via virus-induced fusion, or are released from the cell in the 
exocytotic vesicles. It seems unlikely that any stage of the herpesvirus life cycle 
would have evolved to be inefficient, and therefore further study to examine the 
advantages of this mechanism is required.
There is one main alternative hypothesis for the stages following the primary 
envelopment step. This suggests that the primary enveloped capsids exit the cell 
via the Golgi apparatus and the associated secretory pathway without intermediate 
de-envelopment/re-envelopment steps (Johnson, 1982; Campadelli-Fiume, 1991). 
It remains to be determined conclusively, which pathway is correct.
1.2.3.d Latency
While persistence is a relatively common phenomenon of DNA viruses, latency is 
the hallmark of herpesviruses. The virus attaches and enters the host cell, but does 
not initiate the gene expression cascade characteristic of lytic infection. The viral 
genome is maintained in a genetically identical, but structurally different form, 
compared to that during lytic infection. Latent genomes form closed circles, usually 
as host-histone associated supercoiled episomes (Efstathiou, 1986; Deshmane, 
1989). A very restricted programme of transcription is also usually observed, often 
localised to a small region of the genome (Stevens, 1987; Sugden, 1994).
The physiology and molecular biology of latency is one of the most varied aspects 
of herpesvirus biology. Each herpesvirus has evolved its own unique ecological 
niche within its host, and any host species can harbour multiple herpesvirus 
species. The alphaherpesviruses become latent in ganglionic neurones (Preston, 
2000; Kennedy, 2002). HCMV establishes latency in bone marrow-derived myeloid
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progenitor cells (Jarvis, 2002; Sissons, 2002). EBV resides latent in resting B cells 
(Crawford, 2001). The reservoir for latent HHV-8 is unclear, but based on its 
association with B cell and endothelial tumours, candidates include endothelial 
precursors (KS), pre- (multicentric Castlemans disease) and post-germinal centre B 
cells (primary effusion lymphoma) (Ambroziak, 1995; Cesarman, 1995; Du, 2001).
There are 3 stages to latency: establishment, maintenance and reactivation. 
Establishment involves infection of the appropriate cell type, followed by what 
appears to be failure of the productive gene cascade to be initiated. This is likely to 
be a function of the specific cell type in which latency occurs (Wagner, 1997). HSV- 
1 can maintain latency passively as it does not need to express any of its genes. It 
does, however, express a single latency associated transcript (LAT) for which no 
function, or even protein, has been elucidated (Stevens, 1987). The primary 8.3kb 
LAT is, however, spliced to give an abundant 2.0kb LAT, which is then further 
spliced to a 1.5kb LAT (Spivack, 1987; Garber, 1997). There is also a recent report 
showing that peptides, artificially synthesised using the largest open reading frame 
(ORF) of the LAT as template, become localised to distinct punctuate structures in 
infected cell nuclei, and can function to silence exogenous promoters inserted into 
the viral genome (Thomas, 2002). Therefore, although no LAT protein has been 
found, it certainly has potential to function in latency.
EBV is more active transcriptionally while in its maintenance phase of latency, 
perhaps related to its site of latency being a dividing cell as opposed to a post­
mitotic neurone. EBV expresses a number of genes involved directly in maintaining 
the viral genome, as well as those involved in immune evasion and prevention of 
apoptosis (Sugden, 1994). In fact there are 3 classes of EBV latency, each with a 
different transcriptional profile, and related to the cells in which they are latent.
Reactivation of herpesviruses involves a switch to the productive transcription 
cascade, and is the least understood phase of latency. In particular, the molecular 
trigger for reactivation has eluded discovery. Studies have shown that HSV-1 
reactivation efficiency is reduced if LAT is not expressed, but as no structural RNA 
or LAT protein has been observed, the mechanism behind this reduced reactivation 
requires further study (Bloom, 1994). HCMV appears to have a passive mechanism 
for reactivation. When the myeloid lineage progenitor cells, in which the virus is 
latent, differentiate into macrophages, the change in cellular environment results in 
conditions permissive for IE gene expression. The lytic gene expression cascade 
ensues and progeny virus is released (Sissons, 2002). However, the mechanisms 
of HCMV reactivation are still far from clear. For example it is unknown which
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cytokines and pathways are responsible for the phenotypic changes that trigger 
reactivation.
1.2.4 Genomic Structure and Organisation of MHV-68
1.2.4.a Herpesvirus Genomic Structure
The HSV-1 genome is 152,260 base pairs (bp) in length and 68.3% G + C 
(McGeoch, 1988). The 2 covalently linked components of the genome are known as 
the long and the short. Both of these components contain unique sequences (UL 
and Us) flanked by inverted repeats (ab & a’b’ around UL, and ac & a’c’ around Us). 
The 2 components can invert relative to each other, which results in any population 
of HSV-1 consisting of 4 different genomic arrangements (Sheldrick, 1975; 
Roizman, 2001b). HSV-Ts genome encodes at least 84 proteins, of which 14 are in 
Us, 1 is in the repeat sequences around USl and 4 are in the repeat sequences 
around UL) leaving 65 in UL. Of these 84 genes, 39 have been characterised as 
essential for HSV-1 to complete its productive life cycle in vitro (Roizman, 2001a).
The betaherpesvirus subfamily includes the largest sequenced herpesviruses with 
many genomes of more than 200kb - chimpanzee CM V’s genome is 241,087bp 
(Davison, 2003). Members of the Roseolovirus genus have smaller genomes, HHV- 
6’s genome is 159,321 bp (Gompels, 1995) and has 2 variants, HHV-6A and HHV- 
6B, which differ in the genetic and biological properties (Isegawa, 1999).
Gammaherpesviruses possess genomes in the same size range as HSV-1. EBV’s 
genome is 172kb with 84 predicted s (Baer, 1984), while HHV-8’s is 165kb with 81 
ORFs predicted (Russo, 1996) and MHV-68’s genome is 119kb with 80 predicted 
ORFs. Gammaherpesviruses have collinear genomes, possessing conserved 
blocks of genes, even between y1 and y2 herpesviruses. The majority of MHV-68’s 
genes have homologues in HHV-8 and EBV (Baer, 1984; Russo, 1996; Virgin,
1997). The overall genomic organisation of 4 different gammaherpesviruses is 
shown in Figure 1.4. Virus-specific genes tend to be found interdispersed around 
regions conserved by all gammaherpesviruses (Chee, 1990). For MHV-68, the 
virus-specific genes to the left of ORF 4 and to the right of ORF 69 are of particular 
interest as they are homologous to host genes. While some of HSV-Ts genome 
has been characterised functionally, the genes of gammaherpesviruses remain 
mostly uncharacterised. Instead genes have been assigned putative functions 
based on homology to characterised genes.
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1.2.4.b MHV-68 Genomic Structure
The MHV-68 genome is fully sequenced and has been shown to consist of a 
118,237bp unique region flanked by multiple copies of a 1,213bp terminal repeat 
sequence (Virgin, 1997). It is predicted to encode 80 gene products, 63 of which 
are homologous and collinear to their counterparts in Herpesvirus saimiri (HVS) and 
HHV-8, and designated ORF 4-69. These genes make up the conserved gene 
blocks that are characteristic of gammaherpesviruses as shown in Figure 1.4.
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Figure 1.4 (preceding page). Comparison of gammaherpesvirus genome organisations. 
Blue blocks represent groups of genes, their constituent ORFs are shown in each block. 
Empty blue rectangles represent repeat regions. The name of each herpesvirus is given on 
the left in red: EBV -  Epstein-Barr virus, HVS -  Herpesvirus saimiri, KSHV -  Kaposi’s 
Sarcoma-associated herpesvirus or human herpesvirus 8, MHV-68 -  Murine 
gammaherpesvirus-68 (adapted from Virgin, 1997).
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Interdispersed among these homologous genes, lie MHV-68 specific genes 
designated ORF M1-M14 (the predicted ORFs of MHV-68 are listed in Appendix 
III). ORF M11, however, encodes a bcl-2 homologue common to 
gammaherpesviruses. It has been designated MHV-68 specific gene M11 as there 
is only a weak homology to counterparts in other gammaherpesviruses. M11 is 
found between ORF 72 and 73, at the right-hand end of the genome. This is the 
same position as the EBV bcl-2 homologue, but a different one to HHV-8’s bc!-2 
homologue. The gene in HHV-8 is named ORF 16 due to its position in the 
genome. It seems that in ancestral gammaherpesviruses, the bcl-2 homologue was 
at the right-hand end of the genome, and that some form of recombination event 
occurred in the HHV-8 lineage.
The genomic organisation of MHV-68 is shown in Figure 1.5. Generally speaking, 
herpesviruses are promoter-rich and so polycistronic transcripts are rare (Whitley, 
2001). However, transcripts do often share polyadenylation sites, resulting in 
families of co-terminal transcripts. These sets of co-terminal transcripts also occur 
in the MHV-68 genome, for example ORF 4 and 6 share a polyadenylation site 
although they each have their own promoter (Kapadia, 1999).
As well as the terminal repeat, there are 2 internal repeat sequences. One is 
predicted to lie between positions 26778 and 28191 on the genome and consists of 
a 40bp repeated sequence. A second repeated sequence of 100bp lies between 
positions 98981 to 101170 (Virgin, 1997).
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Figure 1.5. Genomic organisation and ORFs of MHV-68.
The MHV-68 genome’s unique region is shown as a thick blue line. Terminal repeat units are depicted as open rectangles at the ends of the genome. 
Internal repeats are shown in yellow. ORFs homologous to genes found in HVS and HHV-8 genomes are depicted in blue or green depending their 
orientation. ORFs which are homologues of known cellular genes or of genes in non-herpesviruses are depicted in red. ORFs with no significant homology 
to any known cellular or viral gene product are depicted in purple. Also shown clustered near the left end of the unique region are 8 potential tRNA-like 
genes (adapted from Virgin, 1997).
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At the left-hand end of the genome lie 8 novel sequences that encode tRNA-like 
sequences (Bowden, 1997). EBV and HVS are known to also encode families of 
non-coding RNAs with features typical of tRNAs (Lee, 1988; Swaminathan, 1991). 
These occur at similar loci to those of MHV-68, as all 3 lie close to their respective 
origins of replication. The function of these is unclear but in MHV-68, they are 
transcribed abundantly during productive and latent infection (Bowden, 1997). 
However, deleting 4 of the 8 tRNA-like sequences has no effect on replication in 
vitro or on establishment and reactivation of latency in vivo (Simas, 1998a). Similar 
observations were made for EBV and HVS (Murthy, 1989; Swaminathan, 1992). 
Based on these characteristics however, the MHV-68 tRNAs have been used 
successfully as markers of latency (Simas, 1999).
All gene names used in this thesis are based on the sequence analysis performed 
at the time that MHV-68 genome was fully sequenced by Virgin et ai. (1997). 
However, MHV-68 has also been sequenced and analysed a second time (Milligan, 
1998). The second analysis of the MHV-68 genome was more sophisticated than 
that performed in the original study, as Milligan et ai. (1998) mapped features such 
as polyadenylation signals and potential splice sites.
In this analysis, several of the ORFs designated by Virgin et al. were demoted to 
the status of being unlikely to encode proteins. They are ORF M5, M6, M10 (a, b & 
c), M12, M13 and M14. There is little experimental data concerning any of these 
predicted ORFs. Furthermore, M8 was predicted to be an exon of ORF 57. Similarly 
ORF 29a was incorporated into ORF 29. ORF M9 was found to be homologous to a 
gammaherpesvirus capsid protein and has therefore been renamed ORF 65. For 
comparable reasons, M7 and K3 were renamed ORF 51 and ORF 12, respectively. 
Finally, three sequences were elevated to ORF status, ORF 17.5, 28 & 67a. By way 
of summary, a list of the ORFs of MHV-68 and their predicted functions can be 
found in 9.3 Appendix III. Furthermore any genes that were characterised at the 
time of the start of this thesis are also listed.
1.2.4.C MHV-68 Genes with Homologues in Other Viruses
The majority of MHV-68 genes are homologous to other gammaherpesvirus genes. 
Many of these genes have been assigned a putative function based on homology to 
characterised herpesvirus genes. ORF 21 encodes MHV-68’s thymidine kinase (tk) 
which is non-essential in vitro as mutants of MHV-68 lacking it show no phenotype 
(Coleman, 2003). However, in vivo, titres in the lung are severely reduced by a 
factor of 1,000, so that almost no virus can be isolated. However, even with this 
severe restriction of productive viral replication, MHV-68 is able to infect
43
splenocytes and establish latency. Infectious centre assays show that levels of 
latent virus in the spleen are reduced compared to wild type (wt) initially, but by 1 
month pi, levels of latency for the tk deficient virus reach that of wt virus.
It seems that deoxythymidine monophosphate (dTMP) levels in tissue culture cells 
are high enough not to hinder viral replication. While in vivo, the cells infected by 
MHV-68 in the lung do not appear to contain large reserves of dTMP. However, as 
DNA replication is not a feature of the establishment and maintenance of latency, 
levels of latent virus eventually reach the levels observed during wt infection.
There are also 2 genes that are homologues to non-herpesvirus genes. The 
protein predicted to be encoded by ORF M1 is homologous to the serpin proteins of 
the poxviruses, and unique to MHV-68 among the gammaherpesviruses. These 
proteins have been shown to be involved in processes such as control of host 
inflammatory responses and regulating apoptosis (Chua, 1990; Brooks, 1995).
Intraperitoneal (i.p.) infection of mice with insertion or deletion mutants with respect 
to M1, result in decreased splenic titres 9d pi, but levels of latent virus remain 
similar to that observed for wt infections. Interestingly the rate of reactivation was 
increased approximately 5-fold (Clambey, 2000). However, intranasal (i.n.) infection 
of mice with a deletion mutant of MHV-68 missing M1 and tRNAs 1-4 showed no 
phenotype both in vitro and in vivo (Simas, 1998a). Further analysis is required to 
elucidate whether the route of infection or the tRNAs contributed to the discrepancy 
in results.
ORF K3 is homologous to K3 of HHV-8 and the major immediate early protein (IE1) 
of BHV-4 (van Santen, 1991). The main point of homology between these proteins 
is a single motif that is completely conserved (Virgin, 1997). ORF K3 is transcribed 
both during productive infection, and during establishment of latency. Though not 
essential for the virus, it modulates the host immune response by down regulating 
MHC class I expression and helping evade the cytotoxic T lymphocyte response 
(Stevenson, 2002).
1.2.4.d MHV-68 Genes with Homologues in the Host Genome
Four cellular homologues were identified within the MHV-68 genome. ORF 4 is a 
complement regulatory protein homologue, possessing 4 regions with homology to 
many known complement regulatory proteins. This homologue is also found in HVS 
and HHV-8 (Albrecht, 1992; Russo, 1996). In particular, ORF 4 was found to have 
homology to murine decay-accelerating factor and human membrane co-factor 
protein. These proteins regulate serum complement via C3 convertase, as does
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ORF 4 of HVS (Fodor, 1995) and HHV-8 (Spiller, 2003). ORF 4 of MHV-68 was 
found in the supernatant of infected cells, and on their cell surfaces, and has also 
been shown to inhibit complement activation (Kapadia, 1999). Both MHV-68 and 
HHV-8 encode 3 isoforms of the ORF 4 protein, at least one of which is soluble. A 
deletion mutant of MHV-68 lacking ORF 4 replicates in vitro, but with reduced 
growth characteristics (Adler, 2000), which suggests that the protein may have an 
additional role to that of complement regulation.
ORF 72 is predicted to encode a D-type cyclin. HHV-8, HVS and EBV also encode 
cyclin homologues, and EBV’s homologue has been shown to regulate cellular 
cyclin D expression (Nicholas, 1992; Sinclair, 1995; Chang, 1996). This level of 
conservation through the subfamily indicates a conserved role for this gene. ORF 
72 of HVS has been observed to be involved in binding cyclin-dependent kinase 6 
(cdk6) (Jung, 1994), and it’s counterpart in HHV-8, with cdk6 and weakly with cdk4 
(Li, 1997). Although the mechanisms are unclear for MHV-68’s cyclin D homologue, 
it has been classified as an oncogene due to the appearance of lymphoid tumours 
in transgenic mice expressing the gene (van Dyk, 1999). The authors further 
showed that it promotes cell cycling of thymocytes and inhibits their differentiation. 
Furthermore the gene appears to be involved in reactivation, as ORF 72 mutants of 
MHV-68 show reduced levels of reactivation (Hoge, 2000).
ORF M11 has weak homology to the bcl-2 homologues of EBV and HHV-8, which 
are known to inhibit apoptosis (Henderson, 1993; Chang, 1997). ORF M11 has 
been shown to possess antiapoptotic activity as well, however, it differs from the 
products of other gammaherpesviruses as it is digested by caspases (Bellows, 
2000). The products of M11 caspase digestion, unlike the bcl-2 caspase digestion 
products, lack proapoptotic activity. The bcl-2 homologues of EBV, HHV-8 and 
bovine herpesvirus 4 (BHV-4) are not susceptible to caspase digestion and 
therefore retain their antiapoptotic properties by this strategy.
Finally, MHV-68 ORF 74 is homologous to the G-protein-coupled receptor family, in 
particular, the IL-8 receptor. HVS ORF 74 has been shown to function as an IL-8 
receptor (Ahuja, 1993). HHV-8 ORF 74 has been shown to be a constitutively active 
G-protein-coupled receptor. It binds both a  and p chemokines, and is capable of 
producing signals for cell growth (Arvanitakis, 1997). HHV-8 ORF 74 is also found 
to be expressed in tumours cells (Cesarman, 1996).
Recombinant MHV-68 lacking ORF 74 shows no phenotype in vitro. However, the 
reactivation efficiency of this virus, from latently infected splenocytes, is reduced.
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Also while CXC chemokines increase wt MHV-68 replication, the ORF 74-deficient 
recombinant does not respond to these chemokines (Lee, 2003).
1.2.4.e MHV-68 Unique Genes
MHV-68 encodes a number of genes that have no known homologues, designated 
ORFs M1-M14 (Virgin, 1997). Analysis of the predicted amino acid sequence for 
ORF M2 returned no homologues. Studies of gene expression in the S11 B cell 
tumour cell line prompted Husain et al. (1999) to suggest that M2 was transcribed 
during latency.
The S11 line was originally derived from lymphomas of MHV-68-infected mice, and 
has been shown to contain episomal forms of MHV-68’s genome at a ratio of 1:3.0 
to the genome in it’s linear form (Usherwood, 1996a). As the linear form of the 
genome is associated with productive infection, lytic gene expression would also be 
expected to be occurring in this cell line. Indeed infective centres assays showed 2- 
4% of cells gave rise to MHV-68 antigen positive plaques, after 12 weeks in culture. 
This rose to 20-30% by 9 months in culture.
Husain et al. (1999) detected transcription of ORF M2 in the S11 line by northern 
blot analysis. It was the only abundantly expressed viral gene that was observed in 
the S11 cell line. However, when the S11 cell line was chemically induced to 
reactivate, levels of M2 transcripts were seen to rise. ORF M2 transcripts were not 
detected though in lytically infected BHK cells.
RNA protection assays of MHV-68 gene expression show that the M2 transcript is 
expressed in murine 3T3 fibroblasts during lytic infection. Furthermore M2 
expression was not detected in latently infected splenocytes by this method 
(Rochford, 2001). The picture is further obscured by observations made following 
i.p. infection of mice, as a latent infection of peritoneal macrophages is observed 
with this routes of infection. These latently infected macrophages also express M2 
(Virgin, 1999). However, it is not clear how significant these findings are as the i.p. 
route of infection is not a natural one.
Studies using mutant MHV-68 strains with disruptions in M2 have shown that 
growth curves in vitro are identical to those of wt virus. Similarly in vivo, the viral 
titres recovered from lungs of mice infected with the mutant strain are equivalent to 
wt infection titres. In the spleen however, ex vivo reactivation assays show that 
infections with the mutant strain show reduced levels of virus recovered. Therefore, 
it appears that M2 does play a role in latency, or at least reactivation from latency 
(Jacoby, 2002). Interestingly, if mice were infected i.p. as opposed to i.n., the levels
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of reactivating virus from the spleen were equivalent for wt and mutant strain virus 
infections. This suggests that injecting virus directly into the peritoneum may 
compensate for M2 function. Further studies are now required to elucidate the role 
of ORF M2 during the virus’ lytic and latency phases, and also the switch between 
them.
Transcription of ORF M3 produces an unspliced 1287bp polyadenylated mRNAthat 
encodes an abundantly secreted protein (van Berkel, 1999). The M3 protein binds a 
broad range of chemokines including CC, CXC, C and CX3C, although it shares no 
homology to known chemokine receptors (Parry, 2000). Transgenic mice 
expressing M3 and the chemokine CCL21 in the pancreas have been used to study 
the effects of M3 in vivo. CCL21 expression by the pancreas would normally result 
in development of lymphoid aggregates that resemble lymph nodes. While 18% of 
mice expressing just CCL21 did show lymphoid aggregates, only 2% of the mice 
expressing both M3 and CCL21 showed similar symptoms (Jensen, 2003). This 
study demonstrated that M3 can block the activity of a CC chemokine in vivo and 
suggests that M3 could disrupt the mobilisation of lymphoid cells regulated by 
CCL21 as an immune evasion strategy.
ORF M7 encodes MHV-68 glycoprotein 150 (gp150), a protein that is well 
conserved through the herpesvirus family. It has be shown to be present on the 
surface of infected cells, and in virus particles (Stewart, 1996). A recombinant 
vaccinia virus expressing MHV-68 gp150 has been constructed and used to study 
potential vaccines against MHV-68 infection (Stewart, 1999).
1.2.5 Epidemiology and Pathogenesis of MHV-68
Seropositivity of wild rodents to the murine herpesvirus in Slovakia was found to 
vary from 1-12.5% depending on the region (Mistrikova, 1985). In the north of 
England, seropositivity was 13% for the wood mouse (Blasdell, 2003). Although 
murine herpesvirus isolate 68 had originally been isolated from the bank vole, that 
species was only 2.7% seropositive in the north of England. This suggests that the 
murine herpesvirus can infect wood mice and bank voles with similar efficiencies. It 
would be interesting to test for seropositivity in other rodents.
Following i.n. infection, the lung is known to be the primary site of infection (Sunil- 
Chandra, 1992a). Infected mice tend to develop largely subclinical infections, 
although there is a marked splenomegaly associated with a characteristic increase 
in the number of germinal centres (Sunil-Chandra, 1992a). It seems likely that 
naturally occurring MHV-68 infections are generally sub-clinical.
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The productive infection in the lung peaks around 6d post-infection (pi; Sunil- 
Chandra, 1992a). The virus is found associated with alveolar epithelial and 
mononuclear cells in the lung. Infection then resolves 10-12d pi. Virus can 
sometimes be isolated from the various other organs during this phase of infection, 
but generally at lower levels (Svobodova, 1982a).
The splenomegaly and an associated swelling of lymph nodes marks the 
establishment of a population of latently infected B cells, which peaks around 2-3 
weeks pi (Sunil-Chandra, 1992b; Bowden, 1997). The number of infected 
lymphocytes eventually falls to around 1 latently infected cell per 105'6 B cells 
(Nash, 1994). Interestingly, there is evidence that MHV-68 establishes a persistent 
infection, rather than a truly latent infection (Christensen, 1999). Murine myeloma B 
cells infected with MHV-68 show no cytopathic effect (cpe) but produce infectious 
virus. This can be inhibited with acyclovir, but virus remains in the cells as 
determined by infectious centre assay (Sunil-Chandra, 1993). Furthermore, while 
the CD4+ T cell population peaks at 1:50 during the acute response and then falls, 
they remain activated and at stable numbers (1:400 -  1:500) for 14 months pi, 
presumably by continuously reactivating, persistent virus (Christensen, 1999).
It has been suggested that the lungs are a secondary site of latency, as viral DNA 
has been detected in the lungs of infected mice by PCR, 12 months pi (Stewart,
1998). Furthermore, both linear and episomal forms of the viral genome were also 
detected in lung tissue. However, the same study also detect viral DNA 
occasionally in the blood and bone marrow of mice. The source of viral DNA could 
therefore be circulating B cells that are latently infected. If this is the case then it 
seems likely that the source of viral DNA in the lungs could also be latently infected 
B cells. The same group also reported that viral DNA was detectable by PCR in 
lung tissue of pMT mice 35d pi (Usherwood, 1996b). As these mice do not have B 
cells, they could not be acting as template for the PCR. These results suggest that 
the lungs are a second site of latency. However, the progress of MHV-68 infection 
in immunocompromised pMT mice may not be the same as seen in a natural 
infection. Therefore, further analysis of the latent phase of MHV-68’s life cycle is 
required before it can be fully elucidated.
The human gammaherpesviruses are associated with a number of 
lymphoproliferative diseases. Long term persistence of MHV-68 has also been 
associated with lymphoproliferative disease, with one study showing 9% of animals 
developing lymphomas over a 3 year period, half of which were high-grade (Sunil- 
Chandra, 1994). All the tumours were a mixture of B and T cells, however, and not
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every malignant B cell was MHV-68 DNA positive. In fact, positive cells were 
infrequent, reminiscent of EBV and HHV-8
1.3 Studies of Gene Expression in the Post-Genomic Era
1.3.1 Transcriptional Profiling
The regulated expression of genes directs all biological processes including many 
of the pathological changes that occur during disease (Muralidhar, 1998; Dietz, 
2002; Carter, 2002; Jones, 2003; Levine, 2003). Analysis of gene expression can 
therefore elucidate one of the first steps towards producing a phenotype. This 
analysis can be aided by prior knowledge of the transcript population, which can be 
predicted from genomic sequence data (Russo, 1996; Virgin, 1997). There has 
been a recent wealth of genomic sequence data, driven partly by the high profile 
human genome sequencing project (Venter, 2001). Global analyses of transcription 
have been developed to take advantage of this data, and are particular in that they 
are designed to examine all gene expression occurring in a given sample, as 
opposed to focusing on a single or few genes (Spellman, 1998).
1.3.2 Differential Display
The differential display system, developed by Liang and Pardee (Liang, 1992; 
Liang, 1993), is often used in preference to the complementary DNA (cDNA) 
subtraction library technique. cDNA subtraction involves hybridising RNA from one 
sample against cDNA from another sample. The majority of RNA species will 
hybridised to complementary cDNA sequences. Any single stranded sequences 
that remain will represent genes that are differentially expressed in the 2 samples. 
The differential display system has a number of advantages over the subtractive 
hybridisation methods as it is technically simple, yet more sensitive, faster and 
more reproducible. Also unlike other techniques whose success is biased by 
relative mRNA abundances, differential display detects both abundant and rare 
mRNAs, on the condition that there is an arbitrary primer sequence that matches 
the target mRNA.
A further advantage of differential display is that prior knowledge of the geneset of 
an organism is not required. Instead, it simply isolates transcripts that are 
differentially expressed in one sample population, relative to another. The system 
has been used successfully to identify and study the effects on gene expression 
during such diverse events such as: transformation of fibroblasts with the Tax 
protein of human T cell leukaemia virus (Shimizu, 2003), infection of epithelial cells
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with pneumovirus (Domachowske, 2001) and the effects of nitric oxide on the 
apoptotic pathways of hepatocytes (Zamora, 2001).
It has also been used to reveal the cellular changes that occur when latent HSV-1 is 
stimulated to reactivate (Tal-Singer, 1998). In this study, RNA was extracted from 
the trigeminal ganglia of latently infected and control mice, and differential display 
performed. As well as some novel sequences, a number of genes involved in the 
interferon pathway were up-regulated in samples with reactivating virus. Although a 
large proportion of the differential expression could be attributed to the stress of 
explantation, it seems likely that some of the pathways involved in this response 
would also be common to reactivation. The authors suggested that the interferon 
pathway would be a good target for further study of HSV-1 reactivation.
These results indicated how the cellular environment, from a transcriptional 
perspective, differed when HSV-1 reactivates. If a more natural model of 
reactivation could be used, the results would become more representative, as the 
transcriptional noise from the explantation stress could be reduced.
The lytic cycle of herpesviruses has also been studied. Primary human foreskin 
cells were infected with HCMV and RNA isolated 8h pi (Zhu, 1997). The differential 
display returned 57 partial cDNA clones, which corresponded to 26 differentially, 
expressed mRNAs. Eleven of these were virally encoded, while 15 were of cellular 
origin. Of these 15 up-regulated cellular genes, the 11 genes that could be 
identified and the remaining previously uncharacterised genes were all shown to be 
inducible by interferon a. However their up-regulation during infection occurred 
even when antibodies against interferon a  and p were present in the medium.
The results suggested that a constituent of the viral particle could have been 
responsible for inducing the up-regulation of the 15 cellular genes. The differential 
display suggested that elements of the interferon response pathway were up- 
regulated by viral infection. Further study is now required to confirm whether 
expression of these genes were triggered by the virus, or by the cell in response to 
the virus.
An overview of the differential display protocol is shown in Figure 1.6. Having 
isolated RNA from the relevant samples, the RNA is reverse transcribed using 
anchored oligo-dT primers. There follows a PCR amplification for the 3’ terminal 
regions of the poly-adenosine (poly-A) RNAs by using an anchored primer (with a 3 ’ 
string of T residues) and one degenerate primer. Using enough degenerate primers 
in combination with the anchored ones will allow the entire poly-A RNA population 
to be amplified (Liang, 1993).
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Differential gene expressions are visualised by separating the products of each 
amplification out on a large DNA sequencing gel. By comparing the different lane 
profiles of the two RNA samples, and in particular the presence of a band in one 
lane while being absent in another, inferences can be made concerning the 
differential expression of the gene represented by a band. For example, in terms of 
a viral infection, a band absent in an uninfected sample lane but present in the 
infected sample lane would be indicative of a gene that is being expressed during 
infection, and therefore most likely a viral gene. This differential expression can be 
confirmed by northern blotting and the gene represented by the band identified by 
sequencing.
Essential to this technique are the primers used for amplification. It is necessary 
that each primer pair will amplify a subset of the total cDNA population, which can 
then be resolved on a gel. Also, there must be sufficient combinations of primers to 
allow coverage of the whole cDNA population.
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RNA sample 1 RNA sample 2
First strand cDNA synthesis 
using oligo-dT primer
ss cDNA template 1 ss cDNA template 2
1
Differential display PCR 
using pairs of degenerate primers
r 1
ddPCR products 1 ddPCR products 2
Products are separated on 
a 5% acrylamide gel
Primer*: P1/T1 P2/T1 P3/T1 P1/T2 P2/T2 P3/T2
RNA sample: 1 2  1 2  1 2  1 2  1 2  1 2
DNA is isolated from differentially 
expressed bands. 
Differential expression is confirmed by 
northern blot analysis.
Figure 1.6. Overview of the differential display technique.
52
1.3.3 Array Technology
1.3.3.a Overview
The most widely implemented genomic technology at present is that of arrays 
(Schena, 1995). They are also referred to as microarrays, macroarrays, cDNA 
arrays, DNA arrays and oligo arrays, usually depending on the variant of array 
technology used. All arrays, are based around the same technology, that of a large 
collection of probes attached to a solid surface, used to detect transcript 
abundances within a sample (Southern, 1999). Arrays are currently the technique 
that most fully implements genome sequence data. Unlike the differential display 
system, arrays require knowledge of genome sequence and organisation, in order 
to design probes for each possible transcript. They are therefore dependant on 
accurate predictions of ORFs and transcript organisation to design probes. This 
approach has the advantage over differential display in that it is unnecessary to 
sequence and identify differentially expressed transcripts highlighted by the system. 
Each probe is tested using various algorithms at the design phase to reduce the 
chances of redundant probes, poor annealing chemistry and inter-probe 
interference (Mitsuhashi, 1994; Chan, 1995). In other words, more optimisation at 
design is possible than with most other technologies.
An overview of array technology is shown in Figure 1.7. Probes can be BAC clones 
containing appropriate inserts (Greshock, 2004), or cDNA fragments synthesised by 
PCR amplification (Duggan, 1999), or long oligonucleotides synthesised chemically 
(Lipshutz, 1999). The resulting arrays are known as DNA arrays and oligo arrays, 
respectively. The probes for the array are attached to a solid medium, usually a 
glass slide for oligo arrays or nylon membrane for DNA arrays. The resulting array 
of probes will bind complementary sequences from a pool of DNA.
Oligonucleotide probes tend to be smaller in size than cDNA probes and therefore 
can be arrayed at a higher density. cDNA probes are limited in that if PCR 
amplification of a DNA sequence is not possible, then it is difficult to produce a 
probe for the region of DNA. While it is possible to clone these fragments and then 
cut out the probe sequences from plasmids using restriction endonucleases, the 
yield of this technique is insufficient for the needs of an array. The cost of producing 
cDNA probes is far less than that of oligonucleotide probes, due to the expense 
associated with synthesis of long oligonucleotides. However, oligonucleotide probes 
that are synthesised using phosphoramidite chemistry (as opposed to the more 
common methods of soft lithography and optical deproteination; Lipshutz, 1999) 
have the advantage that the probeset can be altered simply by using a different
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software template (Southern, 1999). Therefore, phosphoramidite chemistry-based 
probe synthesis provides flexibility not found in other systems, and is particularly 
useful for the optimisation of array systems. Phosphoramidite chemistry also allows 
the probes to be synthesised directly in situ on the glass slide, attached only at the 
end, which is likely to allow higher specificity than covalently bonding the entire 
probe to the glass slide (Southern, 1999; Cheung, 1999).
Optimise,
redesign
Genomic sequence
Probe sequences
Predict ORFs and 
their organisation
Probe synthesis and 
attachment to solid medium
Genome arrays
PERFORM HYBRIDISATIONS
Target
Isolate RNA to use as template 
for producing labelled target
Sample
Figure 1.7. Overview of array design and experimental procedure.
Typically, mRNA is reverse transcribed using a labelled nucleotide to produce a 
labelled cDNA population representative of the original mRNA population. These 
target cDNAs are then hybridised to arrays, which are then washed stringently to 
remove any non-specifically bound cDNA. The hybridisation pattern can then be 
visualised and quantified in an appropriate manner depending on the label used.
If a radioactive label is used then samples are labelled and hybridisations 
performed singly. The results from each array are compared to those from other 
arrays. If fluorescent labels are used, it is also possible to label 2 target populations
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with different colours and perform a dual colour hybridisation. This has the 
advantage of allowing a direct comparison between 2 samples hybridised to the 
same array, under identical experimental conditions. When comparing the 
hybridisation results of different arrays, as with radioactively labelled target arrays, 
strict controls must be used to take into account variation in experimental 
conditions, such as differences between arrays, differences in labelling and 
hybridisation efficiencies, and differences in radioisotope activities.
1.3.3.b Array Data Analysis
The results of arrays are quantified by a phosphoimager or laser scanner, 
depending on whether radiolabelled or fluorescently labelled nucleotides have been 
used. The amount of labelled cDNA target bound to each probe of the array is 
recorded as a signal intensity. A variety of control measurements, such as 
background and binding pattern of target to probe, may be taken as well to provide 
indications of the data’s reliability.
As arrays tend to be designed to perform genome-wide analyses, the datasets 
produced tend to be large. One study attempting to identify prognostic markers for 
prostate cancer used an array of 9,984 probes (Dhanasekaran, 2001). Forty-four 
experimental and 2 control samples were analysed resulting in 459,264 individual 
data points. Viral analyses tend to produce smaller datasets due to the smaller size 
of their genomes, however even a simple study of HSV-1 transcription at 4 time 
points produced 400 data points, not including controls or repeats (Stingley, 2000).
Interpreting this magnitude of data has become a subject of research itself 
(Hughes, 2001). Although a number of computational analysis tools and packages 
have been introduced (Quackenbush, 2001), the standard method for analysing 
large sets of transcripts and experiments is clustering analysis (Eisen, 1998). This 
allows transcripts to be placed on a hierarchical tree showing the relatedness of 
transcription profiles to each other. Therefore, genes with similar expression 
patterns are clustered into groups, which branch back to form larger groups, much 
like phylogenic trees used for classification of species.
A key advantage of global gene expression studies is that as well as providing 
information about a single gene’s expression, this transcription profile can also be 
analysed within the context of the global transcriptional landscape. Furthermore, 
global changes in transcription can also be analysed. HCMV is known to affect the 
transcription of many cellular genes, including interferon-induced genes, as shown 
by arrays (and also differential display; Zhu, 1997; Zhu, 1998). Array analyses have 
also shown that the global changes in cellular gene expression caused by HCMV
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infection, are the same as that seen when the same cells are stimulated by type I 
interferons (Simmen, 2001). Indeed, the binding of HCMV glycoprotein B alone is 
sufficient to produce the same changes in cellular gene expression. Although the 
human gene array used in this study did not cover the entire human genome, 258 
(of 6,600 on the array) genes were differentially expressed, and it therefore seems 
likely that the binding of glycoprotein B is a key part of inducing the cellular 
response to HCMV infection.
1.3.3.c Applications of and Conclusions from Array Studies
Transcriptional profiles of a number of herpesviruses have been published including 
those of Chambers et al. (1999), Stingley et al. (2000), Paulose-Murphy et al. 
(2001), Jenner et al. (2001) and Sciortino et al. (2001). There have also been a 
number of array-based studies investigating various conditions of infection. For 
example, the transcription of HSV-Ts genes has been studied at 2h and 8h pi 
(Stingley, 2000). Two different global gene expression profiles were seen at these 
time points, with structural genes expressed predominantly at the later time point. 
Therefore, the virus regulated the expression of its genes, as has been shown 
previously (Jones, 1979). Categorisation of HSV-1 transcripts into immediate-early, 
early and late kinetic classes was attempted by using cycloheximide (CX) and 
phosphonoacetic acid to block protein synthesis and viral DNA replication, 
respectively (Stingley, 2000). While the results agreed with previous studies, this 
was interesting as it was the first time that this investigation had been performed at 
the individual transcript level across the whole genome, as opposed to at the 
protein level (Honess, 1974).
Arrays therefore allow a rapid global analysis of transcription and by using samples 
taken at various times pi, it is relatively simple to produce a temporal map of the 
transcription of each gene of the genome. By blocking de novo protein synthesis or 
viral DNA replication, it is also possible to simply categorise viral genes into their 
kinetic classes of expression.
There have been further analyses of immediate-early gene expression centred on 
HSV-1 VP16 (Yang, 2002). This protein is carried into the cell as part of HSV-Ts  
tegument, and activates transcription of the immediate-early genes (reviewed in 
O'Hare, 1993). When a mutant strain of HSV-1, lacking VP16’s activation domain, 
was used to infect cells, all transcript levels were lower than that seen in wt 
infections, and the overall pattern of transcription was aberrant. However, if cells 
were infected by the same mutant strain at higher multiplicities of infection (moi), 
the resulting transcription profiles were far closer to those of wt infections,
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especially at the later time points. While it is a well noted phenomenon that 
infections using high moi’s can sometimes overcome defects in viral gene 
expression, it was very interesting to see this as a function of the viral 
transcriptome, and in particular, the differences between wt and mutant strain 
infections.
Furthermore, while the expression profiles at the later time points were close to 
those seen with wt infections, at earlier time points, there were a number of 
significant differences. Yang et al. (2002) used the mutant strain lacking VP16 to 
model the cellular environment of latent infections of neurones by HSV-1, when 
tegument proteins are not present to initiate the transcription of immediate-early 
genes. They suggested that transcriptional profile observed when infecting cells 
with the VP16 mutant strain, would be similar to the transcription profile occurring 
during reactivation of HSV-1. In addition, they suggested that the low moi infection 
modelled a spontaneous reactivation and that the high moi infection modelled an 
induced reactivation. This shows the ability of arrays to model infections under a 
variety of conditions. It also illustrates the ability they give to dissect phenotypic 
events at the level of global gene expression.
VP16 is a transcriptional activator and primarily responsible for inducing viral gene 
expression during productive HSV-1 infection. Discerning the system-wide changes 
in transcription that occur when VP16 is not functional is of great help in elucidating 
the mechanisms of HSV-1 usurpation of the host cell. Arrays can also be used to 
characterise mutant strains in terms of changes in global gene expression. In this 
way they can simply assess the impact of any particular mutation on the 
transcription of other viral genes.
HHV-8 transcription has been studied and hierarchical clustering performed using a 
primary effusion lymphoma-derived cell line as a model system (Paulose-Murphy, 
2001; Jenner, 2001). As this cell line is latently infected by HHV-8, latent gene 
expression was observed. However, the virus was also induced to reactivate, to 
allow analysis of lytic gene expression. Transcription profiles were clustered 
hierarchically, which sorted genes into functionally-related groups. Although few of 
HHV-8’s genes have been elucidated functionally, putative functions have been 
assigned to many genes based on sequence homology. Cluster analysis of 
reactivation-associated expression profiles returned several functional groups, 
which confirmed the homology-based functional predictions. The array analysis was 
able to confirm these predictions in a simple and rapid manner. Furthermore, as
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those genes with no putative function assigned were also clustered, predictions 
could be made as to the functional role of these wholly uncharacterised genes.
1.3.3.d Disadvantages of Array Analyses
Arrays can be thought of as performing a large number of simple DNA:DNA 
hybridisations simultaneously on a convenient single platform. They possess the 
weaknesses of any DNA hybridisation based technique (principally related to non­
specific hybridisation), although by incorporating multiple probes it is possible to 
overcome some of the limitations and ambiguities that occur when using a single 
probe. One array used to analyse HSV-1 transcription consisted of 99 probes 
(Stingley, 2000), however due to the presence of overlapping transcripts, several of 
these probes bound more than a single transcript. This redundancy in probe 
specificity is unavoidable if transcripts overlap. However, probes can be designed to 
anneal to gene-specific regions of a transcript where possible.
Although there is no need to search the gene databases to identify results as with 
differential display, arrays are limited in a similar fashion in that if the sequence of 
the gene is not known, then it is not possible to design a probe to it. Therefore, 
many of the arrays used to study transcription consist of partial gene sets.
Arrays are not necessarily quantitative. Depending on the labelling method and 
probe design, they can be semi-quantitative. Proven quantitative techniques, such 
as northern blot analysis, are required for quantification of results. For example they 
can be used effectively to examine relative abundances of transcripts between 
samples. Distinct types of diffuse large B cell lymphomas have been successfully 
differentiated by their relative gene expression patterns (Alizadeh, 2000). However, 
absolute quantification of transcript abundances has not been a feature of array 
analyses in general. Instead array analyses tend to present their results as relative 
values, or induction/repression relative to steady state levels of gene expression.
Arrays have however been used successfully for prognostic purposes. Gene 
expression profiles of breast cancer have been used to produce a “poor prognosis” 
signature that can be used as an indicator of disease outcome and also to highlight 
patients that might benefit from more severe forms of therapy, such as adjuvant 
chemotherapy (van 't Veer, 2002). While accurate prognosis can help reduce the 
costs incurred by unnecessary treatments of patients, arrays are still an expensive 
technology and can be technically complicated, especially when interpreting results. 
Therefore, further development is required before they can be adopted by the 
health services.
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1.4 Aims
The aim of this thesis is to further the characterisation of MHV-68 gene expression 
through the lytic phase of its life cycle. Initially, differential display and array 
systems will be developed to enable a global analysis of gene expression during 
MHV-68 infection. The array systems will be focused on viral transcription, while the 
differential display system will detect changes in both host and viral gene 
expression. A transcriptional study of MHV-68 will then be performed at the 
genomic level, to produce a series of expression profiles covering the MHV-68 
genome.
MHV-68 is a recently characterised murine gammaherpesvirus. Its somewhat 
atypical properties, such as a rapid replication cycle and the ability to productively 
infect a wide range of cell lines, recommends its use as a practical small animal and 
in vitro system with which to model other, less amenable gammaherpesviruses. 
While the latent phase of gammaherpesvirus infections has been investigated with 
some success, productive lytic infections remain largely unfamiliar. Therefore, the 
events that occur during primary productive infection are of particular interest in this 
study.
The foundation of information that such a study can provide will prove to be a 
valuable tool in the further development and understanding of gammaherpesvirus 
biology.
59
2 Materials and Methods
2.1 Tissue Culture
2.1.1 General Conditions
All cell lines were maintained in humidified incubators, at 37°C with 5% C 0 2 and 
grown as monolayers in 175cm2 flasks (Falcon), unless otherwise stated. Cells 
were seeded at approximately 2 x 106 cells in 40ml of medium. If cells were 
cultivated in 6-well plates (Falcon), they were seeded at 8 x 105 cells per well. If 
cells were cultivated in roller bottles (Fisher), they were seeded at 2 x 107 cells per 
bottle. All media were supplemented with 100U/ml penicillin, 100jig/ml streptomycin 
and 2mM L-glutamine, unless otherwise stated. Growth media were further 
supplemented with 10% foetal bovine serum (FBS, European, Invitrogen) or 
newborn calf serum (NCS, European, Invitrogen) as indicated. Maintenance media 
were supplemented with 2% of the respective sera. All cells lines were mycoplasma 
negative.
2.1.2 NIH 3T3 Murine Embryonic Fibroblast Cell Line
The NIH 3T3 murine (Mus musculus) embryo fibroblast cell line (ATCC CCL1658) 
was supplied by the American Type Culture Collection in a frozen ampoule. NIH 
3T3 cells were grown in Dulbecco’s modified Eagle medium (DMEM, high glucose, 
without L-glutamine, Invitrogen) supplemented with 10% NCS. Cells were passaged 
at approximately 80% confluency to prevent the loss of contact-inhibited growth 
characteristics.
2.1.3 BHK-21 (Clone 13) Baby Hamster Kidney Fibroblast Cell Line
The baby hamster kidney fibroblast (BHK-21) cell line (Clone 13, ECACC 
85011433; BHK cells) was supplied by the European Collection of Cell Cultures in a 
frozen ampoule. BHK cells were grown in Glasgow minimal essential medium 
(GMEM, with sodium bicarbonate, without L-glutamine; Sigma) supplemented with 
10% FBS and 10% tryptose phosphate buffer (29.5g/l, Sigma). These were seeded 
at approximately 3 x 106 cells in 40ml.
2.1.4 Subcultivation of Cell Lines
Cell lines were subcultured by discarding the growth medium and rinsing the 
monolayer in PBS without magnesium or calcium (Invitrogen). Cells were 
dissociated by adding 5ml of 0.05% trypsin and 0.02% EDTA and incubating at
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37°C in a humidified incubator at 5% C 0 2 for about 1min, being careful to minimise 
the duration of digestion. Complete medium with serum was then added and a 
single cell suspension prepared by repeated pipetting. Live cell counts were 
determined using a haemocytometer and trypan blue staining.
2.1.5 Crvopreservation of Cell Lines
Cells were collected by centrifugation at 500g for 5min and resuspended at 5-10 x 
106 cells/ml in standard growth medium, which was supplemented with 20% serum 
and 10% DMSO. Volumes of 1ml were aliquoted into cryopreservation vials and 
frozen at a cooling rate of -1°C/m in using a Cryo freezing container (Nalgene) 
placed at -80°C  for 16h. Frozen samples were then stored in liquid nitrogen.
2.1.6 Metabolic Inhibition of Cell Lines
2.1.6.a Cycloheximide
A stock solution of CX (Calbiochem) was made up in ethanol to a concentration of 
10mg/ml and stored at -20°C , for up to 6 months. A concentration response curve 
was calculated for CX inhibition of protein synthesis in NIH 3T3 cells over 0.1ng/ml - 
100pg/ml (2.1.7). A concentration of 2pg/ml CX was added to cell media, as this 
resulted in >95% inhibition of protein synthesis. Cells were pre-treated with CX for 
30min prior to use in all experiments involving protein synthesis inhibition.
2.1.6.b 2’-deoxy-5-ethyl-p-4’-thiouridine
A stock solution of the antiviral thionucleoside analogue 2 ’-deoxy-5-ethyl-p-4’- 
thiouridine (4'-S-EtdU, a generous gift of the late Professor R. Walker) was 
dissolved in double distilled water (ddH20 )  to a concentration of 1 mg/ml, at 60°C for 
1h. The solution of 4 ’-S-EtdU was added to cell media to 200ng/ml (Barnes, 1999) 
and used to overlay cell monolayers to inhibit viral DNA replication. Cells were pre­
treated with 4 ’-S-EtdU for 30min prior to use in all experiments involving viral DNA 
replication inhibition.
2.1.7 Protein Synthesis Assay
NIH 3T3 cell monolayers were grown to 75% confluency in 12-well plates. The cell 
sheets were washed with methionine-free medium (Invitrogen), containing 10% 
NCS, before fresh medium was added to each well. Then 1 i^Ci 35S-methionine was 
added per 105 cells. Monolayers were incubated for 6h at 37°C in a humidified 
incubator at 5% C 0 2.
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After this period, the medium was removed and monolayers washed with PBS. The 
wells were drained and the 12-well plates placed on ice. Ice-cold NP-40 lysis buffer 
(0.25ml; 150mM NaCI, 1.0% NP-40, 50mM Tris pH8.0) was added to each well and 
incubated on ice for 30min with gentle agitation to lyse the cells.
Any residual cell layer was then scraped off and the lysate transferred into 1.5ml 
tubes and vortexed for 1min. The cell debris was removed by centrifugation at 
10,000g for 10min and the supernatant transferred into fresh tubes. An aliquot of 
5pl for each supernatant was then spotted onto glass fibre filters in at least triplicate 
for each sample. Filters were then placed into shallow trays that were carefully 
flooded with ice-cold 5% trichloroacetic acid (TCA). These were incubated on ice for 
30min to allow precipitation of protein. The TCA was then drained and replaced 
before incubation at room temperature for 5min with gentle agitation. This was 
repeated twice and then the TCA was replaced with 95% ethanol and incubated 
again at room temperature with gentle agitation for 5min. Filters were then removed 
and left on foil to dry.
Dry filters were added to 4ml of scintillant (HiSafe, Wallac) in counting vials and 
incorporation of labelled-methionine was then quantified (Beckman scintillation 
counter), counting for 1min intervals.
2.2 Virus
2.2.1 Virus Strains
MHV-68 strain g2.4 was kindly provided by Dr Stacy Efstathiou (Division of 
Virology, Department of Pathology, University of Cambridge). Strain g2.4 was 
originally isolated as part of the field work on arboviruses in small rodents that was 
carried out in Slovkia, November 1976, by Blaskovic et al (1980).
2.2.2 Virus Stocks
MHV-68 was propagated in the BHK cell line. Virus stocks were prepared by 
infecting 95% confluent cell monolayers at moi 0.001. The viral inoculum was 
prepared in the minimal volume of maintenance medium appropriate for the 
monolayer, i.e. 20ml for 850cm2 roller bottles, 5ml for 175cm2 flasks. Virus was 
allowed to absorb for 1h at 37°C, with occasional agitation. The inoculum was then 
discarded, the monolayer washed and then replaced, with fresh maintenance 
medium (100ml for 850cm2 roller bottles, 40ml for 175cm2 flasks). Cells were 
incubated and harvested when cytopathic effect (cpe) was at least 95%  
(approximately 5 days).
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The infected cells were scraped off and pelleted at 1,600g for 30min at 4°C, in an 
angled rotor (Beckman JA-21). The supernatent was carefully removed and 
extracellular virus pelleted at 16,000g for 90min at 4°C, in an angled rotor 
(Beckman JA-21). The extracellular virus was resuspended in the minimal volume 
of PBS (25pl PBS per 1 x 107 cells), aliquoted and stored at -80°C. If necessary, 
PBS was added to the viral pellet and left for 16h at 4°C to aid resuspension. Titres 
of around 109 pfu/ml were routinely achieved.
The cellular pellet was resuspended in 200pl of PBS per 1 x 107 cells and sonicated 
at 0°C to free intracellular virus. Cellular debris was removed by centrifugation, at 
1,300g for 5min, and the cellular virus-containing supernatent was aliquoted and 
stored at -80°C . Intracellular virus was used for producing further viral stocks.
2.2.3 Virus Purification
Cell monolayers were infected and virus harvested as previously described (2.2.2) 
with the exception that the extracellular virus was resuspended in double the 
volume of PBS (50pl PBS per 1 x 107 cells).
The extracellular virus was purified by sucrose density centrifugation. Discontinuous 
sucrose gradients (14ml of 10-40% sucrose) were prepared in 18ml ultra-clear 
centrifugation tubes (Beckman). Two ml of each sucrose solution (40-10% in 5%  
steps) was layered carefully into each tube and then left at 4°C for 16h.
Up to 3ml of extracellular virus was loaded onto each gradient and the weight of 
each tube adjusted with additional PBS. Tubes were centrifuged at 20,000g for 1h 
at 4°C under vacuum in an Ultracentrifuge (Beckman; swing-out rotor SW  28.1). 
Viral bands were visualised by shining a narrow beam of light through the tubes at 
an angle. Two slightly blue, opaque bands were seen corresponding to the light 
(upper band) or heavy (lower band) particles. Bands were harvested by inserting a 
needle through the side of the tube, starting with the upper band. Purified virus was 
then pelleted at 83,000g for 1h at 4°C before being resuspended in 2.5pl PBS per 
1x107 cells, aliquoted and stored at -80°C .
2.2.4 Titration of Virus
Cellular, extracellular and purified virus titres were determined by plaque assay.
Ten-fold serial virus dilutions were prepared in maintenance medium and 10Opil of
the appropriate dilution added to NIH 3T3 cell monolayers, grown in 6-well plates.
Virus was adsorbed to the cells at 37°C for 1h with occasional agitation. Monolayers
were then rinsed with fresh maintenance medium before overlaying with 2ml
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maintenance medium containing 0.8% agarose (Invitrogen). Plates were incubated 
at 37°C in a humidified 5% C 0 2 incubator until plaques were formed (3-5 days). 
Cells were then fixed with formol saline (4% formaldehyde, 0.85% NaCI2) for 30min 
and the agarose overlay removed. Cell monolayers were stained with 0.1% crystal 
violet solution (dissolved in a 1:1 mixture of methanol and ddH20 )  and plaques 
were counted.
2.2.5 In Vitro Infection with Virus
Viral inoculum was prepared by serial dilution of virus stocks. Cell monolayers were 
grown to confluency and medium removed. Monolayers were then washed with pre­
warmed maintenance medium. Monolayers were inoculated with virus in the 
minimal volume of maintenance medium (e.g. 100jaI for 6-well plates), and left to 
adsorb for 1h at 37°C, in a 5% C 0 2 humidified incubator with occasional agitation. 
Monolayers were washed and overlaid with warm maintenance medium, and then 
incubated. Mock-infections of monolayers were also set-up, replacing viral inoculum 
with the equivalent volume of maintenance medium.
2.3 Molecular Biology
2.3.1 Viral DNA Isolation
Virus (1ml of viral stocks) was digested with DNAse I (Roche; 2.3.12.b) and then 
washed with PBS by 3 rounds of pelleting (3000g, 5min) and resuspending. The 
virus was then pelleted again and resuspended in 1 ml proteinase K digestion buffer 
(0.01 M Tris pH7.8, 0.005M EDTA, 0.5% SDS) and proteinase K added to a final 
concentration of 400^g/ml. The mixture was vortexed and incubated at 50°C for 3h.
An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) saturated with 
10mM Tris pH8.0 and 1mM EDTA (Sigma) was added and mixed gently on a 
rotator for 10min and then a further 20min if an emulsion had not formed. Phases 
were separated at 3,000g for 10min. The aqueous phase was removed and an 
equal volume of chloroform was added, and the tube vortexed, before being 
centrifuged as above. DNA was precipitated from the aqueous phase with 0.1 
volumes 3M sodium acetate (NaOAc) pH5.2 and 2 volumes of ice-cold ethanol, 
mixed gently and pelleted at 5,000g for 5min. The pellet was washed with 1ml 70%  
ethanol and then the ethanol was removed. Residual ethanol was left to evaporate, 
before the DNA was resuspended in Tris-EDTA buffer (TE buffer). DNA was 
redissolved on ice for 15min with occasional gentle mixing. Integrity of the DNA was
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checked by 0.8% agarose gel electrophoresis (2.3.2), before aliquoting and storage 
at -20°C.
2.3.2 Agarose Gel Analysis of DNA
Agarose gels were prepared at a variety of concentrations ranging from 0.8% to 
2%, depending on the size of the nucleic acid being analysed. Agarose (Ultrapure 
electrophoresis grade, Invitrogen) was melted in 1x Tris-acetate-EDTA buffer (TAE 
buffer; 0.04mM Tris, 0.001 mM EDTA, 0.02M acetic acid) and 2pl/100ml ethidium 
bromide (Sigma) added. The gel was set in a gel rig with the appropriate comb and 
then they were submerged in 1x TAE buffer. Samples (usually 5pl) were mixed with 
6x loading buffer (Sigma) prior to loading. DNA ladders (5pl of 1kb+ DNA marker, 
Invitrogen) were used as reference markers for the electrophoresis, unless 
otherwise indicated. DNA was electrophoresed and then visualised under UV and 
photographed using Gelworks software and camera (UVI).
2.3.3 Isolation of DNA from Agarose Gels
DNA bands were excised from ethidium bromide-stained agarose gels using sterile 
scalpels under UV. DNA was purified from the bands using the QIAquick gel 
purification kit (Qiagen) following the manufacturer’s instructions. This kit uses a 
silica gel membrane to capture the DNA.
2.3.4 Spectrophotometric Analysis of Nucleic Acids
Samples for spectrophotometric analysis were diluted in TE buffer to an appropriate 
volume and compared to a blank sample consisting of TE buffer alone. The 
concentration of nucleic acid was estimated as 1 absorbance unit at 260nm ( A 26onm) 
being equivalent to 50pg/ml dsDNA, 37|ig/ml ssDNA and 40pg/ml RNA. The ratio of 
absorbance at 260nm and 280nm (A26onm:A28onm) was also calculated, as ratios of 
1.8-2.2 indicate pure DNA/RNA with minimal protein contamination.
2.3.5 Restriction Endonuclease Digestion of DNA
Buffer systems and restriction endonucleases (Roche) were used according to the 
manufacturer’s recommendations. Generally, reactions were performed in 10pl 
volumes at 37°C for 1 h, with 10U of enzyme and up to 10pg of DNA.
2.3.6 Polymerase Chain Reaction
Various PCR protocols were used depending on the application. Generally PCR 
was performed using 40U/ml Taq polymerase (Invitrogen), 1x PCR buffer
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(Invitrogen), 1.5mM magnesium chloride (Invitrogen), 0.2mM deoxynucleoside 
triphosphates (dNTPs; Promega), 1pM each primer pair, and template in a final 
volume of 25jJ, using master mixes whenever possible. (Using master mixes 
involved preparing the PCR reagents for all reactions together before aliquoting out 
individual reactions and adding template.) The PCR cycling parameters were 5min 
at 95°C, followed by 30 cycles of 95°C (30s), 58°C (30s) and 72°C (30s), before a 
final elongation of 5min at 72°C and holding at 4°C. The products of the reaction 
were analysed by agarose gel electrophoresis (2.3.2).
2.3.7 Isolation of DNA from PCR Reactions
DNA was isolated from PCR reaction mixes using the QIAquick PCR purification kit 
(Qiagen) following the manufacturer’s instructions. DNA was captured from the 
reaction mixture by a silica gel membrane. Affinity of the DNA for the membrane 
was controlled by changing the ionic interactions between the membrane and the 
DNA.
2.3.8 Cloning of DNA Fragments
The pGEM-T Easy vector system (Promega) was used for all cloning procedures 
following the manufacturer’s protocol. This system employs a plasmid vector with a 
multiple cloning site within a beta galactosidase (lacZ) cassette, resulting in blue 
and white colonies, white indicating an insert. DNA fragments to be cloned were 
gel-purified (2.3.3) and then ligated at room temperature for 1h.
The transformed cultures were plated onto duplicate L-agar plates (Imperial) 
containing 100]ng/ml ampicillin, and which had been spread with 200jil of 100mM 
isopropyl p-D-thiogalactopyranoside (IPTG) and 20^1 of 50mg/ml 5-bromo-4-chloro- 
3-indolyl-p-D- galactopyranoside (X-gal) and left to absorb for 30min at 37°C prior to 
use. White bacterial colonies contained plasmids with successfully ligated inserts 
and were therefore selected over blue colonies.
Following isolation of plasmid DNA (2.3.9), the DNA was digested with the 
appropriate endonucleases (2.3.5) to check for the presence and orientation of any 
insert. One of the chosen endonucleases had a restriction site complementary to 
the plasmid, and the other had one matching the insert sequence. The size of the 
digested fragment would then indicate the orientation of the insert. A second digest 
was performed with a restriction enzyme cutting either side of the insert to show its 
size.
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2.3.9 Small Scale Preparation of Plasmid DNA
Single white colonies were picked from plates and used to inoculate 5ml L-broth 
(Imperial) containing 100jig/ml ampicillin. Cultures were incubated for 16h at 37°C  
with continuous vigorous shaking (180rpm). Each single colony was also dipped 
into a PCR reaction mix to be used as template for a colony PCR (2.3.6), which was 
used to confirm the identity of the insert. Briefly, the primers used in the colony PCR  
reaction were specific for the expected insert and thus successful PCR indicated 
that the correct insert was present. The overnight cultures were collected the next 
day by centrifugation and the QIAprep kit (Qiagen) used for plasmid isolation.
2.3.10 Bacterial Stocks
Bacterial stocks were prepared by freezing cultures in 25% glycerol, 75% L-broth 
(Imperial) at -80°C. To reculture the bacterial stock, a sterile pipette tip was stabbed 
into the frozen stock and used to inoculate L-broth containing ampicillin.
2.3.11 Sequencing
2.3.11.a Manual Sequencing
Plasmid DNA was isolated from 5ml bacterial cultures using the QIAprep kit 
(Qiagen; 2.3.9) and resuspended in 32pil H20 . The plasmid DNA was then prepared 
according to the manufacturer’s protocol (T7 sequenase v2.0 7-deaza-dGTP  
sequencing kit; Amersham). Briefly, plasmid DNA was denatured by adding NaOH  
to 200mM and EDTA to 20mM. This was mixed and incubated at room temperature 
for 5min. The DNA was then precipitated by adding 0.1 volumes 3M sodium acetate 
pH5.2 and 2.5 volumes ice-cold ethanol, and then incubating at -70°C, for at least 
30min. DNA was pelleted for 25min at 13,000g at 4°C, and then washed with 70%  
ethanol before the pellet was dried in a vacuum concentrator.
The manufacturer’s protocol was also followed to perform the actual dideoxy 
sequencing reactions.
Sequencing gel plates were thoroughly cleaned with ethanol and the smaller plate 
siliconised with Sigmacote (Sigma). Following assembly of the plates, 6x Gel-Mix 
(Invitrogen) was used to produce the polyacrylamide sequencing gel following the 
manufacturer’s instructions. Briefly, gel polymerisation was initiated with the 
addition of ammonium persulphate and a 0.4mm gel poured between the 
sequencing gel plates. Following 40min at room temperature to allow the gel to set, 
the glass plate spacers were removed and the gel prerun in a vertical sequencing
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gel tank (Invitrogen) for 1h at 50-70W  to equilibrate the gel with TBE buffer (0.089M  
Tris, 0.089M Boric acid, 0.002M EDTA).
Once the samples had been prepared as per the manufacturers instructions, they 
were denatured at 80°C for 2min and half of each sample was loaded into wells to 
be electrophoresed at 50-70W  for 2h or until the loading dye’s frontline had run out 
completely. The remaining half of each sample was then denatured and loaded into 
adjacent lanes on the gel, for the second run. Therefore, each sample was 
electrophoresed twice, a long 4h run and a short 2h run.
Once finished the glass plates were carefully prised apart and 3MM paper 
(Whatman) used to remove the gel. The exposed side was covered in cling film and 
the gel dried under vacuum at 80°C for 1h before being exposed to film.
2.3.11.b Automated Sequencing
Automated sequencing was performed using the Beckman Coulter CEQ2000XL  
Sequencer and CEQ Dye Terminator Cycle Sequencing kit (Beckman) following the 
manufacturers’ recommendations. Analysis of the resulting output was performed 
using ABI Prism software.
2.3.12 Total RNA Isolation
Special care to avoid RNAse contamination was taken for all procedures involving 
RNA. Separate chemical solutions for RNA work were prepared to minimise RNAse 
contamination. These were prepared from separate chemical stocks and diethyl 
pyrocarbonate-treated water (DEPC-H20 ). All apparatus used for RNA work was 
kept separate where possible, and cleaned regularly with DEPC-H20 . RNAse-free 
DEPC-H20  was prepared by adding 1ml DEPC to 11 H20 . This mixture was shaken 
vigorously to dissolve the DEPC and then left to stand for 16h. Finally the DEPC- 
H20  was autoclaved before use.
This RNA isolation protocol consisted of several steps: initial RNA isolation, DNAse 
treatment and re-isolation of RNA.
2.3.12.a RNA Isolation
Tissue culture samples were prepared by removing media and adding 1 ml Trizol 
per 106 cells directly. Samples were then vortexed vigorously for 1min before being 
left to stand on ice for 5min. Chloroform (0.2ml) was added and vortexed for 1min, 
before being placed on ice for 2min. Phases were separated by centrifugation at 
15,000g for 10min at 4°C. The upper aqueous phase was transferred to a fresh
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tube, being sure to avoid the interphase and RNA precipitated with an equal volume 
of isopropanol for 10min on ice and then pelleted at 15,000g for 30min at 4°C. RNA 
was washed with 1ml 80% ethanol and then repelleted at 15,000g for 5min at 4°C, 
before resuspending the RNA in 88jil DEPC-H20 .
2.3.12.b DNAse I Treatment
DNAse buffer (10pl of 10x stocks: 400mM Tris-HCI pH7.5, 100mM NaCI2, 60mM  
MgCI2) and 2pl DNAse I (10U/jnl, Roche) were added to the sample and incubated 
at 37°C for 30min, at which time 10pl 0.1M EDTA pH8.0 was added to terminate the 
reaction.
2.3.12.c Phenol Chloroform Extraction
The RNA solution was made up to 500jil with DEPC-H20  and phenol:chloroform 
extracted: An equal volume of phenokchloroform 5:1 pH4.7 (Sigma) was added and 
then vortexed for 1min, before incubation on ice for 5min. A further 0.2ml 
chloroform was then added, vortexed for 1min, and placed on ice for 2min. Phases 
were then separated by centrifugation at 15,000gfor 10min at 4°C.
The upper aqueous phase was transferred to a fresh tube, being sure to avoid the 
interphase and RNA precipitated with 0.1 volumes 3M NaOAc pH5.2 and 2.5 
volumes ice-cold ethanol at -80°C  for at least 2h. RNA was pelleted at 15,000g for 
30min at 4°C, washed with 1ml 80% ethanol and then repelleted at 15,000g for 
5min at 4°C, before resuspending the RNA in an appropriate volume of DEPC-H20  
(usually 10-20pl).
2.3.13 Denaturing Gel Analysis of RNA
All RNA was tested for quality by electrophoresis on a denaturing gel and by 
spectrophotometry (2.3.4).
Denaturing agarose gels were prepared by melting 1g agarose in 74ml H20  and 
10ml 10x MOPS buffer (0.2M MOPS, 0.05M, 0.001 M EDTA pH7.0). This was 
allowed to cool to room temperature before addition of 16ml 37% formaldehyde. 
The gel was then poured into a gel rig and left to set, at which stage 1x MOPS  
buffer was added as running buffer.
Two volumes of 1.5x RNA loading buffer (1.5x loading dye (0.06% w/v 
bromophenol blue, 0.06% w/v xylene cyanol), 1.5x MOPS buffer, 9% formaldehyde, 
60% deionised formamine, 5% ethidium bromide) was added to 5ml of each RNA 
sample, and samples denatured at 65°C for 15min before chilling on ice.
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The gel was prerun for 5min at 20V before samples were loaded, and then run until 
the dye had reached approximately two-thirds down the gel. RNA was visualised on 
a UV lightbox.
2.3.14 Analysis of RNA Using RNA LabChips
The manufacturer’s protocol was followed to setup and perform RNA analysis on 
RNA LabChips using a Bioanalyser 2001 (Agilent). Briefly, the fluorescent 
nucleotide dye was mixed with the gel matrix, before being injected into the micro 
capillaries of the RNA LabChip under pressure. The RNA samples were then 
loaded onto the LabChip, along with the supplied RNA marker. The RNA was 
electrophoresed through the microcapillary channels and fluorescence at a set 
point, measured as a function of time. Electropherograms were generated for each 
sample and analysed for signs of RNA degradation.
2.3.15 Northern Blot Analysis
2.3.15.a Northern Blotting
RNA was electrophoresed on a denaturing gel (2.3.13), ensuring that the same 
amount of RNA was loaded in each lane. RNA was visualised briefly on a UV 
lightbox and a picture taken of the gel with a ruler lined up for future reference.
The gel was placed on 3MM paper (Whatman) as shown in Fig. 2.2 and nylon 
membrane (Hybond N+, Amersham) positioned to line up with the wells of the gel. 
The top left corner was cut to aid orientation. Cling film was used on the edges of 
the membrane to prevent shorting of the circuit (i.e. to ensure that no liquid 
bypassed the nylon membrane). The rest of the apparatus was assembled as 
shown and left for 16h.
The membrane was then lifted off avoiding contact with possible sources of nucleic 
acids and the RNA covalently bonded to the nylon by UV irradiation (Strategene).
2.3.15.b Synthesis of Probe for Northern Blot Analysis
An appropriate sequence was selected to be the probe sequence, usually 100- 
500bp in size, and the appropriate primers synthesised commercially (MWG  
Biotech). These primers were used to amplify the probe sequence by PCR from a 
sequence-verified plasmid containing the appropriate DNA insert, and then gel 
purified (2.3.3). The DNA was quantified by electrophoresis on an agarose gel 
along with a quantitative ladder (Bioline).
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The High Prime DNA labelling kit (Roche) was used to produce a 32P-labelled 
probe, following the manufacturer’s instructions. The labelled probe was purified 
using the Nucleospin kit (a silica gel membrane based capture column; Clontech).
Weight
 Stack of paper
Transfer solution 
reservoir
3MM paper 
Nylon membrane 
.Agarose gel
y Gel support
Transfer solution
3MM Whatman 
filter paper wick
Figure 2.1. Diagrammatic representation of apparatus involved in setting up a northern blot.
2.3.15.C Hybridisation and Washing
Membranes were prehybridised in 10ml hybridisation solution (Expresshyb, 
Clontech) containing 1 mg/ml denatured salmon sperm DNA (Sigma) at 65°C for 1h 
in a rotating incubator (Hybaid). The hybridisation solution was then discarded and 
replaced, and 1 mg/ml denatured salmon sperm DNA and probe added for 
hybridisation at 65°C for 1h. The membrane was then washed 3 times in 10ml 2x 
saline-sodium citrate (SSC) buffer (0.03M sodium citrate pH7.0, 0.3M sodium 
chloride), 1% sodium dodecyl sulphate (SDS) for 15min each at room temperature. 
The membrane was then washed again in 10ml 0.1X SSC buffer, 0.5% SDS, 3 
times for 15min each at 58°C. Finally the membrane was wrapped in cling film 
(being careful to avoid bubbles) and visualised by autoradiography or using a 
phosphor screen and imager.
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2.3.16 cDNA Synthesis
Typically for reverse transcription (RT), 2-5jig total RNA, 1x first strand buffer 
(50mM Tris-HCI pH8.3, 75mM potassium chloride, 3mM magnesium chloride; 
Invitrogen), 1mM dithiothreitol (DTT; Invitrogen), 1mM dNTPs, 0.25^iM primers and 
2.5U/^il Mouse Moloney murine leukemia virus (MMLV) reverse transcriptase (RT; 
Invitrogen) were combined in a total volume of 20pil of DEPC-H20 , and incubated at 
42°C for 15min. The reaction was then terminated by 5min incubation at 99°C and 
then cooled to 4°C.
If specific primers were to be used for reverse transcription, then the RNA and 
primers were denatured and annealed by heating to 70°C for 5min and then placing 
on ice. If anchored oligo-dT primer was used then the complete reaction mix was 
incubated at room temperature for 10min prior to the incubation step.
2.3.17 Stripping Membranes for Re-hybridisation
If blots were to be used again, they were stripped: 500 ml 0.5% SDS was boiled 
and then poured into a plastic container with lid. The membranes were immersed in 
the SDS solution and agitated for 1h. Each stripped membrane was then checked 
for any remaining hybridised probe, using a phosphor screen and imager. If residual 
signal was detected, the stripping process was repeated. Care was taken to prevent 
the blots from drying out.
2.3.18 Differential Display
2.3.18.a cDNA Synthesis
Two pg of RNA was mixed with anchored oligo-dT at 0.2pM in a volume of 5jliI 
DEPC-H20  and spun briefly. The mixture was heated to 70°C for 3min and then 
placed on ice for at least 2min before a short centrifugation.
1x first strand buffer (Invitrogen), 1mM dNTPs and 5U/jliI MMLV RT (Invitrogen) 
were added to the RNA and primer mixture to make a total volume of 1 OjllI, using 
master mixes when possible. This was mixed and centrifuged briefly before 
incubating at 42°C for 1 h, 75°C for 10min and then placed on ice.
Each reaction was split into two and diluted: 8pl into 80jliI water (cDNA A) and 2jnl 
into 80pl water (cDNA B). Samples could be stored at -20°C at this stage.
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2.3.18.b Differential Display PCR
The differential display PCR (ddPCR) protocol used a number of degenerate primer 
pairs to generate DNA ‘fingerprints’. Combinations of 5 primers were used initially to 
test the system.
Both dilutions of cDNA were used with each differential display primer combination, 
as was a negative H20  control (H20  instead of cDNA). Furthermore, a number of 
negative RNA controls (RNA instead of cDNA) were also run. This resulted in a 
large number of reactions and therefore tables such as Table 2.2 were employed to 
avoid confusion.
One jul of the cDNA sample was mixed with 1pl each of the two primers to be used. 
The cDNA was substituted with H20  and RNA as appropriate for the controls.
A master mix for the reaction was prepared by combining KlenTaq PCR reaction 
buffer (40mM Tricine-KOH pH9.2 at 25°C, 15mM KOAc, 3.5mM MgOAc, 3.75^g/ml 
bovine serum albumin; Clontech), 50pM dNTPs, Advantage Klentaq polymerase 
and hotstart antibody mix (1% glycerol, 0.8mM Tris-HCI pH7.5, 1.0mM KCI, 0.5mM  
(NH4)2S 0 4, 2.0mM EDTA, 0.1 mM (3-mercaptoethanol, 0.005% Thesit; Clontech), 
50nM [a-33P]dATP (1000-3000 Ci/mmol; Amersham) and ddH20  in a final volume of 
17pl per reaction. The master mix was vortexed and spun briefly before adding to 
the cDNA and primers.
The reaction mixes were cycled as follows:
95°C 5min
40°C 5min
68°C 5min
94°C 30s }
40°C 30s } 2 cycles
68°C 5min }
94°C 20s }
60°C 30s } 23 cycles
68°C 2min }
68°C 7min
4°C hold
Following the ddPCR, reaction mixes could be stored at -20°C .
73
Table 2.1 Sequence of primers used for ddPCR
Name Sequence (5’-3’)
P1 ATTAACCCT CACT AAAT GCT GGGG A
P2 ATTAACCCT C ACT AAAT CGGT CATAG
P3 ATTAACCCTCACTAAATGCTGGTGG
T8 C ATTAT GCT G AGT GATAT C I I I I I T IT IGC
T9 C ATT AT GCT G AGT GATAT C 1 1 1 1 1 1TT IGG
Table 2.2 Sample organisational and labelling chart for setting up ddPCR
Tube cDNA Tube cDNA
Label Sample Primers Label Sample Primers
Experimental displays Water controls for each primer pair
1 1A P1 & T9 H1 Water P1 & T 9
2 1B P1 & T9 H2 Water P1 & T8
3 2A P1 & T9 H3 Water P2 & T9
4 2B P1 & T9 Etc.
5 1A P1 &T8 Total RNA controls for each RNA
6 1B P1 &T8 (Use any of above primer pairs)
7 2A P1 &T8 R1 RNA 1 P1 & T9
8 2B P1 &T8 R2 RNA 2 P 1 & T 9  
Etc.
9 1A P 2& T 9
10 1B P 2& T 9
11 2A P 2& T 9
12 2B P 2& T 9
Etc.
2.3.18.c Electrophoresis and Autoradiography
A denaturing polyacrylamide urea gel was prepared and prerun (2.3.11.a). Five pi 
of each PCR reaction was mixed with 5pl of ddPCR loading buffer (95% formamide, 
0.2% bromophenol blue, 0.2% xylene cyanol), denatured at 95°C, 2min and then 
placed on ice. Two pi of each reaction was loaded and the gel run at 70W  for 2h or 
until the xylene had run out of the gel. Each reaction was then loaded again and the 
gel run for another 2h resulting in a long and short run. The gel was dried (2.3.11.a) 
and exposed to a phosphor screen (Fuji BAS Image Analysis System). After 
reading on the phosphoimager, the gel was carefully aligned and used to expose a
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film. Three corners of the gel and film were cut to aid location of bands of interest 
on the gel.
2.3.18.d Purification of DNA Fragments from Dried Acrylamide Gels
Following analysis of the differential display, bands of interest were identified and 
located on the autoradiography film. The film was then lined up with the dried gel 
and the two taped together. The positions of bands identified on the film were 
marked on the gel by pushing a sharp pin through both surfaces. The film was then 
removed and bands cut out of the gel using a fresh scalpel for each one. Care was 
taken to cut out gel fragments without taking any paper. Gel fragments were 
transferred to 0.5ml tubes containing 40pJ of TE buffer. These were heated at 
100°C for 5min to melt the agarose and release the DNA into the TE buffer. At this 
stage samples could be stored at -20°C .
Gels were re-exposed and visualised to confirm that the correct bands had been 
excised.
2.3.18.e Reamplification of Bands of Interest
Seven pi of the DNA solution (2.3.18.d) was used as a template for PCR to amplify 
the band of interest. The DNA solution was mixed with KlenTaq PCR reaction buffer 
(2.3.18.b), 50pM dNTPs, Advantage KlenTaq polymerase and hotstart antibody mix 
(2.3.18.b), 1pM of each primer that was used originally to produce the band and 
sterile water in a final volume of 50pl.
This reaction mix was cycled at 94°C for 1min, 60°C for 1min and 68°C for 2min for 
a total of 20 cycles, before 10pl was analysed by electrophoresis through a 2%  
agarose gel.
2.3.18.f Northern Blot Confirmation of ddPCR
The reamplified band of interest was excised and purified from the gel (2.3.3) and 
then cloned into a plasmid (2.3.8). This plasmid was then purified (2.3.9) and 
sequenced (2.3.11) to identify the band of interest. Finally, the plasmid was used to 
prepare probe for a northern blot analysis (2.3.15) to confirm the differential 
expression seen with the ddPCR.
2.3.19 Preparation of Probes for DNA Arrays
Primers were designed to PCR amplify approximately 300bp fragments of DNA 
from the 5 ’ end of each predicted MHV-68 ORF. In addition to the predicted ORFs,
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inter-gene regions of MHV-68’s genome of greater than 100bp were also included. 
If the inter-genic regions exceeded 300bp (e.g. approximately 840bp between ORF 
K3 and M5) then two cDNA were amplified to correspond to the 5’ end of a potential 
transcript that could be transcribed in either direction. Appendix I list the primers 
used for generation of probe cDNA sequences.
The following genes were chosen as positive and negative hybridisation controls: 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; accession no. NM008084), 
myosin 1 (L00923), murine ornithine decarboxylase (MOD; M10624), (3-actin 
(X03672), calcium binding protein (Cab) 45 (U45977), ribosomal protein S29 
(NM009093), ubiquitin (AF285162), phospholipase A2 (D78647), hypoxanthinie 
phosphoribosyl transferase (HPRT; J00423), pBluescript II (SK+) plasmid 
(Stratagene), tobacco mosaic virus (TMV) 180kDa protein (D78608) and water. 
Luciferase (E15166) was included as an internal control for normalisation of arrays.
All PCR products were cloned into pGEM-T Easy vectors (2.3.8) and the presence 
of the correct insert verified by PCR (2.3.6) with insert-specific primers, and the 
presence of a single insert verified by PCR with pGEM-T Easy vector-specific 
primers (5’-CCA TGG CGG CCG CGG GAA TT-3 \ 5’-GGC GGC CGC GAA TTC  
ACT AG-3’). Finally, the sequence of the DNA insert was verified (2.3.11.b) to 
ensure that there had been no misincorporation of bases during the PCR  
amplification.
DNA species were then reamplified from the relevant plasmids using a high yield 
PCR protocol: 1x PCR buffer (Invitrogen), 1.5mM MgCI2> 2mM dNTPs (Promega), 
4^M pGEM-T Easy vector-specific primers, 50U/ml Taq polymerase (Invitrogen) 
and 30pg/jil template in a final volume of 10Ojul, using master mixes whenever 
possible. This reaction was incubated for 5min at 95°C, followed by 30 cycles of 
95°C (30s), 55°C (30s) and 72°C (30s), before a final elongation of 5min at 72°C, 
and then placed on ice. The amplified probes were purified (2.3.3) and then 
analysed by spectrophotometry (2.3.4). This protocol returned yields of 
approximately 5^g per reaction.
2.3.20 Vacuum-Spotting DNA Arrays
DNA (800ng) was made up to 1 OOjli.1 with Tris buffer (10mM Tris-HCI pH8.5) and 
then denatured at 95°C for 5min, before placing on ice. Each sample was 
denatured with 1vol 20x SSC.
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The Bio-Dot microfiltration apparatus (Bio-Rad) was assembled according to the 
manufacturer’s instructions using Hybond N+ nylon membrane (Amersham) 
prewetted in 10x SSC, and 2 sheets of Bio-Dot filter paper (Bio-Rad), also 
prewetted. A corner of the membrane was cut to aid orientation. Briefly, 200pl of 
10x SSC was drawn through the wells under a gentle vacuum twice, and then 
followed by the actual samples. A further 200jliI of 10x SCC was drawn through and 
then the apparatus was disassembled and the membrane placed on several sheets 
of filter paper soaked in denaturing solution (1.5M NaCI, 0.5M NaOH) for 5min. The 
membrane was then transferred to several sheets Of filter paper soaked in 
neutralising solution (1.5M NaCI, 0.5M Tris-HCI pH7.2, 1mM EDTA) for 5min, 
before drying and cross-linking (Stratagene). Arrays were stored in cling-film at 4°C. 
The layout of these vacuum-spotted arrays is shown in Appendix II.
2.3.21 Automated Manufacture of DNA Arrays
The Beckman Biomek 2000 robot was programmed to print arrays using the 
integrated tools. Each probe was spotted in triplicate at 4 concentrations: 100ng/^l, 
50ng/pl, 25ng/|ul, 12.5ng/pl, onto Hybond N+ nylon membranes (Amersham). The 
layout of these Biomek arrays is shown in Appendix II.
2.3.22 Manually Spotted DNA Arrays Using the Multiblotter Pin-Tool
Arrays were spotted with 50ng of probe DNA in duplicate onto Hybond N+ nylon 
membranes (Amersham) using a 384-pin multiblotter (V&P Scientific) and the 
membranes denatured prior to use (2.3.24). Arrays were stored at room 
temperature in sealed bags. The layout of these pin-tool arrays is shown in 
Appendix II.
2.3.23 Automated Manufacture of Oliqo Arrays
Oligonucleotide-based arrays (oligo arrays) were manufactured using a robot 
system (Rosetta and Agilent). The arrays were manufactured by the array group at 
Arrow Therapeutics, following standardised protocols. Briefly, probes were 
synthesised in situ on glass slides using standard phosphoramidite chemistry. Each 
feature on the array was individually spatially addressed by 2 ink-jet printer nozzles, 
one providing a tetrazole activator (necessary for the coupling reaction), and the 
second providing the appropriate base monomer for that layer's addition. The 
ancillary reagents for DNA synthesis (oxidiser, deblocking reagent and acetonitrile 
washes) were delivered by flooding across the array. The layout of these oligo 
arrays is shown in Appendix II.
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2.3.24 Denaturing Probes Spotted on DNA Array Membranes
Arrays with probes that had not been denatured prior to spotting were placed on 
filter paper soaked with denaturation buffer (0.66M NaCI, 0.5M NaOH) for 10min 
and then washed in ddH20  for 10min and finally in 40mM phosphate buffer pH7.3 
for 10min. Membranes were then dried and stored in plastic at 4°C.
2.3.25 Preparation of Radiolabelled cDNA Target for DNA Array 
Analysis
Labelled cDNA target for hybridisation to arrays was prepared by reverse 
transcription of RNA, whilst incorporating radiolabelled nucleotides. Generally, 10pg 
RNA (2.3.12; 2.3.13) was spiked with 10ng luciferase RNA (2.3.29), and primed 
with a mixture of primers complementary to the 3’ sequence of the DNA probes 
(0.2mM; array primer mix). The RNA and primers were annealed by incubating at 
70°C for 5min and then placed on ice.
The reverse transcription was carried out in 1x first strand buffer, 1mM DTT, 1mM 
dT/G/CTP, 2.5pCi/pl [<x-33P] dATP (2500 Ci/mmol, Amersham) and 5U/pl 
Superscript II reverse transcriptase (Invitrogen), combined in a total volume of 20pl. 
The reaction mixture was incubated at 50°C for 90min, before terminating with 1 jil 
100mM EDTA and placing on ice.
The labelled target was purified using the Nucleospin kit (Clontech) and denatured 
at 95°C for 5min prior to hybridisation.
2.3.26 Preparation of Fluorescentlv-labelled cDNA Target for Oligo 
Array Analysis
Labelled cDNA target for hybridisation to arrays was prepared by reverse 
transcription of RNA, whilst incorporating fluorescently labelled nucleotides. 
Generally, 10pg RNA (2.3.12; 2.3.13) spiked with 10ng luciferase RNA (2.3.29), 
was primed with random hexamers (0.2mM). RNA and primers were annealed by 
incubating at 70°C for 5min and then placing on ice.
The reverse transcription was carried out in 1x first strand buffer, 1mM DTT, 1mM 
dT/G/ATP, 0.05mM Cy5-dATP (NEN) and 5U/^I Superscript II reverse 
transcriptase, combined in a total volume of 20pl, and incubated at 37°C for 16h. 
The reaction was then terminated with 1.5 pi 20mM EDTA. The RNA was 
hydrolysed by adding 15pl freshly prepared 0.1M NaOH and incubating at 70°C for 
10min. Finally 15pl of 0.1 M HCI was added to neutralise the alkali.
78
The labelled target was purified using the QIAquick PCR purification kit (Qiagen), 
following the manufacturer’s protocol except for using ddH20  as the final elutant. 
The labelled target was denatured at 95°C for 5min prior to hybridisation.
2.3.27 DNA Array Hybridisation
Membranes were prehybridised in the hybridisation solution (Expresshyb, Clontech) 
containing 1 mg/ml denatured salmon sperm DNA and 0.1 mg/ml murine C0T-1 DNA 
(Invitrogen) at 60°C for at least 30min in a rotating incubator. The hybridisation 
solution was then discarded and replaced along with fresh denatured salmon sperm 
DNA and C0T-1 DNA. Finally the denatured target was added and hybridised to the 
array at 60°C for 16h. The membrane was then washed 3 times in 2x SSC buffer, 
1% SDS for 15min each at room temperature. The membrane was then washed 
again in 0.1X SSC buffer, 0.5% SDS, 3 times for 15min each at 60°C. Finally the 
membrane was wrapped in cling film and placed on a phosphor screen.
2.3.28 Oligo Array Hybridisation
The glass arrays were placed into hybridisation chambers and hybridisation solution 
added (1M NaCI, 1 x MES buffer pH6.4, 20mM EDTA, 20% formamide, 1% TritonX 
100). Denatured target was then injected into the chamber. The hybridisation was 
performed for 16h at 75°C in a rotating incubator. The arrays were then washed in 
Rosetta buffer 1 (6 x SSPE, 0.005% sarcosine) for 5min and then Rosetta buffer 2 
(0.06 x SSPE, 0.18% PEG 200) for 5min. Finally, the arrays were dipped in ether 
and air-dried with the aid of a compressed air gun. Dry arrays were stored away 
from light until ready to be scanned.
2.3.29 SP6 RNA Polymerase Amplification of Luciferase RNA
The SP6 Ribomax RNA amplification kit (Promega) was used to produce luciferase 
RNA, following the manufacturer’s protocol. Briefly, linear dsDNA encoding a SP6 
RNA polymerase promotor and the luciferase gene (Promega) was used as 
template. The template was added to the reaction buffer, ribonucleotides and T7 
RNA polymerase, and incubated at 37°C for 4h. The DNA template was then 
removed by digestion with DNAse I. The RNA was purified by a standard phenol 
chloroform extraction, and then precipitated with NaOAc and ethanol (2.3.12.c). The 
precipitation step was performed 3 times to remove unincorporated nucleotides.
The resulting luciferase was electrophoresed through a denaturing RNA gel (2.3.13) 
to confirm that a single sized RNA species was present and then quantified by
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spectrophotometry (2.3.4). The luciferase RNA was stored in 1 mg/ml aliquots at - 
80°C.
2.4 Bioinformatics and Data Analysis
2.4.1 Statistical Tests and Measures
Statistical analysis was routinely employed on all datasets that were of sufficient 
size. Commonly applied tests and measures included calculating the correlation 
coefficient, standard deviation and coefficient of variation.
2.4.2 Basic Local Alignment Search Tool
Sequence similarity searches were performed using programs employing the 
BLAST (basic local alignment search tool) algorithm (Altschul, 1990), if query 
sequences were more than 100bp in length.
2.4.3 FastA
The FastA program, version 34t10d3 (Pearson, 1988), was used to compare 
sequences to a database of reference sequences. Alignments were forced to be 
based on the Smith-Waterman algorithm (Smith, 1981), and default parameters 
used for all other options.
2.4.3.a Cluster
Gene expression profiles were transformed onto a relative scale so that peak 
transcript abundance = 1, and then onto a logarithmic scale by taking the square 
root of each data point. This transformed data was analysed by pairwise 
comparisons using the Cluster algorithm (Eisen, 1998). The program was 
configured to perform hierarchical clustering using the average-linkage algorithm 
and an uncentred correlation matrix. The results of these analyses were visualised 
with Treeview software (Eisen, 1998).
2.4.4 Design of Oligonucleotide Primers for PCR
Primers were designed using the Primer3 software developed by the Whitehead 
Institute for Biomedical Research (Rozen, 2000). Primers for PCR were designed 
using the following parameters:
•  Primer size -  minimum 18bp, optimum 20bp, maximum 22bp.
•  Primer melting temperature -  minimum 58°C, optimum 60°C, maximum 
62°C.
•  Primer GC content - minimum 40%, optimum 50%, maximum 60%.
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•  3 ’ GC clamp -  2bp
•  All other variables were left at default values.
2.4.5 Design of the Oligo Array Probeset
The MHV-68 genome was split into 100bp sections and one 60-mer oligonucleotide 
probe was designed for each 100bp section using Hotspots software (Arrow 
Therapeutics, London). Where possible, the oligonucleotide probes were designed 
to match up with the DNA probes used for the DNA array so that comparisons 
between the 2 platforms could be made at a later stage. The Hotspots software was 
used to analyse each 100bp section and identify regions of low cross-hybridisation 
potential. The software then calculated the thermodynamic characteristics of every 
probe that could potentially represent these regions. Probes were then selected by 
the software based on thermodynamic profile best matches to the hybridisation 
conditions and to the other probes on the array. Probes exhibiting self­
complementarity and defined 'tip' sequences that produce aberrant hybridisation 
results were excluded by the software . This part of designing the probeset was 
performed by the array group at Arrow Therapeutics.
To check the validity of probes designed by the custom software, all probes were 
aligned against the whole genome sequence for MHV-68 using the FastA algorithm 
to ensure that each probe matched MHV-68’s genomic sequence (2.4.3). The 
probes were also aligned against MHV-68 ORF sequences and the DNA array 
probe sequences.
Any probes that did not match the genomic sequence uniquely and perfectly were 
removed from the probeset. Any probes found to extend beyond the limits of an 
ORF were also discarded. Finally, any probes that showed complementarity to 
more than one ORF, were discarded as well.
All probes that matched with the DNA array probe sequences were highlighted for 
later comparison to DNA array data. Probes that were incomplete matches to the 
DNA array data were also noted.
Each probe was replicated 5 times in the probeset, and then randomly allocated a 
position on the array. The overall design was inputted to the Rosetta/Agilent robot 
for manufacture of the arrays (2.3.23). The oligo array probeset is listed in Appendix 
III.
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2.4.6 Quantification of DNA Array Data
Hybridised arrays were used to expose SR phosphor screens (Packard). Screens 
were scanned with the Cyclone Storage Phosphor System and analysed with 
Optiquant software (Packard). Quantification of signals on arrays was standardised: 
scanned images were overlaid with a fixed template, which defined signal regions 
corresponding to probes on the array. Quantified signal values were imported into 
spreadsheet software for further analysis. Replicate signals on each array were 
averaged (mean) and background subtracted. Background was defined as the 
hybridisation signal value of negative control probes on the array (pBluescript II 
plasmid and TMV 180kDa protein). All signal values were then normalised to the 
internal control luciferase to give a signal ratio that was relative to 10ng luciferase 
mRNA.
2.4.7 Quantification of Oligo Array Data
Each Agilent array was quantified using a DNA microarray scanner with 5pm 
resolution and 2 lasers, with confocal autofocus (Agilent). The image analysis 
software on the scanner produced a TIFF file and identified probes on the array 
image, based on the oligo array design template used to synthesise the probes. 
The software then removed background effects and identified features that were 
outliers and could therefore possibly distort the data. Finally, the software 
normalised the data for different dye incorporation rates and then calculated a 
differential gene expression value based on Cy5:Cy3 intensities if double-labelling 
was used, or returned absolute values if single colour labelling was used. The 
numerical values for each probe along with supporting statistical data were 
exported into spreadsheet software for further analysis.
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3 Differential Display
3.1 The Differential Display System
The differential display system is a powerful technique first developed by Liang and 
Pardee, that allows the comparison of two RNA populations, by highlighting any 
differences between them (Liang, 1992). In the instance of a viral infection, a 
differential display of the RNA population can highlight viral RNAs, as well as any 
host genes that are regulated by the virus. This provides a complete transcriptional 
representation of the effects of a viral infection in a host cell.
The aim of this study was to design and optimise a differential display system to 
examine MHV-68 infection in vitro. The changes in host and virus gene expression 
that occur during infection could then be analysed using the differential display 
system.
The original protocol (Liang, 1992) and various commercially available protocols 
(Clontech, GenHunter, Beckman Coulter) were examined. Of these, one protocol 
(Delta Differential Display System, Clontech) was chosen as the template protocol 
for this study, as it incorporates improvements made by various groups (Ralph, 
1993; Bauer, 1993; Wong, 1994). An overview of the protocol is shown in Figure 
3.1.
3.2 Preparation of RNA Template
High quality RNA template is essential for the differential display system as all 
subsequent steps are dependent on it. Two methods for isolation of RNA were 
assessed: A phenol:chloroform isolation (TRIzol, Invitrogen), and a silica gel 
isolation (RNAeasy, Qiagen). Both methods use a guanidium isothiocyanate 
denaturation step to release the RNA from cells with minimal RNA degradation. The 
first method then employs a standard phenohchloroform extraction to purify the 
RNA, whereas the second method uses a silica gel membrane to capture the RNA.
Total RNA was isolated from 106 BHK cells following the 2 protocols. The resulting 
RNA samples were separated on a denaturing agarose gel for comparison and also 
analysed by spectrophotometry. This showed that both methods returned similar 
quality RNA but that phenol:chloroform isolation resulted in increased yields of RNA 
(data not shown). In addition, the yield of RNA isolated in this way was further 
improved when all vortexing steps were increased to 1min. Therefore, all 
subsequent phenol:chloroform extractions used increased vortex times.
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RNA from uninfected sample RNA from infected sample
First strand cDNA synthesis 
using oligo dT primer
ss cDNA template 1 ss cDNA template 2
Differential display PCR using 
pairs of arbitrary primers
ddPCR products 1 (uninfected) ddPCR products 2 (infected)
Products are separated 
on 5% acrylamide gel
Primers: P1/T1 P2/T1 P3/T1 P1/T2 P2/T2 P3/T2
RNA sample: 1 2  1 2  1 2  1 2  1 2  1 2
Zkb
100 bp
DNA is isolated from differentially 
expressed bands. 
Differential expression is confirmed by
Differentially expressed DNA species are 
identified by searching their sequences 
against gene databases
Figure 3.1. Overview of the differential display protocol for identification of differentially 
expressed genes during MHV-68 infection.
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An example of RNA quality analysis, by separation on a denaturing agarose gel, is 
shown in Figure 3.2A. Both lanes 1 and 2 represent the same RNA sample, but at 
different quantities. Lane 2 was analysed by densitometry in Figure 3.2B. The 2 
largest peaks represent the 28S (4.8kb) and 18S (1.8kb) ribosomal RNA (rRNA) 
subunits. The low molecular weight peak consists of the 5S rRNA subunit and 
tRNAs. Finally, the 2 small high molecular-weight peaks represent the 45S and 32S 
rRNA precursors. If all of these peaks are detected, then the RNA is likely to be of 
good quality. Ideally, each peak should be well defined and sharp, indicating 
minimal degradation of RNA. In addition, the 28S rRNA peak should be higher than 
the 18S rRNA peak.
Each RNA sample was also analysed by spectrophotometry. Absorbance at 260nm  
was used to calculate yield. Absorbance at 280nm was used to indicate protein 
contamination; samples showing A260:A28o ratios below 2 were discarded as this 
indicated protein contamination.
5S&
tRNA’s
Figure 3.2. Denaturing agarose gel analysis of RNA samples.
A. Denaturing 1% agarose gel analysis of RNA isolated using TRIzol. RNA isolated from 5 x 
105 BHK cells was electrophoresed in Lane 1. RNA isolated from 2.5 x 105 BHK cells was 
electrophoresed in Lane 2. M represents the RNA marker (Invitrogen). B. Densitometric 
analysis of lane 2 (UVIsoft gel analysis software, UVItech). The peaks on the graph 
represent the ribosomal subunits. The identity of each ribosomal subunit is indicated.
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3.2.1 Minimising DNA Contamination
To minimise DNA contamination of RNA, all samples were incubated with DNAse I. 
PCR amplification of RNA template (Figure 3.3) was used to show that any DNA  
contamination had been removed. As the differential display was also PCR-based, 
this was a valid measure of DNA contamination for this system. Therefore, all 
subsequent RNA samples for the differential display were DNAse treated.
M 1 2
500bp - 
400bp -
Figure 3.3. Assessing DNA contamination of RNA samples.
RNA was isolated from BHK cells and then incubated with DNAse I to remove any DNA 
contamination. PCR amplification, using primers against (3-actin, showed that DNA 
contamination was removed by DNAse treatment. Lane 1 shows PCR amplification p-actin 
sequence from cDNA template, which was reverse transcribed from DNAse-treated RNA. 
Lane 2 shows PCR amplification p-actin sequence from DNAse-treated RNA template. M 
indicates the DNA marker (1kb+ marker, Invitrogen).
3.3 cDNA Synthesis
3.3.1 Yield of cDNA
The RNA samples are reverse transcribed to cDNA, which the differential display 
system uses as template to produce a “display”. To increase the quality and 
quantity of the cDNA template, the incubation time for cDNA synthesis was 
increased from 15min to 1 h, as suggested in some protocols (Ralph, 1993; Tal-
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Singer, 1998). Extending the incubation time would also increase the probability of 
rare RNAs being reverse transcribed.
RNA was reverse transcribed for 15min and 1h and separated on an agarose gel to 
confirm that cDNA yield was increased when incubation time was increased. Lanes 
1 and 2 of Figure 3.4 show cDNA produced following 15min incubation, while lanes 
3 and 4 show the results of 1h incubation. As more cDNA was produced when 1h 
incubation was used, subsequent cDNA was synthesised with 1h incubation.
M 1 2 3 4 5
5000kb - 
2000kb -
1000kb -
500bp -
Figure 3.4. Assessing yield of the cDNA synthesis reaction.
RNA was reverse transcribed using two different incubation periods. Both reactions were 
primed with oligo-dT. Lanes 1 & 2 show the cDNA resulting from a reverse transcription with 
a 15min incubation. Lanes 3 & 4 show the cDNA resulting from a reverse transcription with 
a 1h incubation. Lane 5 shows a control where H20  was used instead of RNA template. M 
indicates the DNA marker.
3.3.2 Integrity of cDNA
In Figure 3.4, single stranded DNA (ssDNA) was electrophoresed through an 
agarose gel. However, the DNA marker that was used was double stranded DNA  
(dsDNA). As these two forms of DNA possess different electrophoretic properties, it 
was not possible to be certain of the size range of cDNA produced by reverse 
transcription. As the size range of cDNA synthesised from RNA is an indicator of 
the quality, it is useful to ascertain the size of the cDNAs produced. Typically, cDNA  
produced from mammalian poly-A RNA ranges from 0.5 -  10kb in size (Chenchik,
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1995). Therefore, a similar size range was expected for cDNA derived from BHK 
cell RNA.
The single stranded cDNA shown in Figure 3.4 was therefore used to synthesise 
double stranded cDNA. This was electrophoresed through an agarose gel as shown 
in lane 1 of Figure 3.5. As a positive control, double stranded cDNA was 
synthesised from human placental poly-A RNA (Clontech) and this is shown in lane 
2. The dsDNA produced from BHK RNA ranged from around 100bp to more than 
10kb. The control reaction with human placental poly-A RNA showed similar 
results. This suggested that RNA of all sizes was successfully reverse transcribed 
to cDNA.
12kb -
1 kb -
100bp -
Figure 3.5. Size range of cDNA synthesised from BHK cell RNA.
dsDNA was synthesised from BHK cell RNA (lane 1), and as a control, from placental poly- 
A RNA (Clontech; lane 2). The products were separated on a 1.2% agarose gel. M indicates 
the DNA marker.
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3.3.3 Identification of the Limiting Factor in cDNA Synthesis
The previous experiments confirmed that cDNA synthesis was efficient, However, it 
was also important that the only limiting factor in the reaction was the amount of 
RNA template. This would ensure that reverse transcription was not terminated 
prematurely due to a lack of reagents, and would result in a cDNA population that 
was representative of the original poly-A RNA population. Therefore, three-fold 
serial dilutions of RNA (equivalent to 1 x 105, 3.3 x 104 and 1 x 104 BHK cells, 
respectively) were used as template to produce cDNA.
The reaction products were electrophoresed on a 2% agarose gel, as shown in 
Figure 3.6A, lanes 4 - 6. The intensity of each cDNA smear was calculated by 
densitometry (UVGelWorks software) to provide an estimate of the yield of each 
reaction. Plotting these measurements on a graph, as shown in Figure 3.6B, 
showed a linear relationship between the amount of RNA template and yield of 
cDNA (R2 = 0.995). This showed that RNA concentration was the limiting factor for 
cDNA synthesis, when the RNA isolated from 1 x 1 04 - 1 x 1 05 BHK cells was used.
The reverse transcription reaction was performed with 15min (lanes 1 - 3 )  and 1h 
(lanes 4 - 6 )  incubations. This confirmed again that increasing incubation time had 
a significant effect on yield, as the cDNA smears seen in lanes 4 - 6  were more 
intense than those in lanes 1 - 3 .
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A
M 1 2 3 4 5 6
1 4----------------------------------------- ,------------------------------------ ,
4 5 6
Lane
Figure 3.6. Effect of RNA template concentration and incubation time on yield of cDNA.
A. Two sets of cDNA synthesis reactions were performed with a 15min (lanes 1 -  3) and 1h 
(lanes 4 - 6 )  incubation period. Each set of reactions used 3-fold dilutions of RNA, 
corresponding to 1 x 105, 3.3 x 104 and 1 x 104 BHK cells, respectively. B. Linearity of cDNA 
synthesis. The cDNA yield was estimated by calculating signal intensities of each lane using 
UVGelWorks software. The results for lanes 4-6 were plotted to show that the relationship 
between quantity of RNA template and cDNA yield was linear.
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3.4 Differential Display of MHV-68 Infected and Uninfected 
Cells
3.4.1 Trial Run
As isolation of RNA and synthesis of cDNA was now optimised, the differential 
display PCR (ddPCR) step was investigated. RNA was isolated from 105 BHK cells 
and reverse transcribed. The Delta differential display protocol (Clontech) was used 
to provide primer sequences and reaction conditions for the ddPCR. The cDNA was 
diluted 1:10 and 1:40, and each dilution was PCR amplified separately. This served 
as an internal control and only results duplicated in both PCR amplifications would 
be considered valid.
Initially, 12 combinations of 5 degenerate primers (primers P1, P2, P3 and T8, T9) 
were used to amplify the cDNAs. P-primers refer to general degenerate primers and 
T-primers refer to anchored primers designed to bind to the poly-T tail of cDNA 
species. Unlabelled nucleotides were used for this trial run. Table 3.1 shows a 
scheme of the ddPCR reactions set up for this trial run.
The ddPCR was performed and each ddPCR amplification product was 
electrophoresed on a 1% agarose gel, as shown in Figure 3.7. A key to the reaction 
conditions represented in each lane of the gel can be found in Table 3.2 Each 
primer pair was used to amplify the 2 dilutions of cDNA, and also a water template 
reaction to act as a negative control. Initial analysis of the gel suggested that 
different primer pairs produced different amplification products. Also many more 
bands were seen on the gel for some primer combinations than others. For 
example the primer combination of P3T9 gave many bands while the P2T8 primer 
pair gave few bands.
Densitometry was performed on the gel image and lane profiles were calculated. 
Sets of 3 lanes representing each primer pair with the 2 dilutions of cDNA, and the 
relevant negative control were plotted together as shown in Figure 3.8. These lane 
profiles showed that the same products resulted from both cDNA template 
concentrations, and therefore each band could be considered a valid result. The 
water negative control lanes showed that there was little background signal present.
Another group of controls used BHK RNA as template for the PCR amplification. 
Lanes 19 & 20 show these controls. A few bands can be seen in these lanes. Any 
bands of the same size were disregarded. However, overall there were very few  
bands in the RNA control lanes, which increased confidence in the system.
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Table 3.1. ddPCR trial run setup.
Tube cDNA Tube cDNA
Label Sample Primers Label Sample Primers
Experimental displays Water CQntro|s for each prjmer pajr
1 1A P1 & T9 H1 Water P1 & T9
2 1B P1 & T9 H2 Water P1 &T8
3 1A P1 &T8 H3 Water P 2& T9
P2&
4 1B P1 &T8 H4 Water T8
5 1A P 2& T9 H5 Water P3 &T9
6 1B P 2& T9 H6 Water P3 &T8
7 1A P 2& T8
8 1B P 2& T8
9 1A P3 &T9
10 1B P3 &T9 Total RNA controls for each RNA
11 1A P3 &T8 R1 RNA P1 & T9
12 1B P3 &T8 R2 RNA/100 P1 & T9
Figure 3.7. Results of the trial ddPCR run.
A key to the reactions shown in each lane can be found in Table 3.2.
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Table 3.2. Key to the ddPCR reactions shown in Figure 3.7.
Lane 1 2 3 4 5 6 7 8 9 10
Primers P1T9 P1T8 P2T9 P2T8
Template cDNAA
cDNA
B H20
cDNA
A
cDNA
B H20
cDNA
A
cDNA
B H20
cDNA
A
Lane 11 | 12 13 14 15 16 17 18 19 20
Primers P2T8 P3T9 P3T8 P1T9
Template cDNAB H20
cDNA
A
cDNA
B H20
cDNA
A
cDNA
B H20
1ml
RNA
0.01ml
RNA
»;
iso
2C<
ICC
S'
Mmel rce itiM
1M 2CC 259 XC KC
25C-
ISO •
19
20
Figure 3.8. Lane profiles of trial ddPCR. Lane intensities were plotted to show the reaction 
products clearly, as well as the effects of diluting template.
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3.4.2 Radiolabelled Trial Run
As the ddPCR was producing a display, a second trial run was performed using 
radiolabelled nucleotides. For this trial, RNA was isolated from BHK cells 24h pi 
with MHV-68 (moi 10). As RNA was being isolated towards the end of the MHV-68  
life-cycle, the accumulation of a significant quantity of viral RNA was expected. 
Mock-infected BHK cells were used as a negative control. The experimental design 
was identical to that used for the first trial run, except for the inclusion of [a-33P] 
dATP in the reaction mix. The reaction details are summarised in Table 3.3.
The ddPCR reaction products were separated on a sequencing gel to allow greater 
resolution of the display. The gel was dried and used to expose both film and a 
phosphor screen. The phosphoimager was found to give a clearer and sharper 
picture than the film. The image, shown in Figure 3.9, shows 6 groups of 5 lanes 
each, which consist of 2 uninfected lanes (both cDNA concentrations), 2 infected 
lanes (both cDNA concentrations) and a negative control lane (water template), 
respectively. The final group of 6 lanes represent the RNA controls, one for each 
primer combination used.
There were many examples of differentially displayed bands in each group of lanes. 
Some of these are highlighted with black boxes in Figure 3.9. These bands, which 
were present in one lane and absent in another, are examples of those that could 
be analysed further, to potentially identify differentially expressed genes.
Again the two dilutions of each cDNA template gave the same profile, as seen in 
Figure 3.10A and Figure 3.1 OB, which shows the lane profiles of small sections of 
the gel. Differences between infected and control cells can be seen in panels C & D 
of Figure 3.10.
Unfortunately, only bands in the top half of the gel were clearly visible. To overcome 
this problem, each ddPCR reaction product was electrophoresed twice, once for 2h 
and once for 4h, to give a short and long run. The two runs allowed larger and 
smaller amplification products, respectively, to be analysed at the same time.
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Table 3.3. ddPCR hot run setup.
Lane 1 2 3 4 5 6 7 8 9 10
Primers P1T9 P1T8
Template Uninf.*A*
Uninf.
B*
Inf.*
A
Inf.
B H20
Uninf.
A
Uninf.
B
Inf.
A
Inf.
B H20
Lane 11 12 13 14 15 16 17 18 19 20
Primers P2T9 P2T8
Template Uninf.A
Uninf.
B
Inf.
A
Inf.
B H20
Uninf.
A
Uninf.
B
Inf.
A
Inf.
B H20
Lane 21 22 23 24 25 26 27 28 29 30
Primers P3T9 P3T8
Template Uninf.A
Uninf.
B
Inf.
A
Inf.
B H20
Uninf.
A
Uninf.
B
Inf.
A
Inf.
B H20
Lane 31 32 33 34 35 36
Primers P1T9 P1T8 P2T9 P1T9 P1T8 P2T9
Template RNAA
RNA
A
RNA
A
RNA
B
RNA
B
RNA
B
Uninf* -  uninfected 
Inf* -  infected
A* - less diluted 1:10 cDNA samples 
B* - more diluted 1:40 cDNA samples
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| P1T8 | P2T9 | P2T8 | P3T9 | P3T8
Figure 3.9. Differential display of MHV-68 infection.
BHK cells were infected for 24h at moi 10. RNA was isolated from these cells, as well as 
from a mock-infected control sample, and reverse transcribed. Each resulting cDNA 
sampled was diluted to 1:10 (A) and 1:40 (B) and amplified by ddPCR. The reaction 
products were electrophoresed for 2h and used to expose a phosphor screen. A section of 
the resulting image is shown. The primers used in each group of reactions are shown above 
each panel. The details of each reaction are summarised in Table 3.3. Each of the 6 groups 
of 5 lanes consists of uninfected cDNA dilution A, uninfected cDNA dilution B, infected 
cDNA dilution A, infected cDNA dilution B and a water control, respectively. The last group 
of 6 lanes consists of the RNA controls, with one lane for each primer pair. Examples of 
differentially expressed bands have been highlighted with black boxes.
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A Uninfected lane profiles. B Infected lane profiles.
C Infected and uninfected lane profiles. D Infected and uninfected lane profiles
Uninfected
Infected
Figure 3.10. Lane profiles of radiolabelled ddPCR trial run.
Sections of the gel were analysed using Bas software (Fuji). The profiles of 2 lanes are 
shown in each panel. A. Profiles of two adjacent lanes, both uninfected, showing the 
amplification of 2 concentrations of the same cDNA. B. Profiles of two adjacent lanes, both 
infected, showing the amplification of 2 concentrations of the same cDNA. C. & D. 
Contrasting profiles of an uninfected and infected lane, showing differentially expressed 
RNAs.
3.4.3 E xperim en tal Run
RNA was isolated from MHV-68 infected (moi 10) BHK cells and mock-infected 
BHK cells 24h pi, as described previously. cDNA was synthesised and used as 
template at two dilutions for the ddPCR amplification. The reaction products were 
separated on a sequencing gel for both 2h (short run) and 4h (long run). The gel 
was then dried and visualised by exposure to both film and a phosphor screen.
A scan of the gel is shown in Figure 3.11. As before there are 6 groups of 5 lanes
followed this time by a full set of 12 RNA control lanes. There were a number of
global differences between infected and uninfected lanes. The uninfected lanes had
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Uninfected
more bands than the infected ones, suggesting that there was a greater diversity of 
host-derived RNAs than viral ones. Most bands present in the uninfected lanes 
were absent in the infected lanes, suggesting that host protein synthesis shutoff 
was occurring. There were a significant number of bands present only in the 
infected lanes, which indicated that many viral RNAs were present in infected cells 
24h pi. There were also some bands that appeared to be present in both the 
uninfected and infected lanes, mostly at a lower intensity in the infected lanes. This 
suggested that some host-derived mRNAs were either still being transcribed at a 
lower rate than in uninfected cells, or that their transcripts had not degraded 24h pi.
Initially, 11 bands were selected for further analysis. Eight of these are shown in 
Figure 3.12. These differentially expressed bands fell into the following categories: 
Bands present only in uninfected lanes (Figure 3.12A & Figure 3.12B). Bands 
present only in infected lanes (Figure 3.12C & Figure 3.12D). Bands present in both 
uninfected and infected lanes but of reduced intensity in the latter (Figure 3.12E & 
Figure 3.12F). Bands present in both uninfected and infected lanes but of increased 
intensity in the latter (Figure 3.12G & Figure 3.12H).
Figure 3.11 (following page). Differential display of MHV-68 infection.
BHK cells were infected for 24h at moi 10. RNA was isolated from these cells, as well as 
from a mock-infected control sample, and reverse transcribed. Each resulting cDNA 
sampled was diluted to 1:10 and 1:40, and amplified by ddPCR. The reaction products were 
electrophoresed for 2h and 4h, to aid separation of the large range of product sizes. The gel 
was dried and visualised on a phosphoimager. A. A section of the resulting image is shown.
B. Part of the image in panel A is shown magnified. The primers used in each group of 
reactions are shown above each panel. Each of groups of lanes consists of 2 lanes 
corresponding to differential display amplification of uninfected samples (using 2 dilutions of 
cDNA dilution 1:10 and 1:40), 2 lanes corresponding to differential display amplification of 
infected samples (using 2 dilutions of cDNA dilution 1:10 and 1:40), and the fifth lane show 
a water template negative control. The last group of 12 lanes consists of the RNA controls, 
with one lane for each primer pair.
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RNA controls
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Figure 3.12. Examples of differentially expressed bands.
Each panel shows an example of a band that was differentially amplified from mock-infected 
and infected samples, as shown in Figure 3.11. Each panel shows 4 lanes representing 
uninfected cDNA dilution A (lane 1), uninfected cDNA dilution B (lane 2), infected cDNA 
dilution A (lane 3), infected cDNA dilution B (lane 4). A fifth lane (not marked) shows the 
water template control. A. & B. Bands representative of genes only expressed in mock- 
infected cells. C. & D. Bands representative of genes only expressed in infected cells. E. & 
F. Bands representative of genes expressed in mock-infected cells, but also to a lesser 
degree in infected cells. G. & H. Bands representative of genes expressed in mock-infected 
cells, but expressed at higher levels in infected cells.
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3.5 Elution of DNA from Differentially Displayed Bands
The bands selected for further analysis were marked on the autoradiography film 
and then lined up carefully with the gel. The bands were excised from the gel and 
the DNA eluted by boiling the gel fragments in TE buffer. The eluted DNA was 
reamplified by PCR reaction using the appropriate primers, which had produced the 
corresponding band at the ddPCR stage. To check that the bands had been 
correctly excised, the gel was used to expose a phosphor screen a second time 
and the absence of the selected band confirmed.
DNA was initially eluted from gel fragments by boiling in TE buffer for 20min. This 
DNA solution was used to reamplify the bands of interest. The reamplification 
products are shown in Figure 3.13. Only 6 of 11 bands were successfully 
reamplified. As an attempt to optimise the elution protocol, the incubation period for 
gel fragments in TE buffer was reduced to 10min. This resulted in an increased 
success rate for reamplification of bands. Of 14 bands excised from the 
polyacrylamide gel, 13 were successfully reamplified. The reamplification products 
are shown in Figure 3.14. Further DNA elutions were performed with a 10min 
incubation.
In some instances, several bands resulted following the reamplification of the DNA 
eluted from a single original band, as shown in Figure 3.14. This was due to the 
degenerate nature of the differential display primers used for this reamplification: 
The degenerate primers were designed to bind to more than one site on the DNA 
template. Also, more than one DNA species could be observed as a single band on 
the polyacrylamide gel if they possessed similar electrophoretic properties. In fact, 
both these phenomenon could be occurring at the same time.
If more than one DNA species was present in a single original band on the 
polyacrylamide gel, it was not clear which DNA species had been differentially 
expressed. Therefore, it was necessary to take all the reamplification products for 
further analysis and confirm which of these represented a differentially expressed 
gene. This was achieved by northern blot analysis.
Figure 3.15 shows the results of northern blot analysis for the reamplified DNA 
shown in lane 7 of Figure 3.14. A single DNA species was gel purified from the 
band seen in Figure 3.14, and used to produce a radiolabelled probe. The northern 
blot analysis confirmed that the DNA species represented a differentially expressed
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gene that was only expressed in MHV-68 infected cells. While most probably a viral 
gene, cloning and sequencing were required to positively identify this gene.
M 1 8 9 10 11
Figure 3.13. Reamplification of differentially expressed bands.
Bands representing differentially expressed genes were excised from dried polyacrylamide 
gels. The DNA was eluted from these gel fragments by boiling for 20min in TE buffer. The 
eluted DNA was then reamplified by PCR using the corresponding primers that had 
produced the band at the ddPCR stage (see Table 3.3). Lanes 1 - 1 1  represent 11 bands 
that were selected for further analysis. M indicates the DNA marker.
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Figure 3.14. Further reamplification of differentially expressed bands.
Bands representing differentially expressed genes were excised from dried polyacrylamide 
gels. The DNA was eluted from these gel fragments by boiling for 10min in TE buffer. The 
eluted DNA was then reamplified by PCR using the corresponding primers that had 
produced the band at the ddPCR stage (see Table 3.3). Lanes 1 - 1 4  represent 14 bands 
that were selected for further analysis. M indicates the DNA marker.
Figure 3.15. Northern blot analysis to confirm a differentially expressed gene identified by 
ddPCR.
The DNA from band showing differentially expression was eluted from the ddPCR 
polyacrylamide gel and reamplified. The DNA shown in lane 7 of Figure 3.14 was used to 
probe a northern blot of RNA from cells infected with MHV-68 (moi 10, 24h pi; marked as 
I) and mock-infected cells (marked as U).
3.6 Sequencing of Differentially Displayed DNA
For practical reasons, potential differentially expressed genes were cloned and 
sequenced, and then if they could be identified, were used to probe northern blots. 
Therefore, the bands seen in Figure 3.14 were gel purified and ligated into the 
pGEM -T Easy vector system for cloning. As this cloning system uses a plasmid with 
a multiple cloning site within a p-galactosidase cassette, blue/white screening was 
used to select 2 transformed bacterial colonies for each cloned DNA species. 
Colony PCR was used to further confirm that cloning had been successful.
Initially 8 bands were cloned. The results of the colony PCR for 16 bacterial 
colonies are shown in Figure 3.16. This showed that 13 out of 16 colonies 
contained an insert. Of the remaining 3, lane 3 appeared to show a mixed colony, 
as 2 bands were present in this lane. Lanes 14 & 16 had bands of approximately 
170bp, which indicated that no insert was present (175bp = the distance between 
the primers binding to a pGEM vector without an insert). Therefore, the culture 
represented by lane 3 was streaked out and new colonies picked. Colony PCR was
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used again to confirm the presence of an insert. The cultures represented by lanes 
14 & 16 were discarded.
All cultures containing successfully cloned DNA species were grown up and 
plasmid extracted. The purified plasmid was then used as template for sequencing. 
The resulting sequence data was used to perform BLAST searches to identify the 
potential differentially expressed genes.
M 1 2 3 4 5 6 7 8 M 9 10 11 12 13 14 15 16
Figure 3.16. Colony PCR to check for presence of an insert.
Blue/white screening was used to select colonies containing insert-containing plasmids. 
These colonies were then used as template for colony PCR to confirm the blue/white 
screening. SP6 and T7 primers (see Appendix I) that bound to either side of pGEM multiple 
cloning site were used. Absence of an insert was indicated by a band of 175bp, which 
corresponded to the distance between the primer binding sites for plasmids without an 
insert. Lanes 1 - 1 6  represent white colonies of transformed bacteria.
3.7 Querying Public Databases via BLAST
For all DNA species that were successfully sequenced, the data was used to query 
the National Centre for Biotechnology Information (NCBI) databases via BLAST. 
Sequences that had matches in the NCBI databases were used to probe northern 
blots to confirm their differential expression. The results of these database searches 
and subsequent northern blot analyses are summarised in Table 3.4. Examples of 
these northern blot analyses are shown in Figure 3.17.
Of the potential differentially expressed genes that were successfully identified 
through BLAST, all genes whose expression had increased 24h pi were identified
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as viral, e.g. MHV-68 ORF 25, 57 and 66. All the genes whose expression was 
decreased following infection were found to be host genes, e.g. adenine 
phosphoribosyltransferase and fibronectin. A degree of redundancy appeared in the 
results, as a number of potential differentially expressed genes were found to be 
the same gene. For example, MHV-68 ORF 25 (major capsid protein) was identified 
4 times from 3 independently isolated differentially displayed bands.
Table 3.4. Results of BLAST searches with sequenced, differentially expressed DNA
species.
Band BLAST result Score1 P value2
Confirmation 
by northern
1 U97553: MHV-68 ORF25 1298
8.60E-
100 Up
3 X03603: Mus pahari adenine 
phosphoribosyltransferase
528 8.10E-62 Down
4 X93167: Mus musculus mRNA for 
fibronectin
1134 3.20E-86 Down
7 U97553: MHV-68 ORF57 1045 8.70E-80 Up
8 U97553: MHV-68 ORF57 1021 8.50E-80 Up
10 U97553: MHV-68 ORF25 1008
3.70E-
111 Up
12 AF111102: Mus musculus major 
histocompatibility complex class
129 4.00E-28 Down
14
AI449820: Stratagene mouse testis, Mus 
musculus cDNA clone 917572, mRNA 
sequence
103 5.60E-24 Down
17 U97553: MHV-68 ORF25 884 0 Up
19 U97553: MHV-68 ORF58 656 0 Up
20 U97553: MHV-68 ORF25 640 0 Up
24 NM_145507: Mus musculus similar to 
Aspartyl-tRNA Synthetase
54 6.00E-05 Down
25 U97553: MHV-68 ORF58 & 59 485 7.20E-92 Up
28 U97553: MHV-68 ORF66 264 6.00E-70 Up
1The score of an alignment, calculated as the sum of substitution and gap scores. 
Substitution scores are given by a look-up table and gap scores are typically calculated as 
the sum of the gap opening penalty and the gap extension penalty.
2The probability of an alignment occurring with the score in question or better. The p value is 
calculated by relating the observed alignment score to the expected distribution of high 
scoring pair scores from comparisons of random sequences of the same length and 
composition as the query to the database. The most highly significant P values will be those 
close to 0.
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Band 25 listed in Table 3.4 is of particular interest as when submitted via BLAST to 
the databases, the nucleotide sequence was found to match both ORF 58 and 59 of 
MHV-68. This suggested that the DNA species in band 25 was synthesised from a 
RNA species that spanned the reading frames of ORF 58 and 59. It therefore 
seems likely that these two ORFs are transcribed together as part of a polycistronic 
mRNA.
There were a large number of sequences that did not have matches in the NCBI 
databases. Since the time of these searches (2000), the databases have grown as 
more genes have been sequenced. Therefore, the unresolved sequences, and also 
the previously identified genes, were resubmitted via BLAST to query the 
databases again.
The results are presented in Table 3.5. This confirmed that the databases have 
indeed become more comprehensive, reflecting in particular the concerted efforts of 
the mouse genome project. Several of the previously unidentified sequences now 
returned hits from the database, although there were still some sequences with no 
matches. Furthermore, bands 12 & 14 that had been identified in 2000 but with 
weak scores, now returned matches with higher scores. This illustrates the need to 
search the databases at regular intervals, until definitive identification is possible.
B 0 24
Figure 3.17. Northern blot confirmation of differential display.
Bands were excised from the ddPCR gel, amplified and sequenced, before being used to 
probe RNA blots. Band 14 is shown in A and band 1 (MHV-68 major capsid protein) in B, 
hybridised to blots with RNA harvested at various h pi indicated above each lane.
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Table 3.5. Results of repeated BLAST searches following development of gene databases.
Band BLAST result Score1 P value**
11 AF109905.1: Mus musculus major histocompatibility 
locus class III regions Hsc70t gene, partial cds; smRNP, 
G7A, NG23, MutS homolog, CLCP, NG24, NG25, and 
NG26 genes, complete cds; and unknown genes
78 5.00E-
12
12 Mus musculus DNA sequence from clone RP23-6103 on 
chromosome 2, complete sequence
145 3.00E-
32
13 No match found
14 Mus musculus RIKEN cDNA 1700020L11 gene 
(1700020L11 Rik), mRNA
410 1.00E-
111
15 No match found
16 Y08839.1: Mus auratus mRNA for delta-sarcoglycan, 
alternative first exon
123 9.00E-
26
18 AF283763.1: Mus musculus thyrotropin-releasing 
hormone receptor 2 (TRH-R2) gene
66 3.00E-
08
21 Mus musculus DNA sequence from clone RP23-338K8 
on chromosome 11, complete sequence
42 0.26
22 Mus musculus DNA sequence from clone RP23-297J14 
on chromosome 11, complete sequence
62 4.00E-
07
23 No match found
26 No match found
27 Mus musculus clone RP24-491P21, complete sequence 38 7.1
29 No match found
1The score of an alignment, calculated as the sum of substitution and gap scores. 
Substitution scores are given by a look-up table and gap scores are typically calculated as 
the sum of the gap opening penalty and the gap extension penalty.
2The probability of an alignment occurring with the score in question or better. The p value is 
calculated by relating the observed alignment score to the expected distribution of high 
scoring pair scores from comparisons of random sequences of the same length and 
composition as the query to the database. The most highly significant P values will be those 
close to 0.
3.8 Discussion
The differential display system was developed as a means of analysing changes in 
gene expression during MHV-68 infection in vitro. To assess the potential of this 
system for the study of MHV-68, the system was setup and optimised using a single 
time point pi. The resulting data was then analysed and used as an indication of the 
system’s capabilities.
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Each step of the differential display protocol (see Figure 3.1) was examined and 
optimised. RNA samples were treated with DNAse I and then thoroughly checked 
by denaturing gel electrophoresis and spectrophotometry to ensure that only high 
quality RNA template was used. Reverse transcription of RNA was optimised to 
increase the quality and yield of cDNA, whilst ensuring that the amount of template 
RNA was the limiting factor for this reaction.
Twelve primer pairs were used to assess the differential display system. The 
displays of RNA from MHV-68 infected BHK cells (24h pi) were compared against 
those from mock-infected controls. This showed clearly that the system was 
working and producing data. The results were further analysed to assess the 
potential of the system for investigating transcriptional events through MHV-68 
infection.
Bands on the differential display gel could be categorised into those appearing only 
in lanes for infected samples, only in lanes for mock-infected samples, in both lanes 
but brighter in uninfected lanes, and in both lanes but brighter in infected lanes. The 
first group consisted of viral genes that were expressed by MHV-68 during infection. 
Several examples were isolated, sequenced and confirmed to be viral genes such 
as ORFs 25, 57 and 66, predicted to encode major capsid protein, an IE protein 
and capsid protein, respectively (see Table 3.4 and Table 3.5). The second and 
third groups consisted of host genes that were either no longer expressed or 
present at reduced transcript abundances 24h pi. This was presumably due to 
virally-induced shutoff of host protein synthesis. These 2 groups were not analysed 
further as these genes were the least interesting at this stage of the study. Of 
course identifying host genes that are rapidly shutoff at very early stages of 
infection could provide valuable data for further analysis.
Of those bands that appeared in both infected and uninfected lanes, those that 
showed increased abundance following infection were particularly interesting. Such 
an increased expression would suggest that these host genes in question were 
directly involved in the viral infection, either initiated by the host as a defence 
mechanism, or conversely by the virus to aid infection. However, it was not possible 
to confirm this differential expression via northern blot analysis. While the northern 
blot analyses showed that DNA species identified as viral genes were indeed all up- 
regulated following infection in agreement with the differential display gel, those 
DNA species identified as host genes were all found to be down-regulated following 
infection, although the differential display gels may have suggested otherwise.
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This discrepancy could have arisen in one of three ways: Although the band in the 
infected and uninfected lane appeared to be the same DNA species, it is possible 
that they were in fact different DNAs of about the same size. As the RNA 
populations of infected and uninfected cells are very different, and as degenerate 
primers are used to initiate amplification, this is easily conceivable. It is also 
possible that more than a single DNA species may have been present in the gel 
fragment that was excised. Obviously this is undesirable and attempts were made 
to reduce the chances of this occurring by using a sensitive DNA labelling system 
and performing a long and short run for each ddPCR amplification product. Finally, 
several DNA species are reamplified from each gel fragment and only some of 
these may represent the original differentially expressed gene observed on the gel. 
Therefore, “non-signal” reamplified DNA species would be sequenced and used to 
probe northern blots. It became clear that some or all these potential pitfalls were 
occurring and therefore significantly increasing the noise in the differential display 
data.
These factors are potentially a major limitation of the differential display system. In 
particular the reamplification of DNA eluted from gel fragments was particularly 
problematic as it appeared to be difficult to cleanly isolate the DNA that was shown 
to be differentially expressed on the gel. Although the ddPCR successfully amplified 
the RNA samples, the polyacrylamide gel electrophoresis of the amplified products 
was not sufficient to separate them. The same type of gel electrophoresis is used 
successfully to separate sequencing reaction products, which only differ by 1 bp. 
Therefore, the differential display gel should also be capable of resolving 1bp 
differences. However, the ddPCR products are labelled with much higher levels of 
radioactivity and comprise a much larger size range. Optimisation of the 
electrophoresis could possibly further increase the resolution of the gel. However, 
this still leaves the other problems that increase the level of noise in the data. This 
noise results in an exponential increase in the workload required to isolate true 
signals from the differential display. It would be interesting to perform differential 
displays of infection at very early time points to see if these problems are as 
considerable when the 2 sample RNA populations are very similar.
There are also a number of limitations to the techniques used to interpret and
analyse the differential display data: Of 30 DNA species that were isolated from the
differential display gel, only 23 were successfully sequenced (77% sequencing
success). Of these, only 14 found matches in the databases (47% database
matches). However, these limitations would be reduced with further optimisation of
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the sequencing techniques and the continuing growth of the gene databases, as 
new genes are characterised. Indeed, of 13 resubmissions, 8 returned matches at 
this second attempt, which show a promising 62% success upon resubmission after 
a period of 2 years (listed in Table 3.5).
One unexpected result was returned with the sequence of band 25. This DNA 
species matched both MHV-68 ORF 58 and 59, which therefore suggested that 
they were transcribed as part of the same mRNA. Indeed subsequent sequence 
analysis (Milligan, 1998) has shown that ORF 58, 59 and 60 are likely to share a 
poly-A tail.
It should also be noted that the cells infected with MHV-68 in this study were firstly 
tissue culture adapted, i.e. immortalised, cells and also that they were derived from 
baby hamster kidney cells. How closely related the behaviour of tissue culture cells 
and cells in a living organism are, has been often conjectured. In particular, with 
respect to attempts made to highlight host genes that are up-regulated by the virus 
following infection, the merits of using a hamster tissue culture cell line to simulate 
small changes that are occurring in mice infected with MHV-68 could be argued. 
However, for the purposes of this study, namely setting up and optimising a 
differential display system to study MHV-68, using the well characterised BHK cell 
line in which the virus was known to replicate efficiently was perfectly satisfactory. 
For further study of MHV-68 infection in vitro, switching to a contact-inhibited 
murine cell line (such as NIH 3T3 cells) could be valuable to better simulate the in 
vivo environment.
In conclusion, a differential display system was set up and optimised for the study 
of MHV-68 infections in vitro. Data was produced that was independently confirmed 
using northern blots. The potential of the differential display system to identify 
qualitative differences has been amply demonstrated here. However, the 
quantitative aspect of the data was not so clear. Without a more exhaustive data set 
it is difficult to be certain but the differential display developed in this study was not 
able to consistently resolve relative differences in expression.
It could be that differential displays are best suited for looking at differences in the 
expression of a small subset of the transcript population between samples. Such 
small differences would be far easier to identify and increase in noise at the 
reamplification stage would be less of a hindrance than in the comprehensive 
analysis of transcriptional changes during infection that is being attempted in this 
study. Also, even in this small study, there was a level of redundancy appearing in
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the data which would also be problematic for a comprehensive analysis but less so 
when looking for changes in a small number of genes.
As the differential display technique has been optimised, it could be used to 
examine different aspects of MHV-68 infection. As noted previously, there could be 
a smaller number of differentially expressed genes at very early stages of infection. 
Therefore, the differential display could be used for a focused study of these 
events. In particular, the host response at the start of infection could be very 
interesting to dissect transcriptionally.
However, for the purposes of this study, a different system for analysis of gene 
expression appears to be required. Relatively little is known of MHV-68 gene 
expression and function of those genes. A suitable technique requires that the 
transcription of a large number of genes can be examined simultaneously. Of the 
technologies that are accessible, arrays appear to fulfil the needs of this study 
better than the differential display system. Therefore, the differential display was put 
on hold and an array system was investigated.
112
4 Design and Development of an Array System for the 
Analysis of MHV-68 Gene Expression
4.1 DNA Array Design Strategy for MHV-68
The aim of the work presented in this chapter was to design and develop a global 
DNA array system for the analysis of MHV-68 gene expression. An array for the 
analysis of HHV-8 gene expression was used as a guide (Jenner, 2001). The 
chosen strategy consisted of arrays made by spotting cDNA probes onto nylon 
membranes. Hybridisations were performed with radiolabelled target reverse 
transcribed from total cellular RNA.
The following plan was devised to produce the MHV-68 arrays (see in Figure 4.1): 
Primers were designed (Primer3 software, Rozen, 2000) to PCR amplify the probe 
sequences from M HV-68 DNA. The resulting PCR products were cloned into 
plasmids to allow sequence verification, and also to provide a master template for 
subsequent amplifications. Once the probe sequences were confirmed, they were 
then reamplified from the relevant plasmid stocks, purified and quantified. The 
probes were spotted onto nylon membranes, and denatured prior to hybridisation.
Primers for amplification of probe sequences
Redesign 
primers if 
necessary
PCR from 
MHV-68 DNA
Probe Sequences
Purify and ligate 
Clone probes into plasmid vectors
PCR from 
plasmid
Reamplify probes Glycerol stocks
Purify and quantify
Spot probes onto membranes
Figure 4.1. MHV-68 DNA array production process outline.
113
4.2 Design of the Probeset
All 80 predicted MHV-68 genes (Virgin, 1997) and any inter-genic regions larger 
than 100bp were represented in the probeset. Nine host-cell housekeeping genes 
were included to allow normalisation, and therefore inter-array comparisons. Three 
negative controls were also present to set non-specific hybridisation levels. Each 
probe sequence was approximately 300bp in size and corresponded to the 5’ end 
of it’s ORF.
4.2.1 Viral Probes
Primers for the amplification of viral probes were designed based on the published 
sequence data and genome analysis (Virgin, 1997). This analysis showed 80 MHV- 
68 genes, and so probes were designed to each of the 80 ORFs. For ease of 
identification, probes were arbitrarily named A1-A12, B1-B12, C1-C12, D1-D12, E1- 
E12, F1-F12 and G1-G8. A list of viral probes and the identities of each probe are 
shown in Table 4.1.
4.2.2 Inter-genic Probes
Initial analysis of the coding content of the MHV-68 genome had been performed 
using AceDB (a genome database system originally designed for the C. elegans 
genome project), and then individual ORFs were analysed by BLAST, allowing 
comparison with other herpesviruses (Virgin, 1997). Therefore, all MHV-68 gene 
designations were based purely on bioinformatics and not experimental evidence.
This left the possibility that some MHV-68 genes could have been missed. 
Therefore, probes were also designed to inter-gene regions, whenever they were 
larger than 100bp in size. Furthermore, to cover the possibility of coding strands 
being present on either strand of the MHV-68 genome, these inter-genic probes 
were designed in both orientations.
There were 6 such inter-genic regions, resulting in 12 probes designated G9-G12 
and H1-H8.
4.2.3 Housekeeping and Negative Control probes
Nine housekeeping genes were selected due to their maintained expression in a 
number of physiological states and their universal adoption for this role in a number 
of similar systems (Adams, 1995; Clontech, 1998). Therefore, probes were 
designed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), myosin 1, 
murine ornithine decarboxylase (MOD), p-actin, calcium binding protein 45 (Cab45), 
ribosomal protein S29, ubiquitin, phospholipase A2 and hypoxanthinie
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phosphoribosyl transferase (HPRT). The probes of these housekeeping genes were 
designated H9-12 and J1-5.
Three negative controls were also included to assess non-specific binding of target 
to probes: pBluescript II (SK+) plasmid (Stratagene), TMV 180kDa protein and 
water. The TMV probe was designated J6. The pBluescript plasmid was spotted 
directly onto membranes.
4.3 Production of Probe Sequences to be Spotted onto 
Arrays
4.3.1 Primer Design
The primers for amplification of probe sequences were designed using Primer3 
software (Rozen, 2000). Every primer was designed to have the same properties: 
Primer size 18-22bp, optimal 20. Primer melting temperature 58-62°C, optimal 
60°C. Primer GC% 40-60%, optimal 50%. 3’ GC clamp 2bp. Optimal product size 
300bp. Template sequence was the viral genome. For the housekeeping genes, the 
mRNA sequences for the respective genes were used. All other properties were set 
to the default settings in the software. Primers for the TM V probe were kindly 
provided by Dr Paul Kellam (Wohl Virion Centre, UCL).
To minimise any potential non-specific hybridisations between probes and targets, 
the probe sequences were entered into a database and the BLAST algorithm used 
to check for potential cross-hybridisations. The same process was repeated with 
the primers used to amplify the probes, as they would be used together in the array 
primer mix, to prime the target synthesis and labelling reaction. None of the probe 
or primer sequences showed significant homology to each other.
Occasionally the primer design conditions could not be met due to the presence of 
overlapping genes, or genes shorter than 300bp. As each probe had to be gene- 
specific and therefore unique, this required the design conditions to be changed in 
these cases. For example the MHV-68 ORF M10a, M10b and M10c are 
overlapping. Any part of a ORF that overlapped another ORF was removed from 
the template sequence used for primer design. This meant that the M10c probe was 
only 196bp in size as there was only around 200bp of unique sequence for M10c. 
ORF 53, M12 and M13 also had probes smaller than 300bp for the same reasons. 
Unfortunately, ORF M10a or M10b had no regions of unique sequence and 
therefore no probes were designed for these ORFs. A table of primer sequences 
can be found in Appendix I. Table 4.1 lists the probes and their product sizes.
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Table 4.1. DNA Array probes and their sizes.
Designation Gene Probe Size
A1 M1 320
A2 M2 301
A3 M3 305
A4 M4 301
A5 ORF4 318
A6 ORF6 285
A7 ORF7 291
A8 ORF8 316
A9 ORF9 304
A10 ORF10 299
A11 ORF11 300
A12 K3 281
C1 ORF27 300
C2 ORF29b 303
C3 ORF30 222
C4 ORF31 285
C5 ORF32 299
C6 ORF33 323
C7 ORF29a 288
C8 ORF34 314
C9 ORF35 309
C10 ORF36 301
C11 ORF37 304
C12 ORF38 210
E1 ORF52 285
E2 ORF53 170
E3 ORF54 320
E4 ORF55 318
E5 ORF56 283
E6 M8 301
E7 ORF57 292
E8 ORF58 308
E9 ORF59 308
E10 ORF60 311
E11 ORF61 289
E12 ORF62 320
G1 ORF73 298
G2 ORF74 307
G3 ORF75C 318
G4 ORF75b 301
G5 ORF75a 304
G6 M12 147
G7 M13 99
G8 M14 275
G9 M1-M2 292
G10 M2-M1 313
G11 M2-M3 301
G12 M3-M2 309
J1 Cab453 314
J2 RS294 219
J3 Ubiquitin 296
J4 Phospholipase A2 291
J5 HPRT5 304
J6 TMV6
Designation Gene Probe Size
B1 M5 320
B2 M6 303
B3 ORF17 311
B4 ORF18 308
B5 ORF19 298
B6 ORF20 320
B7 ORF21 310
B8 ORF22 316
B9 ORF23 317
B10 ORF24 292
B11 ORF25 300
B12 ORF26 306
D1 ORF39 320
D2 ORF40 304
D3 ORF42 289
D4 ORF43 301
D5 ORF44 288
D6 ORF45 287
D7 ORF46 298
D8 ORF47 294
D9 ORF48 290
D10 ORF49 301
D11 ORF50 307
D12 M7 318
F1 ORF63 293
F2 ORF64 302
F3 M9 283
F4 ORF66 294
F5 ORF67 320
F6 ORF68 293
F7 ORF69 298
F8 M10a None
F9 M10b None
F10 M10c 196
F11 ORF72 310
F12 M11 309
H1 M3-M4 311
H2 M4-M3 298
H3 K3-M5 293
H4 M5-K3 289
H5 ORF27-29b 154
H6 ORF29-27 154
H7 M10C-ORF72 313
H8 ORF72-M10C 313
H9 GAPDH1 293
H10 Myosin 1 301
H11 MOD2 299
H12 p-actin 309
1Glyceraldehyde-3 phosphate dehydrogenase
2Murine ornithine decarboxylase
3Calcium binding protein 45
4Ribosomal protein S29
sHypoxanthinie phosphoribosyl transferase
^Tobacco mosaic virus 180kDa protein______
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4.3.2 MHV-68 DNA Isolation
To provide template for PCR amplification of probe cDNAs, MHV-68 DNA was 
isolated from 200pl of purified MHV-68 stock and the integrity of the resultant DNA 
was tested by PCR for a number of the larger viral genes (data not shown). This 
showed that the isolated viral DNA was of sufficient quality to act as template for 
the amplification of 300bp cDNA probes.
4.3.3 PCR Amplification of Viral Probe Sequences
High yields of cDNA were preferable as large stocks of cDNA were required for 
spotting onto arrays. Reaction conditions for the amplification of probe cDNA were 
optimised. Varying the amount of template DNA was found to effect yield (Figure
4.2): Amplifications with higher template concentrations of DNA produced smeared 
bands, however smearing below 300bp was removed when lower DNA template 
concentrations were used. Also a high molecular weight band, possibly template 
DNA, was observed at the highest template concentrations (lanes 1 and 2, Figure
4.2). Diluting out MHV-68 DNA template resulted in the loss of this high molecular 
weight band. Therefore, the MHV-68 DNA working stock was set at 1/1000 dilution 
of original stocks.
Initially, PCR reactions were performed using the following conditions: 1x PCR  
buffer (Invitrogen), 1.5mM MgCI2, 1mM dNTPs (Promega), 2^M pGEM-T Easy 
vector-specific primers, 50U/ml Taq polymerase (Invitrogen) and 1pl working stock 
MHV-68 DNA as template in a final volume of 25|J. This reaction mix was incubated 
for 5min at 95°C, followed by 30 cycles of 95°C (30s), 58°C (30s) and 72°C (30s), 
before a final elongation of 5min at 72°C. The reaction was then held at 4°C, before 
products were analysed by agarose gel electrophoresis.
Ninety viral probe sequences (ORF and inter-gene) were amplified under these 
conditions, as listed in Table 4.1. The reaction products were electrophoresed on 
an agarose gel as shown in Figure 4.3. Seventy-two probe sequences were 
successfully amplified in this way, although some of these successful reactions 
showed low yields. The remaining 18 reactions produced multiple products, 
products of the wrong size or no product at all.
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Figure 4.2. Agarose gel analysis of PCR amplification of viral genes using MHV-68 DNA 
template.
Lane M shows the molecular weight marker. Lanes 1-5 show the results of amplification with 
ORF 2 primers, with reducing template concentrations: 1/100, 1/200, 1/500, 1/1,000, 
1/10,000 dilutions of the stock, respectively. Lanes 6 is a positive control: ORF25 was 
amplified with tried and tested primers from MHV-68 DNA. Lane 7 is a control for the MHV- 
68 DNA template. Again ORF 25 was amplified as in lane 6, but the template used was 
cDNA that had been reverse transcribed from RNA isolated from MHV-68 infected NIH 3T3 
cells. Oligo-dT was used to prime the reverse transcription. Lanes 8 is a negative control in 
which no DNA template was included in the reaction mix.
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Figure 4.3. PCR amplification of viral DNA array probe sequences.
Probe sequences were amplified from MHV-68 DNA, using an annealing temperature of 
58°C. Individual probes are identified in Table 4.1.
Amplification of probes A7, C2, C6, C11 and H5 resulted in multiple reaction 
products, or a product of the wrong size. This suggested that the amplification had 
been non-specific. Therefore, amplification of probe sequences was repeated with 
an increased annealing temperature of the 60°C, which would increase the 
specificity of primer binding to template. This resulted in the successful amplification 
of 3 sequences: probes A7, C2 and C 1 1.
Reactions producing no product were repeated with reduced annealing 
temperatures of 56°C and 54°C. Also the effects of increasing and reducing 
template concentration were evaluated. However, none of these modifications 
resulted in successful amplification of product.
119
M 1 2 3 4 5 6
m
IM
300bp
Figure 4.4. PCR amplification of viral probe sequences with increased annealing 
temperature.
PCR amplification of probe sequences was repeated with an annealing temperature of 
60°C. Lanes 1-8 represent probes A7, B6, C2, C6, C11, & H5, respectively. M denotes the 
marker lane.
For the remaining 15 probe sequences (A1, A4, A9, B2, B5, B8, C1, C6, E1, F8, F9, 
G8, G12, H5, H6) new primers were designed. Repeating the amplification with the 
new primers was successful for all remaining probe sequences, except G8. The 
agarose gel electrophoresis is shown in Figure 4.5. It should be noted that H5 (lane 
14) and H6 (lane 15) are the expected sizes, as there was only approximately 
150bp of unique sequence for these probes.
For G8, the PCR amplification was repeated varying the annealing temperature, 
MgCI2 concentration and template concentration. However, none of these changes 
allowed probe G8 to be amplified successfully. Therefore, a third set of primers 
were designed and used for PCR amplification reactions, but again without 
success. Examining the sequence data of the G8 gene (M HV-68 ORF M14) 
showed that the sequence contained a high proportion of GC bases. Therefore, the 
PCR reaction was repeated with the inclusion of DMSO, as certain sulphoxides are 
well known to aid in the amplification of GC-rich templates (Bookstein, 1990; Pomp, 
1991). In addition, an alternate, high efficiency, heat activated Taq polymerase was 
also tested (without DMSO; Advantage Taq, Clontech). The agarose gel 
electrophoresis of reaction products is shown in Figure 4.6. Inclusion of 10% DMSO  
in lane 1 proved successful and although 2 bands resulted, 1 was the correct size 
and therefore excised and purified. Using Advantage Taq for PCR amplification, 
shown in lane 3, proved unsuccessful.
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Figure 4.5. PCR amplification of further viral probe sequences.
PCR amplification was repeated using new primers. Lanes 1-15 show A1, A4, A9, B2, B5, 
B8, C1, C6, E1, F8, F9, G8, G12, H5 & H6, respectively.
1 2 3
Figure 4.6. Amplification of probe G8 sequence.
PCR amplification of G8 using with 10% and 20% DMSO in lanes 1 & 2, respectively. Lane 
3 shows a PCR reaction using Advantage Taq polymerase (Clontech) and no DMSO.
4.3.4 PCR Amplification of Control Probe Sequences
RNA was isolated from NIH 3T3 cells and reverse transcribed with anchored oligo- 
dT primers. The resulting cDNA was then used as template for PCR amplification of 
the control probes to feature on the array as shown in Figure 4.7. All housekeeping 
genes, as listed in Table 4.1, were successfully amplified.
A pGEM-T Easy plasmid containing the TM V probe was kindly donated by Dr P. 
Kellam (Wohl Virion Centre, UCL). Bluescript plasmid was obtained from 
Stratagene for spotting directly onto array membranes.
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Figure 4.7. PCR amplification of DNA array control probe sequences.
Control probe cDNA were amplified by PCR from 3T3 cell cDNA using the appropriate 
primers (Table 4.1). Lanes 1-9 represent probes H9-12 and J1-5, respectively.
4.3.5 Cloning of Probe Sequences
All probe sequences were cloned into the pGEM-T Easy system for sequence 
verification. This system allowed direct ligation of purified PCR products into the 
pGEM-T cloning vector. After transformation, the E. coli JM109 culture was plated 
out for colour screening. Successful ligation of an insert into cloning vector resulted 
in the disruption of a (3-galactosidase coding region. By plating the transformed 
bacteria on agar plates containing X-gal and IPTG, presence of an insert was 
indicated by white as opposed to blue colonies. Positive colonies were picked, 
cultured and glycerol stocks frozen down.
Glycerol stocks were checked for presence of the correct probe sequence insert by 
PCR. Both the presence of the correct insert and the presence of a single insert 
was checked using insert-specific (see Appendix I for sequences) and plasmid- 
specific primers (see 2.3.19 for sequences). The plasmid-specific primers were 
designed to amplify any sequence ligated into the multiple cloning site of the 
pGEM-T vector. Any mis-clones were discarded and the relevant probe sequence 
re-cloned. All probe sequences were successfully cloned.
As a precaution, cultures were prepared from the glycerol stocks, and plasmid 
isolated. Each plasmid was verified to contain the correct insert. This ensured that 
the glycerol stocks were viable and confirmed that the probe sequences had been 
successfully cloned.
1 2 2
4.3.6 Verification of Cloned Probe Sequences
Bacterial cultures were prepared from glycerol stocks and plasmid isolated. These 
plasmids were sequenced in house to verify the insert. The sequence data for each 
plasmid was used to search nucleotide databases with BLAST. Any plasmids that 
contained the wrong insert were discarded.
All plasmids were sequence verified to contain the appropriate insert, except probe 
G5 (MHV-68 ORF 75a) and G8 (MHV-68 ORF M14). PCR amplification of these 
plasmids using probe-specific primers resulted in a band of the expected size; 
however the plasmid could not be sequenced. Due to the GC-rich nature of the 
inserts DMSO, was added to the sequencing reaction but this also failed. Even 
commercial sequencing by MWG Biotech was unsuccessful. These 2 probes were 
incorporated into the array but with the caveat that these probes were not sequence 
verified.
4.3.7 Amplification of Probe Sequence cDNA from Plasmid
Large amounts of probe sequence cDNA were required for spotting onto arrays. A  
standard high efficiency PCR amplification was set up to allow efficient amplification 
of cDNA from the plasmids for each probe. Plasmid-specific primers were used in 
an optimised protocol (see Chapter 2.4.20) that used high concentrations of Taq 
polymerase, primers and deoxynucleotides: 1x PCR buffer, 1.5mM MgCI2, 2mM  
dNTPs, 4pM pGEM-T Easy vector-specific primers, 50U/ml Taq polymerase and 
30fig/|il plasmid template in a final volume of 100jxl. This reaction was incubated for 
5min at 95°C, followed by 40 cycles of 95°C (30s), 55°C (30s) and 72°C (30s), 
before a final elongation of 5min at 72°C. The reaction was then held at 4°C.
4.3.8 Quantification of Probe cDNA
Three methods for the quantification of the probe cDNA were used: Fluorescence of 
DNA spotted onto ethidium bromide containing agarose gels, weight-standardised 
DNA hyperladders and spectrophotometry.
To test ethidium bromide-based quantification, known quantities of salmon sperm 
DNA were spotting onto an ethidium bromide containing agarose gel and the 
fluorescence under UV light was measured. Plotting these measurements returned 
the standard curve shown in Figure 4.8a, with most points lying within the 95%  
confidence limits, and a correlation coefficient of 0.93. However, this method was 
found to give inconsistent results when a second set of standards were spotted 
randomly and the calculated values compared to actual values, as shown in Figure 
4.8b. Therefore, ethidium bromide quantification was unsuitable for quantification of
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amplified probe sequences. DNA hyperladders also produced inconsistent results 
and were therefore also unsuitable.
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Figure 4.8. Ethidium bromide quantification of DNA.
A. Known quantities of salmon sperm DNA were spotted onto an agarose gel containing 
ethidium bromide. DNA quantity was plotted against fluorescence and linear regression 
used to produce a standard curve. B. Consistency of ethidium bromide quantification. 
Known quantities of DNA were spotted randomly onto an agarose gel containing ethidium 
bromide. Each spot was quantified using the standard curve derived in A. The calculated 
values were plotted as a percentage of their actual values. Each quantity of DNA was 
spotted 5 times.
Although spectrophotometry had the disadvantage of requiring large amounts of 
DNA relative to the other methods, it was the most accurate and reliable one. 
Therefore, this method was used to quantify probe sequence DNA. Additional PCR  
amplifications of probe cDNAs were performed to provide enough DNA for 
quantification, as DNA that had been quantified was no longer suitable for spotting
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onto arrays. Amplifications of probe sequences from plasmid, using the optimised 
protocol, were found to produce approximately 5pg of cDNA per reaction. Once 
quantified, all probe cDNAs were diluted to 0.2pg/pl and stored at -20°C.
4.4 Array Manufacture and Optimisation of the System
4.4.1 Initial Array Protocol
In order to test array designs, an initial array hybridisation protocol was necessary. 
An overview is shown in Figure 4.9. The following protocol was used: NIH 3T3 cell 
monolayers were infected with MHV-68 at moi 10. Control cells were mock-infected. 
At the appropriate time pi, the monolayers were lysed with TRIzol and total RNA 
isolated. The RNA was treated with DNAse I to remove any contaminating DNA. 
Each RNA sample was quantified and run out on a denaturing gel to assess quality.
Experimental samples
Isolate RNA, DNAse treat, 
assess quality
▼
Total RNA
Prime with array primer 
mix. Reverse transcribe 
with radiolabelled dATP
▼
Labelled cDNA target
Purify target
▼
Hybridisation to arrays 
Figure 4.9. Overview of DNA array protocol.
Total RNA was used as template for the labelling reverse transcription reaction. 
Labelled target was synthesised by reverse transcription, with the inclusion of 33P- 
dATP. The reaction was primed with a primer mix consisting of all the 3’ primers 
that had been used to amplify probe sequences. The final concentration of each
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primer in the reaction was 0.1 pM. The reaction was terminated by the addition of 
EDTA.
The labelled pool of target cDNA was purified to remove unbound 33P-dATP and 
hybridised to arrays. Arrays were prehybridised for 1h at 60°C in Expresshyb and 
sheared salmon sperm DNA. Hybridisation was performed in fresh Expresshyb and 
sheared salmon sperm DNA at 60°C for 16h. Arrays were then washed 3 times at 
low stringency, followed by 3 washes at high stringency.
4.4.2 Testing Membranes
Before manufacturing whole arrays, the membrane to be used was tested. The 2 
membranes tested were uncharged nylon and positively charged nylon. A number 
of probes were spotted onto the uncharged nylon (Biorad) and on to the positively 
charged nylon membrane (Amersham).They included MHV-68 O RF M3, 53, 67 and 
housekeeping gene probes GAPDH, myosin and phospholipase. Both arrays were 
used in a test hybridisation, as shown in Figure 4.10. It was clear that the positively 
charged membrane in A performed much better than the uncharged membrane in 
B. Therefore, the positively charged nylon membrane was chosen for making all 
subsequent arrays.
Figure 4.10. Comparison of array membranes.
A. Negatively charged nylon membrane (Amersham). B. Uncharged nylon membrane 
(Biorad). MHV-68 probes for ORF M3 (1), 53 (2), 67 (3) and housekeeping gene probes D- 
glyceraldehyde -3-phosphate dehydrogenase (4; GAPDH), myosin (5) and phospholipase 
(6) were spotted using a gilson pipette. Labelled target cDNA was hybridised to both 
membranes and then visualised on a phosphoimager.
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4.4.3 Initial Hybridisation
Arrays were produced by vacuum-spotting 400ng of each probe DNA onto 
membranes. The layout of the 96 spot vacuum-spotted array is shown in Appendix 
II. The top left corner of each array was cut to aid orientation. An initial test 
hybridisation to a 96 spot vacuum-spotted array using the initial array protocol is 
shown in Figure 4.11. Overall the array showed weak hybridisation between probes 
and targets. This suggested that hybridisation efficiency was low, due possibly to 
insufficient labelled cDNA target, insufficient probe, or suboptimal hybridisation 
conditions. Furthermore, the control probes for housekeeping genes (present in the 
bottom row of spots on each array) did not appear to bind target.
4.4.4 Optimising Synthesis and Labelling of Target cDNA
Increasing the quantity of target cDNA was attempted by optimising reaction 
conditions. A number of target synthesis reactions were set up to assess the effects 
of varying the concentrations of constituents and also varying the reaction 
conditions themselves. (This optimisation was performed without radiolabelled 
dATP to minimise the use of radioisotopes.) To increase the efficiency of priming, 
RNA was incubated with the array primer mix for 5min at 70°C and then placed on 
ice, prior to addition of the reaction mix.
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Figure 4.11 (this and preceding page). Testing vacuum-blotted DNA arrays.
Hybridisations with labelled cDNA target derived from NIH 3T3 cells infected for 2h and 24h 
are shown here. A key to the layout of the array is shown in Appendix II.
Replacing MMLV reverse transcriptase with Superscript II reverse transcriptase 
was found to improve the yield of cDNA, as a longer incubation at a higher 
temperature was possible. This was due to Superscript II lacking the RNAse H 
activity usually associated with reverse transcriptases.
Increasing primer concentration was also found to improve the yield of cDNA, which 
suggested that insufficient primer had been included in the initial target synthesis 
reactions.
Therefore, optimal yields for target cDNA synthesis were found to be achieved with 
the following conditions:
1. Firstly, template RNA was annealed to primers for 5min at 70°C, before
being placed on ice, to increase the efficiency of priming.
2. The reaction mix was then added and consisted of 1x first strand buffer,
1mM dA/T/G/CTP and 5U/pl Superscript II reverse transcriptase, in a final
volume of 20pl. The reaction mix was then incubated at 50°C for 90min. For 
actual labelling reactions the dATP was replaced with 2.5pCi/pl [a-33P] 
dATP.
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4.4.5 Optimising Purification of Labelled Target
The following methods of purifying labelled cDNA were assessed: NICK columns 
(Amersham), Chromaspin columns (Clontech) and Nucleospin columns (Clontech). 
The Chromaspin and Nucleospin columns achieved the best results as measured 
by ability to remove 20bp oligonucleotides whilst retaining DNA fragments 100bp 
and greater in size. The Nucleospin columns were the more practical choice, as 
they could be used in a standard benchtop centrifuge. They were therefore selected 
as the method of choice.
4.4.6 Optimising Hybridisation Conditions
A second hybridisation was performed, using the protocol as optimised so far. RNA 
was isolated from cells infected for 2h and 20h, as well as from a mock-infected 
control. The results of the hybridisation are shown in Figure 4.12. Although signal 
strengths had increased compared to the initial hybridisation, there was little 
difference between the hybridisation patterns of infected and uninfected 
hybridisations. Labelled target had hybridised to viral probes even in the 
hybridisation using target derived from mock-infected cell RNA. (The housekeeping 
gene probes on these arrays were along the bottom row, and the rest of the array 
consisted of viral probes, as shown in Appendix II). This suggested that the results 
of these hybridisations were due largely to non-specific binding, as opposed to true 
signals.
The arrays were then subjected to additional washes at high stringency, to establish 
whether inefficient washing has been responsible for the non-specific signals seen 
in Figure 4.12. However, these further washes had no effect. The RNA samples 
were checked for presence of viral mRNAs by RT-PCR, which confirmed that the 
mock-infected RNA sample did not contain viral RNAs.
4.4.7 Use of Miniarravs for Further Optimisation of Hybridisation 
Conditions
To further optimise the system, vacuum-spotted miniarrays were made. Each 
consisted of a small membrane with 6 viral and 2 housekeeping probes (MHV-68  
ORF M6, 22, 43, 52, 57, 61 and (3-actin, GADPH). These were used as multiple 
array hybridisations are easier to setup with smaller arrays, and the analysis of 8 
probe signals was far simpler than analysing full arrays.
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Figure 4.12 (this and preceding page). Hybridisation to vacuum-spotted MHV-68 DNA 
arrays.
Hybridisations were performed with labelled cDNA derived from mock-infected cells (A.), cell 
infected for 2h (B.) and for 20h (C.). A key the layout of the array is shown in Appendix II.
Hybridisations with varying conditions (temperature, time and hybridisation chamber 
rotation speed) were performed with these miniarrays to observe their effects on 
non-specific binding between targets and probes. However, no significant reduction 
of non-specific binding was observed by changing these hybridisation conditions.
The amount of RNA used as template was doubled to 4pg to see if there was a lack 
of specific binding due to lack of target cDNAs, but this also had little effect. The 
results of this hybridisation are shown in Figure 4.13.
4.4 .7 .a  O ptim isation  o f Probe C oncentration
A second set of miniarrays were made to test the effects of changing the amount of 
probe in each spot on the array. Four probes were vacuum-blotted onto 
membranes in 3 quantities each: 800ng, 400ng and 200ng. Hybridisations using 
these miniarrays showed that spots with higher concentrations of probe gave 
stronger signals. Therefore, the amount of probe in each spot was a significant 
factor in the resulting signal strengths. Nonetheless, background levels were still 
high at all probe concentrations, as seen with hybridisations of uninfected sample- 
derived cDNA.
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Figure 4.13. Hybridisation to DNA miniarrays.
Each miniarray was spotted with 6 viral and 2 murine gene probes: GADPH, (3-actin and 
MHV-68 ORF 61, 57, 52, 43, 22 and M6 from top to bottom, respectively. Miniarrays had 
The top left corner of each miniarray was cut to aid orientation. A. Hybridisation to labelled 
target derived from uninfected cells. 2pg RNA template was used. B. Hybridisation to 
labelled target derived from cells infected for 12h. 2pg RNA template was used. C. 
Hybridisation to labelled target derived from cells infected for 12h. 4pg RNA template was 
used.
4.4.8 Summary of Optimising Hybridisation Conditions Using Vacuum- 
Spotted Arrays
Optimisation of hybridisation conditions had proved to be more complex than 
optimisation of target synthesis. In particular the results were often found to be 
inconsistent when repeating these experiments. This suggested that the arrays 
were not reproducible at this stage. Varying individual hybridisation conditions such 
as temperature, duration, speed of rotation and stringency of washing all had little 
effect in reducing non-specific binding of target to probe. The only factor identified 
to reduce background hybridisation levels consistently, was the addition of murine 
C0T-1 DNA fragments to the hybridisation solution. However, this alone was not 
sufficient to allow considerable differences to be observed between infected and
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uninfected samples. The amount of probe present in each spot was also found to 
influence binding of target, although its effects on non-specific binding were 
unclear.
Although many facets of the array had been optimised or attempts made to 
optimise them, the actual method of spotting the arrays had not been examined 
thus far. However, changing the concentration of probe in each spot was known to 
affect binding. Therefore, the method of spotting arrays, and the nature of the spots 
themselves was modified.
4.4.9 Pin-Spotted Arrays
Pin-spotting uses a very different mechanism to produce arrays, compared to 
vacuum-spotting. A fixed volume of probe solution is held as a droplet at the end of 
a pin. The droplet is then placed onto a dry nylon membrane by bringing the two 
into contact. With vacuum-spotting, the probe solution is drawn through a wet 
membrane under vacuum. The nature of the nylon membrane results in probe 
cDNA being left on the membrane, while smaller molecules pass through. Also the 
2 methods differed in the denaturation of probe cDNA. The probes for vacuum- 
spotted arrays were denatured prior to spotting, and then cross-linked under UV  
light. Pin-spotted arrays were stored prior to denaturation of probes, which was 
instead performed just before use.
Pin-spotted arrays use a gentler mechanical force than vacuum-spotted ones to 
produce arrays. Also the spots produced by pin-spotting are approximately 1 mm in 
diameter, around one third of that for vacuum-spotting. Therefore, very different 
mechanics of binding potentially exist for the two types of spot.
4.4.10 Biomek Pin-Spotted Arrays
As the amount of probe to be spotted onto membranes had yet to be optimised, 
arrays were produced with each probe spotted at 4 concentrations: 100ng/pl, 
50ng/pl, 25ng/pl and 12.5ng/pl. As it was available, a Beckman Biomek 2000 robot 
was used to produce these. As this robot was capable of spotting 1,152 features 
onto a single membrane, each probe was spotted 3 times so that replicate probes 
featured on the array. The layout of this array is as shown in Appendix II. The 
bottom right corner of each array was cut to aid orientation.
A hybridisation was performed using target derived from NIH 3T3 cells infected with 
MHV-68 for 12h, as well as from a mock-infected control, to assess the effects of 
using pin-spotted arrays. The optimised protocols were followed for target cDNA
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synthesis and purification. The standard hybridisation and wash protocol was 
followed as used for the initial hybridisation.
The results of this hybridisation are shown in Figure 4.14. The non-specific binding 
seen previously with target derived from uninfected cells was no longer present. 
Instead, only the housekeeping gene probes were seen to bind target on the control 
hybridisation (as seen in Figure 4.14A). With target derived from infected cells, 
almost all probes were seen to bind target, and there was also a large range of 
signal strengths (as seen in B). These results suggested using pin-spotted arrays 
resulted in much reduced levels of non-specific binding, compared to hybridisations 
with vacuum-spotted arrays.
Figure 4.14 (following page). Hybridisation of Biomek pin-spotted arrays.
These arrays featured each probe at 4 concentrations: 10Ong/pil, 50ng/pl, 25ng/pl and 
12.5ng/pl, with the most concentrated towards the bottom of each set. Each probe was 
spotted as one of three replicates, resulting in sets of 12 spots per probe. A. Control 
hybridisation representing RNA from uninfected cells. Signals for housekeeping genes can 
be seen towards the bottom of the array. B. Hybridisation representing NIH 3T3 cells 
infected with MHV-68 for 12h. The layout of these arrays is as shown in Appendix II. The 
bottom right corner of each array was cut to aid orientation.
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4 .4 .10.a Effects o f Probe C oncentration  on S ignal S trength
As a range of probe concentrations were spotted onto the Biomek arrays, the 
effects of changing probe concentration were also observed. The graph in Figure 
4.15 shows signal strengths for a probe plotted against the concentration of that 
probe. Four probes were selected to represent a broad range of signal strengths, 
from the array shown in Figure 4.14B. All probes showed a linear relationship 
between 25ng/pl and 100ng/pl. At the lowest concentration of probe, 12.5ng/pl, the 
linear relationship was lost for probes 1 & 4. As these probes represented higher 
signals, it seems likely that at the lowest concentration of 12.5ng/pl, these probes 
were saturated with target. Therefore, 50ng/pl was set as the working probe 
concentration for future arrays.
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Figure 4.15. The effects of probe concentration on signal strength on DNA arrays.
Four probes were selected to represent the range of signals seen on the array and plotted 
to show their signal strengths varying with their concentrations.
4 .4 .10.b  E ffects o f Using O ligo-dT  to  Prim e T arg et Synthesis
The M HV-68 array system had been designed to use a mix of probe-specific 
primers to prime the target labelling reverse transcription. However, a comparison 
between specific priming and oligo-dT priming was also investigated here to clarify 
the differences resulting from these alternate methods. The hybridisations of the 
target resulting from these 2 priming methods are shown in Figure 4.16. Generally,
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the signals seen on the array hybridised to target synthesised via a specific primer 
mix (Figure 4.16A), are stronger than those seen when oligo-dT was used (Figure 
4.16B). It is possible that the labelled DNA targets produced via specific priming are 
shorter and therefore bind more efficiently to the probes on the array, compared to 
those produced by oligo d(T) priming. Furthermore, the relative signal strengths 
observed after hybridisation differed slightly depending on the priming method. This 
is also likely to be due to the nature of the targets that result from the priming 
method used. Specific primers will tend to produce approximately 300bp products, 
whereas oligo d(T) primed products will be the length of the RNA transcripts.
The results of the hybridisation suggested that the specific primer mix was the more 
efficient method of labelling target, compared to oligo-dT primers. This validated the 
design of the array, and therefore, the specific array primer mix was retained as the 
method for priming RNA.
Figure 4.16 (following page). Comparison of 2 priming methods for DNA array target 
synthesis.
RNA was isolated from NIH 3T3 cells infected for 12h by MHV-68. Target was prepared by 
reverse transcription of the RNA using A. a specific primer mix, or B. oligo-dT primers. The 
results of hybridising the targets to arrays are shown above. The layout of these arrays is as 
shown in Appendix II. The bottom right corner of each array was cut to aid orientation.
137
A. Specific primers ..................................... . . . .
* ♦ * . . .  #  *  *  •  •  •  •  • • •  •  ♦  •
•  •  •  • * *
I I I  Us i n  :::* ♦ ♦ x f v f  » % * * * •
i
B. Oligo-dT primers ......................
138
4.4.11 Manual Pin-Spotted Arrays
Unfortunately, the Biomek robot became unavailable for use and therefore a 
manual pin-spotting tool was adopted (384-pin multiblotter; V&P Scientific). This 
tool has the same droplet volume as the tool used by the robot, and therefore the 
same protocol for producing arrays was used as before.
On this array, 2 replicates of each probe were spotted at a concentration of 50ng/pl. 
The layout of the manual pin-tool arrays are shown in Appendix II. The top left 
corner of each array was cut to aid orientation.
An example of a hybridisation with a manually pin-tool spotted array is shown in 
Figure 4.17. Mock-infected and 12h pi sample hybridisations are shown. The 
housekeeping gene probes found towards the bottom of the arrays are seen to bind 
target in both hybridisations. Viral probes are seen to bind target only in the 12 pi 
sample hybridisation.
Figure 4.17 (following page). Examples of hybridisation to pin-tool spotted DNA arrays.
NIH 3T3 cells were A. mock-infected, or B. infected for 12h by MHV-68. RNA was isolated 
and target synthesised, before hybridisation. To aid orientation, the top left corner of each 
array was cut, and is denoted above by a triangle. The layout of the arrays is as shown in 
Appendix II.
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4.5 RNA Template Titration
Target synthesis, array manufacture and hybridisation conditions had now been 
optimised. However, the amount of starting RNA template had yet to be optimised. 
The reverse transcription of target cDNA had been optimised using 5pg total RNA 
as template. A series of hybridisations were now performed to investigate the 
effects that varying RNA template concentration had on the signal strengths seen 
on the array.
The hybridised arrays were scanned on a phosphoimager and the signals for each 
probe quantified. The mean signal for each probe was then plotted on a bar chart, 
as shown in Figure 4.18. The 3 panels show 5pg, 10pg or 20pg of template, 
respectively. All 3 graphs were plotted on the same scale to help aid comparison of 
varying RNA template concentration. A smaller graph set into each panel shows the 
results of each hybridisation plotted on a scale appropriate to that hybridisation. 
These smaller graphs allow comparison of the profile for each array. In other words, 
the larger graphs allow a quantitative comparison of hybridisations (due to the 
absolute scale), while the smaller graphs allow a qualitative comparison (due to the 
relative scale).
As RNA template concentration was increased, the strength of signal also 
increased. This was particularly evident for the stronger signals, e.g. F3, F4, F5, 
and F6. As signal strength relates to the amount of target binding to probe, this 
indicated that more RNA resulted in more labelled target cDNA.
While the stronger signals were seen to get increasingly stronger with RNA 
concentration, the weaker signals (e.g. B1-8) did not increase significantly in 
intensity between 10pg (Figure 4.18b) and 20pg (Figure 4.18c) of template RNA. 
This suggested that there was some selectivity during the labelling reaction for 
those RNA species present in more abundant quantities.
Plotting each array’s signals on a relative scale for each array, as shown in the 
smaller graphs, made the observations above clearer. Whilst the overall profiles for 
hybridisations at each RNA template concentration were very similar, as RNA 
concentration was increased, the profile appeared to be stretched along the y-axis. 
This resulted in the difference between the largest and smallest signals being 
accentuated when 20pg of RNA was used (Figure 4.18c). This also resulted in the 
difference between smaller signals becoming smaller, making differentiation of 
these small signals more difficult.
141
High signal strengths were desirable as were signals that could be easily 
differentiated from each other, at any level of signal intensity. Therefore, 10pg was 
set as the amount of RNA template to be used for future arrays.
Figure 4.18 (following page). Effects of varying template RNA concentration on final 
hybridisation signal strengths.
RNA isolated from NIH 3T3 cells infected for 24h was isolated and used as template to 
produce labelled target that was hybridised to arrays. The signals on the array were 
quantified on a phosphoimager and plotted for each probe. Each probe is identified by a 
letter and number shown on the x-axis and in the key. The signal strength is shown on the 
y-axis in arbitrary units. A set of smaller graphs are presented within each panel, to show 
the overall profile for each RNA concentration relative to itself. Each probe was designated 
a letter and number and corresponds to a gene, as listed in Table 4.1. A. The results of 
using 5pg total RNA template. B. The results of using 10pg total RNA template. C. The 
results of using 20pg total RNA template. The layout of these arrays is as shown in 
Appendix II.
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4.6 Normalisation of Array Data
While optimising the array, it had been noted that the housekeeping gene probes 
consistently showed very low signals when analysing infected samples. A 
comparison between the housekeeping gene signals from arrays hybridised with 
target derived from uninfected cells, and target derived from infected cells is shown 
in Figure 4.19. It is clear that MHV-68 infected cells show a significant reduction in 
levels of housekeeping gene RNA, relative to uninfected cells. Therefore, the 
transcription of housekeeping genes could not be used for normalising data from 
separate arrays, as their levels were shown to vary through the course of an 
infection.
□ 24h pi 
■ Oh pi
H2 H5
Housekeeping Gene Probes
Figure 4.19. Comparison of signals for housekeeping gene probes between arrays 
hybridised to target derived from RNA of uninfected cells and those infected for 24h. 
Housekeeping gene probe signals for the uninfected cell array are plotted behind, with the 
corresponding signals from the infected array plotted to the front of the graph.
As a method of normalisation for data from separate arrays was required, a 
separate internal control was developed. An additional probe to luciferase mRNA  
was designed, and incorporated into the M HV-68 array. To act as an internal 
control, 10ng of luciferase RNA was added to each RNA sample, prior to synthesis
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of labelled cDNA target. All hybridisation signals on arrays could now be expressed 
as a signal ratio relative to the luciferase signal. As the hybridisation signal for 
luciferase corresponded to the same quantity of RNA, signals from separate arrays 
(that would be subject to variations in labelling efficiencies, hybridisation efficiencies 
etc) could be compared directly.
To assess the efficiency of this process of normalisation, NIH 3T3 cells were 
infected with MHV-68 for 5h and then analysed with the array. This was then 
repeated. Each step from initial infection to quantification of signal was performed 
independently for each array analysis. Background was calculated as the mean of 
signals recorded for the negative control probes for TMV and plasmid (but not the 
“water probe”, which was excluded from background calculations). The background 
subtracted signals from these 2 independent array analyses were then plotted 
against each other. Linear regression returned a line of gradient 0.80, and the 2 
datasets had a correlation coefficient of r = 0.76 (see Figure 4.20A). This showed 
that data derived from independent array experiments did not match each other 
quantitatively. The data was now normalised by conversion into signal ratios 
relative to the internal luciferase control. The same graph as in panel A was re­
plotted using normalised data. Linear regression of this plot returned a line of 
gradient 0.99, while the correlation coefficient for the 2 datasets was r = 0.94 (see 
Figure 4.20B). This showed that normalisation of data from independent arrays was 
successful by this method. Therefore, the luciferase normalisation would be used 
before comparing data from all subsequent arrays.
Finally, to simulate comparing multiple arrays with each other, the same process 
was repeated a further 2 times. This allowed a cross-comparison of 4 independent 
analyses of transcription at 5h pi. The scatter plot is shown in Figure 4.20, panel C. 
Linear regression returned a gradient of 1.01 and a correlation coefficient of r =
0.91. This confirmed that multiple arrays could be compared directly to each other 
using luciferase normalised data. It also served to further reinforce confidence in 
this method of normalisation.
Furthermore this experiment was a measure of the reproducibility of the MHV-68 
array. The gradient of 1.01 suggested that the array was indeed a reproducible 
system, based on 4 independent array experiments.
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Figure 4.20. Scatter plots of DNA array data showing effects of normalisation.
A. Background-subtracted data from two repeated arrays (time point 5h pi) were plotted 
against each other. Linear regression analysis gives a line of gradient 0.80 (r = 0.76). B. The 
data from the array in (A) were subjected to normalisation via the internal control and these 
normalised data were plotted against each other. Linear regression analysis gives a line of 
gradient 0.99 (r = 0.94). (C) Reproducibility of arrays was assessed by plotting four repeated 
arrays (time point 5h pi) against each other in all combinations. Linear regression analysis 
gives a line of gradient 1.01 (r = 0.91).
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4.7 Assessing Sensitivity of Arrays
Having optimised the array system and a method to allow comparison of data 
across arrays, its sensitivity was now assessed. NIH 3T3 cells were infected with 
MHV-68 at moi’s ranging from 1 pfu/106 cells -  20pfu/cell, and RNA isolated 5h pi. 
The RNA was used as template to reverse transcribe labelled target, which was 
hybridised to arrays.
Mean signal values were calculated from the 2 replicates of each probe, and 
normalised to the internal luciferase control. The global transcription profiles at 5h 
pi, following infection at moi 1 - 0.001 are shown in Figure 4.21A-D. The strength of 
transcription signals were seen to decrease with moi. The detection of a 
representative selection of transcripts, ORF 52-58, is shown in panel E of Figure 
4.21. The selection includes both abundantly and weakly expressed genes. This 
graph shows the results for infections at moi 1 pfu/cell -  1 pfu/106 cells.
These results suggest a lower limit of sensitivity for the MHV-68 array, of 1 infected 
cell in 100 cells. However, a working limit of 1 infected cell in 10 was set to ensure 
that all experimental data were significantly within the limits of sensitivity.
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Figure 4.21. Sensitivity of the MHV-68 array.
NIH 3T3 cells were infected with MHV-68 at a range of moi’s. RNA was isolated 5h pi and 
used as template for reverse transcription of labelled target. Following hybridisation, the 
normalised signal ratios were calculated and are shown here as bar charts. Global 
transcription profiles are shown in panels A -  D, representing infections at moi 1 (A), 0.1 (B), 
0.01 (C) and 0.001 (D) pfu/cell. E. A representative selection of transcripts is shown 
separately (ORF 52-58). The selection was made to include abundantly and weakly 
expressed transcripts. Moi’s are indicated as a value of pfu/cell. The layout of these arrays 
is as shown in Appendix II but the probe signals are shown in a different order to that in 
Figure 4.18.
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4.8 Discussion
The aim of the work presented in this chapter was to design and develop an array 
system to study the transcriptional profile of MHV-68 at a global level. Similar array 
systems already in use were used as templates and guides for this array system 
(Zhu, 1998; Chambers, 1999; Stingley, 2000; Jenner, 2001). A membrane-based 
cDNA probe array system hybridising radio-labelled cDNA target was decided upon 
as a suitable system for this analysis of MHV-68 gene expression. This solution 
provided the best combination of performance and practicality.
Bioinformatics software was used to design primer sequences for the amplification 
of probe sequences using MHV-68 DNA as template. Every primer was designed to 
have the same biochemical properties. This allowed the whole set of 3’ primers to 
be used together to prime the labelling reaction. Software was also used to 
minimise the possibility of cross hybridisation between primers, and non-specific 
binding between probes and targets.
Each probe sequence was cloned and sequence verified. Attempts to sequence 
probes G5 and G8 were unsuccessful, possibly due to their high GC content. 
However, as they appeared to be the correct probe sequence based on PCR  
amplification with probe-specific primers, they were included on the array as non­
sequence verified probes. A high efficiency protocol for amplification of probes from 
plasmid stocks was developed to allow simple generation of probe stocks for 
spotting onto arrays.
The actual array itself was based on a charged nylon membrane. Probe sequences 
were spotted onto these membranes using a manual 384-pin tool. Probe 
concentrations of 25ng/pl to 100ng/pl were found to show a linear relationship with 
signal strength. The concentration of probe for spotting onto array membranes was 
set at 50ng/pl.
Total RNA was used as the initial template for the MHV-68 array. RNA was isolated 
from samples using the optimised RNA isolation protocol developed in Chapter 3.2. 
RNA template concentration was set at 10pg following hybridisations with varying 
amounts of template. These hybridisations showed that increasing RNA template 
increased signal strengths overall, which made reading the arrays clearer and any 
non-specific background levels were smaller in comparison. However, with 
increased template, the highest signals became higher and the lowest signals 
became lower, relative to each other. Ten pg total RNA was set as the template 
concentration.
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The labelling reaction was found to return consistently better results when using 
Superscript II reverse transcriptase. This enzyme also made it possible to increase 
incubation temperature and time which greatly increased yield. Primer 
concentrations were increased to 0.2mM. The hybridisation process was optimised 
to reduce non-specific binding by adding C0T-1 DNA to the hybridisation solution.
An overview of the optimised protocol is shown in Figure 4.22. The specifics of the 
optimised protocol are as follows:
1. Isolate total RNA from samples using the protocol developed for the 
differential display system, including DNAse treatment, quantification and 
quality assessment.
2. 10(xg RNA was spiked with 10ng of luciferase mRNA, and primed with the 
array primer mix (0.2pM) for 5min at 70°C, then place on ice.
3. Add the reverse transcription reaction mix: 1x first strand buffer, 1mM 
dT/G/CTP, 2.5|iCi/jLil a -33P dATP and 5U/pJ Superscript II reverse 
transcriptase, in a final volume of 20|xl. Incubate for 90min at 50°C. The 
reaction was terminated by adding 1^1100mM EDTA, before placing on ice.
4. The labelled target was purified using the Nucleospin kit and denatured at 
95°C for 5min prior to hybridisation.
5. At the same time, arrays were denatured by placing them on a filter paper 
soaked with denaturation buffer (0.66M NaCI, 0.5M NaOH) for 10 min and 
then washing in ddH20  for 10min. Finally they were washed in 40mM  
phosphate buffer pH7.3 for 10min.
6. Arrays were prehybridised at 60°C for at least 30min in Expresshyb 
containing salmon sperm DNA and murine C0T-1 DNA.
7. The denatured target was hybridised to arrays in fresh Expresshyb with 
salmon sperm DNA and murine C0T-1 DNA at 60°C for approximately 16h.
8. The arrays were washed 3 times for 15min each at low stringency. They 
were then washed another 3 times for 15min each at high stringency.
9. Arrays were covered in cling film and used to expose phosphor screens.
10. Arrays signals were quantified using a phosphoimager. The data was 
background subtracted and normalised to the luciferase signal. Analyses of 
the data were performed.
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Figure 4.22. Overview of the MHV-68 Array system.
151
The optimisation of the MHV-68 array was performed bearing consideration to the 
global nature of the system. It was important that the system was capable of 
distinguishing each of the individual probe signals that make up the global 
transcription profile. Such a system should be able to process data across a large 
dynamic scale, encompassing the potential transcription levels of each gene. In this 
way the data produced by the array data becomes more than the sum of its 
individual probes, as it also provides a complete picture of gene expression, one 
gene’s expression relative to all other genes represented on the array.
However, developing a working array system proved to be complicated. The series 
of optimisation experiments showed that the methods used to produce arrays were 
important factors in the successful subsequent application of arrays. The vacuum- 
spotted arrays appeared to bind high levels of background signal and therefore did 
not produce reliable data. The pin-spotted arrays however, were successfully used. 
The main difference between these 2 array systems was the nature of the probes. 
The probes on the vacuum-spotted arrays were much larger in diameter and 
covered a larger area of the membrane than their counterparts on the pin-spotted 
arrays. While the total amount of DNA in each probe on the 2 arrays differed 
greatly, the concentration of DNA per unit area was equal for both arrays. The 
much higher quantities of probe DNA on the vacuum-spotted array could result in 
increased background to signal ratios, as the total background noise would 
increase with the amount of probe DNA, whereas actual signal would only increase 
until all target DNA was hybridised.
Another key difference between the two arrays was that the probe DNA was 
denatured in situ for the pin-spotted arrays as opposed to the vacuum-spotted array 
probes, which were denatured prior to spotting. It is possible that the probes on the 
vacuum-spotted arrays were not fully denatured by the time the probes were fixed 
onto the array membrane, which would reduce the specificity of the vacuum-spotted 
arrays. This would also have the result of increasing the background to signal ratio. 
It seems likely that these differences between the 2 arrays were responsible for the 
difference in results, when the 2 arrays were tested.
With a working MHV-68 array, other factors such as hybridisation conditions and 
the target synthesis reaction could be optimised. Sensitivity and reproducibility of 
the MHV-68 array system was then assessed and a method of normalisation 
developed to allow cross-comparison of array data.
This process from design through optimisation to a final working array system has 
now provided the opportunity to investigate MHV-68 at the level of gene expression.
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The array technology will now be implemented to perform this investigation. 
However, it remains necessary to test the array system in a real experimental 
situation, before its efficacy can be fully determined.
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5 DNA Array Analysis of MHV-68 Transcription during an In 
Vitro Lytic Infection
While there have been several gene expression studies of gammaherpesvirus 
latency (Heller, 1982; Hall, 2000) and also reactivation (Miller, 1994; Zalani, 1996; 
Speck, 1997), few have focused on de novo productive infection due to a lack of 
suitable in vitro systems in which to study it. The aim of the work presented here 
was to perform a global study of MHV-68 gene expression using the membrane- 
based DNA array system, designed and optimised as described in Chapter 4. To 
this end, a productive lytic infection was followed in a permissive tissue culture 
system.
5.1 DNA Array Analysis of MHV-68 Transcription In Vitro
Confluent NIH 3T3 cell monolayers were infected with extracellular virus at moi 10 
and cells harvested at 1, 3, 5, 8, 12 and 18h pi. Mock-infected cells were also taken 
at 1h and 24h pi. Total RNA was extracted at each time point, reverse transcribed 
and the resulting radiolabelled cDNA targets hybridised to arrays, using the 
optimised protocols described in Chapter 4.
The signals from each array were quantified and mean signal ratios were calculated 
for each probe from the replicate arrays (n = 4, except 1h pi (n = 2) and 5h pi 
(n=6)). The data for each time point was plotted as a bar chart and can be seen in 
Figure 5.1 - Figure 5.7. This series of hybridisations showed that MHV-68’s global 
transcriptional profile changes as it progresses through its life cycle, and that 
individual genes have individual expression kinetics.
5.1.1 DNA Array Analysis of Uninfected Cells
The MHV-68 array includes probes for 9 housekeeping genes. When mock-infected 
NIH 3T3 cells were screened with the array, a range of signals for these 
housekeeping genes were observed (Figure 5.1). Of these, ubiquitin was the most 
highly expressed, showing approximately half the signal observed for the luciferase 
probe. Signals for GAPDH, (3-actin, ribosomal protein S29, and HPRT were evident 
as well. The probes for myosin 1, MOD, Cab45 and phospholipase showed very 
little signal. This suggests that there were only low levels of these transcripts in 
confluent NIH 3T3 cells, and that the abundance of these transcripts were below 
the sensitivity threshold of the array. It may be possible to optimise the sequence of 
the probes for these genes and increase their sensitivity. The housekeeping genes 
were selected based on general maintained expression in a number of
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physiological states (4.2.3), and therefore it was not surprising that some were not 
highly expressed in NIH 3T3 cells. As expected, the 100ng of luciferase RNA added 
to the template RNA produced one of the highest signals on the array, both here 
and on subsequent infected sample arrays.
There were also a few viral probes (ORF 35, 46, M10c-72, M14) that bound very 
low levels of target. Although levels of non-specific hybridisation were estimated 
and subtracted from the array data, this shows that it was not completely effective 
as no viral RNAs were present in this RNA sample. It may be possible to optimise 
the background probes to more accurately simulate non-specific hybridisation to the 
array probeset, and also to make the viral probes more specific to their target 
cDNA. For the purposes of this analysis, an arbitrary cut off point of 0.05 was set. 
This arbitrary value was twice the highest background signal seen on the array 
hybridised to mock-infected samples.
RNA samples was also isolated from mock-infected cells 18h pi and analysed on 
the array. This hybridisation showed the same results as those from mock-infected 
samples taken 1 h pi (data not shown). This indicated that any changes in 
housekeeping gene transcript levels, observed between 1h and 18h pi, were likely 
to be due to the effects of MHV-68 infection.
5.1.2 DNA Array Analysis of Cells Infected for 1h
The viral transcription profile at 1h pi (Figure 5.2) was similar to that seen in mock- 
infected cells (shown in Figure 5.1) as almost no viral signals were observed. 
Again, a small number of viral probes (ORF 4, 35 46, M14) bound low levels of 
target, but none were above the cut-off point (5.1.1). However, even at this early 
time after infection, the abundance of housekeeping gene transcripts was reduced 
relative to their levels in uninfected samples. This suggested that MHV-68 very 
quickly down-regulated host transcription, within 1h pi. Rapid shutoff of host gene 
expression has also been observed in other herpesvirus infections (Read, 1983; 
Bigger, 2002).
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Figure 5.1. DNA array analysis of mock-infected cells.
NIH 3T3 cells were mock-infected and harvested and RNA isolated for the synthesis of 
radiolabelled cDNA target. Target was hybridised to the MHV-68 DNA array, and signals 
quantified with a phosphoimager. The mean signals for each probe were normalised against 
the luciferase signal. The dataset was then plotted to aid analysis. The bar chart shown 
represents the mean dataset of independent experiments (n = 4).
Figure 5.2. DNA array analysis of cells infected by MHV-68 1h pi.
NIH 3T3 cells were infected and harvested 1h pi! The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n = 2).
Figure 5.3. DNA array analysis of cells infected by MHV-68 3h pi.
NIH 3T3 cells were infected and harvested 3h pi. The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n = 4).
Figure 5.4. DNA array analysis of cells infected by MHV-68 5h pi.
NIH 3T3 cells were infected and harvested 5h pi. The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n = 6).
Figure 5.5. DNA array analysis of cells infected by MHV-68 8h pi.
A. NIH 3T3 cells were infected and harvested 8h pi. The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n = 4). B. Changes in transcript abundances 
between 5h and 8h pi. The relative changes in signal ratios, between the 2 time points for 
each probe were plotted. The relative change was calculated by subtracting the signal ratio 
at the previous time point, from the current signal ratio. An increase in signal ratio between 
the 2 time points is represented as a bar rising above the x-axis, and a decrease as a bar 
falling below the x-axis.
Figure 5.6. DNA array analysis of cells infected by MHV-68 12h pi.
A. NIH 3T3 cells were infected and harvested 12h pi. The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n = 4). B. Changes in transcript abundances
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between 8h and 12h pi. The relative changes in signal ratios were calculated as detailed for 
Figure 5.5.
Figure 5.7. DNA array analysis of cells infected by MHV-68 18h pi.
A. NIH 3T3 cells were infected and harvested 18h pi. The array hybridisation was performed 
and resulting data analysed as detailed for Figure 5.1. The bar chart shown represents the 
mean dataset of independent experiments (n -  4). B. Changes in transcript abundances 
between 12h and 18h pi. The relative changes in signal ratios were calculated as detailed 
for Figure 5.5.
5.1.3 DNA Array Analysis of Cells Infected for 3h
At 3h pi there was still little viral transcription overall (Figure 5.3) but the signals for 
some transcripts were above the cut-off point. They are listed in Table 5.1. Of 
these, ORF 59 (homologous to the processivity subunit of herpesvirus DNA 
polymerase) was detected at much higher levels than any other transcript, with a 
signal ratio of 0.35. Interestingly, most of the genes listed in Table 5.1 are predicted 
to encode proteins involved in DNA replication (ORF 6, 7, 54, 59, 60, and 61). 
Similarly, in HSV-1, the ribonucleotide reductase genes are transcribed at a very 
early stage of infection (Swain, 1986; Wymer, 1992; Hanson, 1994).
In addition to DNA replication, other highlighted transcripts consisted of a 
chemokine-binding protein (ORF M3), a predicted a  protein (ORF 57) and also, 2 
structural genes (ORF 35, 58) and a DNA packaging protein (ORF 7). M3 is known 
to be a chemokine binding protein (Parry, 2000) and it is interesting to see that a 
gene involved in immune system evasion is expressed at this early time point post­
infection. a  gene transcripts would be expected to be detected at this early stage of 
infection, and therefore the putative function of a-protein assigned to ORF 57 
seems corroborated by its relatively high transcript levels 3h pi. The detection of 2 
structural genes and a DNA packaging protein is a little surprising as these y gene 
products are not required by the virus at this early stage of infection. However, y1 
genes are transcribed prior to viral DNA replication and this is likely to be the case 
here. ORF 10 was also highlighted, but there are no functional predictions for this 
ORF.
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Table 5.1. Viral transcripts present at relatively high levels (more than twice the background 
signal) in NIH 3T3 cell infected for 3h by MHV-68.
Probe Putative Function
M3 Chemokine binding protein (Parry, 2000)
6 ssDNA binding protein
7 DNA packaging
10 Unknown
35 Tegument protein
54 UTPase
57 a  protein
58 Membrane protein
59 DNA polymerase, processivity subunit
60 Ribonucleotide reductase, small subunit
61 Ribonucleotide reductase, large subunit
5.1.4 DNA Array Analysis of Cells Infected for 5h
There was a considerable increase in viral transcript levels at 5h pi compared to 
previous time points (Figure 5.4). This was evident across the whole of the MHV-68 
genome, indicating a rapid escalation of viral gene expression between 3h and 5h 
pi. Indeed, every viral probe showed higher signal ratios at 5h pi than at 3h pi.
The signals for ORF M3 and 59 were significantly higher than those of other genes, 
with signal ratios of 1.8 and 1.6, respectively. Seventeen probes returned signal 
ratios greater than 0.25, and these are listed in Table 5.2. The 6 DNA replication 
genes highlighted at 3h pi, are also highlighted here in Table 5.2, with the addition 
of ORF 9 (putative catalytic subunit of DNA polymerase). Four genes predicted to 
encode structural proteins (ORF 58, M9, 66, 67), and 2 genes involved in immune 
system evasion (ORF M3, 4) are also listed in Table 5.2 (Virgin, 1997; Milligan, 
1998). There are also 4 genes with no putative function, which would be interesting 
to study further.
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Table 5.2. Viral transcripts with signal ratios great than 0.25 in NIH 3T3 cells infected with
MHV-68 for 5h.
Probe Putative Function
M3 Chemokine binding protein (Parry, 2000)
M4 Unknown
6 ssDNA binding protein
7 DNA packaging protein
9 DNA polymerase, catalytic subunit
M6 Unknown
18 Unknown
52 Unknown
54 UTPase
57 a  protein
58 Membrane protein
59 DNA polymerase, processivity subunit
60 Ribonucleotide reductase, small subunit
61 Ribonucleotide reductase, large subunit
M9 Capsid protein
66 Capsid protein
67 Tegument protein
5.1.5 DNA Array Analysis of Cells Infected for 8h
Between 5h and 8h pi, the viral transcriptome changed considerably (Figure 5.5A). 
Of 88 viral probes, 68 showed increased signal ratios relative to levels at 5h pi. 
Many of the transcripts that had been highlighted for their relatively high signal 
ratios at previous time points were now observed to have fallen in abundance.
Twenty-seven probes returned signal ratios of greater than 0.25, which was an 
indication of the generally high level of viral gene expression occurring. The sum 
signal on the array was highest at this time point, which showed that viral 
transcription was maximal around 8h pi. Seven probes returned signal ratios of 
greater than 0.5, and these are listed in Table 5.3.
169
Table 5.3. Viral transcripts with signal ratios great than 0.5 in NIH 3T3 cells infected with
MHV-68 for 8h.
ORF Putative Function
M3 Chemokine binding protein (Parry, 2000)
45 Unknown but required for efficient replication in v /W
52 Unknown
59 DNA polymerase, processivity subunit
M9 Capsid protein
66 Capsid protein
67 Tegument protein
inhibition of ORF 45 expression leads to reduction of viral replication (Jia, 2003)
ORF M3 and 52 still dominated the transcriptional profile at 8h pi, both with signal 
ratios of 2.15. ORF 59 was also highly expressed, but was the only gene involved in 
DNA replication with a signal ratio above 0.5. Three structural transcripts were also 
abundant (ORF M9, 66, 67), as well as 2 genes of unknown function.
However it should be noted that transcripts present in low abundances can be as 
significant as transcripts that are abundant. Indeed the abundance of a transcript is 
only one measure of gene expression. For example, changes in expression 
patterns may be more functionally significant than absolute levels. Therefore, these 
relative changes in transcript abundance were plotted, as shown in Figure 5.5B.
This shows that the levels of 19 transcripts fell between 5h and 8h pi, as listed in 
Table 5.4. Levels of ORF 59 had decreased by the greatest extent, which shows 
that while ORF 59 was one of the most abundant transcripts at this time point, its 
levels were actually falling. As ORF 9 levels also fell between these 2 time points, it 
seems likely that the synthesis of DNA polymerase had peaked by 8h pi. In total, 6 
genes involved in DNA replication that had previously been highlighted for their high 
transcript levels, were all found to have fallen in abundance between 5h and 8h pi 
(ORF 6, 7, 9, 59, 60, 61). This suggests that the synthesis of proteins for replication 
of MHV-68 DNA had peaked by 8h pi. However, the relationship between synthesis 
of DNA replication proteins and viral DNA replication remains unclear.
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Table 5.4. Viral transcripts decreasing in abundance between 5h and 8h pi with MHV-68.
Probe Putative Function Signal
Reduction
M1-M2 Unknown -0 .18
M2-M1 Unknown -0 .3 4
M2-M3 Unknown -0 .0 2
M4 Unknown -0 .0 3
6 ssDNA binding protein -0 .0 7
7 DNA packaging protein -0 .0 5
9 DNA polymerase, catalytic subunit -0 .0 9
10 Unknown -0 .12
11 Unknown -0 .02
K3 Bovine herpesvirus 4 a  protein homologue -0 .02
M6 Unknown -0 .24
48 Unknown -0 .09
M8 Exon of ORF 57 -0 .04
57 a  protein -0.11
58 Membrane protein -0.21
59 DNA polymerase, processivity subunit -0 .57
60 Ribonucleotide reductase, small subunit -0 .22
61 Ribonucleotide reductase, large subunit -0 .13
M10c Unknown -0 .02
Two putative a  gene transcripts (ORF K3, 57) fell in abundance between 5h and 8h 
pi. This was unsurprising for a  gene transcription. However, the fall in abundance of 
a structural protein transcript (ORF 58) was surprising, as a y gene would be 
expected to be transcribed up to the later stages of the infection cycle. This, 
combined with the relatively high levels of ORF 58 transcripts detected at early time 
points, seems incompatible with its sequence homology to a membrane protein of 
other herpesviruses. However, examining the genetic organisation around ORF 58 
shows that it lies downstream of ORF 59, with which it is predicted to share a 
polyadenylation site. Therefore, the ORF 59 transcript would contain the ORF 58 
sequence, and the ORF 58 probe would detect both ORF 58 and 59 transcripts. As 
ORF 58 is a highly expressed p gene, it seems likely that the unexpected 
expression profile for ORF 59 is due to binding of the ORF 59 transcript to the ORF
58 probe. Indeed ORF 59 transcripts were observed to fall in abundance between 
5h and 8h pi. Nine probes for unknown genes and inter-genic regions also showed 
reduced signals at this time point. These would be interesting to analyse further.
5.1.6 DNA Array Analysis of Cells Infected for 12h
At 12h pi, the global transcription profile is in sharp contrast to that seen at 5h and 
8h pi, as shown in Figure 5.6A. In particular a cluster of structural genes (ORF M9, 
66, 67 & 68) now dominate the transcriptome, with signal ratios of 2.35, 1.61, 1.17 
and 0.82, respectively. These represent 4  of the 7 probes with signal ratios above 
0.5, which are listed in Table 5.5. ORF M3 and 2 genes with no predicted function 
also have signal ratios above 0.5. A further 13 probes returned signal ratios greater 
than 0.25 at this time point.
Table 5.5. Viral transcripts with signal ratios great than 0.5 in NIH 3T3 cells infected with 
MHV-68 for 12h.
Probe Putative Function
M3 Chemokine binding protein (Parry, 2000)
45 Unknown
52 Unknown
M9 Capsid protein
66 Capsid protein
67 Tegument protein
68 Glycoprotein
The change in transcript abundances between 12h and 8h pi is shown in Figure 
5.6B. This highlights the changes between the 2 time points, and shows that the 
majority of transcripts have fallen in abundance. This suggests that few genes were 
expressed at this stage of the lytic infection cycle. In particular ORF M3, 52 and 59 
transcript levels had fallen greatly, although their overall levels were still relatively 
high. Ten transcripts did increase in abundance between these time points (Table 
5.6), including the cluster of predominantly structural genes (ORF M9, 66, 67, 68). 
The products of these genes are likely to be required by MHV-68 towards the final 
stages of the replication cycle.
ORF 75C also increased in abundance to a relatively high degree. ORF 75B, which 
is thought to be another copy of the A/-formylglycinamide ribotide amidotransferase 
enzyme encoded by ORF 75C, does not show a similar increase. However, as the 
2 ORFs are predicted to share a polyadenylation site, the signal detected by the
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ORF 75C probe would be expected to be higher than that by the ORF 75B probe, 
as is the case for ORFs 58 and 59 (see 5.1.5).
The remaining genes listed in Table 5.6 showed relatively small increases in 
transcript abundance of +0.05 or less and therefore may not be significant. For 
example, the probe for M2-M3 is amongst these. The signal ratio for this probe fell 
by 0.02 between 5h and 8h pi, and then increased by 0.04 between 8h and 12h pi. 
Overall the M2-M3 probe bound little signal, and its profile showed a gradual 
increase up to a signal ratio of 0.13 at 12h pi. The generally low signal detected by 
this probe, and the fluctuation in its expression profile combine to suggest that the 
signal detected by the M2-M3 probe does not represent a transcript, and most likely 
represents non-specific hybridisation.
Table 5.6. Transcripts increasing in abundance between 8h and 12h pi by MHV-68.
Probe Putative Function Signal
Increase
M2-M3 Unknown 0.04
4 Complement regulatory protein (Kapadia, 1999) 0.03
M6 Unknown 0.03
19 DNA packaging protein 0.04
M9 Capsid protein 1.30
66 Unknown 0.86
67 Membrane protein 0.37
68 DNA packaging protein 0.32
M10c Unknown 0.02
74 G-protein coupled receptor 0.05
75C /V-formylglycinamide ribotide amidotransferase 0.19
5.1.7 Array Analysis of Cells Infected for 18h
The transcription profile at 18h pi (Figure 5.7A) was very similar to the profile at 12h 
pi (Figure 5.6A). The main difference was that the cluster of structural genes (ORF 
M9, 66, 67, 68) no longer dominated the transcriptome. Instead, their expression 
levels were now similar to those of ORF M3 and 52. The same 7 genes showed 
signal ratios greater than 0.5 at 18h pi (Table 5.5) as had done at 12h pi (Table 
5.4).
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Generally, the trend that was observed between 8h and 12h pi continued to 18h pi; 
few transcripts increased in abundance. Even the cluster of structural genes that 
had shown increasing abundance between 8h and 12h pi, was now falling in 
abundance. This suggests that few structural genes are transcribed after 12h pi, 
and that by 18h pi, active transcription of viral genes is no longer occurring. 
However, as overall transcript levels remain high (Figure 5.7A), translation of viral 
genes is likely to continue.
ORF 52 is highlighted in Figure 5.7B, as it shows a large increase in transcript 
abundance. However, from 8h pi to 18h pi, its signal ratio decreased by 0.32. 
Therefore, while there was an increase in signal ratio seen at 18h pi, overall ORF 
52 transcript levels were lower at 18h pi than at 8h pi.
5.1.8 Cluster Analysis of Expression Profiles
The analyses performed in 5.1.1 - 5.1.7 are based on the absolute levels of 
transcript detected by each probe. While quantitative in nature, this approach tends 
to emphasise highly expressed genes. It is also useful to examine each 
transcription profile relative to itself, so that features such as the point at which a 
transcript’s abundance peaks, and rate at which that peak is reached, are 
emphasised. Therefore, the MHV-68 transcription data was converted onto a 
relative scale so that peak transcript abundance = 1 (2.4.2b). Cluster analysis of the 
transformed data grouped genes with similar expression profiles (Eisen, 1998). This 
technique allows groups of genes that are transcribed with similar kinetics but not 
necessarily at similar levels to be identified. The resulting clusters of genes can be 
used to make functional predictions for genes that have not been characterised, or 
that have no characterised homologues (for example ORF 52), as functionally- 
related genes are often transcribed with similar kinetics (Eisen, 1998).
The results of this analysis were visualised using Treeview software (Eisen, 1998), 
and are shown in Figure 5.8. Treeview software formats the output as a tree 
diagram showing the relatedness of expression profiles. To the right of the tree, 
each gene’s expression profile is shown as a series of coloured boxes, with 
intensity of colour proportional to relative transcript abundance. The gene that the 
profile represents is given to the far right of Figure 5.8.
The expression profiles clustered into groups representing 4 general profiles, and 
these are represented in the 4 line graphs, shown on the left of Figure 5.8. The 
branches of the tree diagram and the line graphs have been colour coordinated to 
show which group each graph refers to. It’s interesting to note that while protein-
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based studies of viral gene expression kinetics generally produce 3 groups (a, (3 
and y), this RNA-based study has produced 4 groups.
The red cluster consists of transcripts that start to be expressed the earliest, which 
peak at 5h pi and then fall in abundance. This group of genes includes several 
genes predicted to be involved in DNA replication (ORFs 6, 9, 59, 60 and 61, r2 = 
0.992), which demonstrates the function-related grouping that results from cluster 
analysis. The group also contains 3 putative a  genes (ORFs K3, M8 and 57, r2 = 
0.997), which suggests that viral DNA replication proteins start to be synthesised at 
an early stage of the MHV-68 life cycle. This analysis confirms the results of the 
previous one based on absolute transcript levels (5.1.1 - 5.1.7).
The cluster shown in green showed a peak in expression at 5h pi followed by a 
more gradual fall, in comparison to the previous cluster (shown in red). This cluster 
was the largest, containing 41 genes. Functional groupings were also observed 
within this cluster. For example the genes homologous to glycoprotein L and H of 
other herpesviruses were placed on adjacent branches of the tree. These 2 
glycoproteins are expressed together as the 2 form a heteromeric complex 
(Hutchinson, 1992). Similarly, the transcription profiles of ORFs 40 and 56 lie 
adjacent to each other. Both these genes are homologous to characterised genes 
that are constituents of herpesvirus DNA helicase-primase complexes (Crute, 
1989b). ORF 44, which is homologous to the third constituent of the helicase- 
primase complex, is found to cluster very close to ORFs 40 and 56 as well.
Figure 5.8 (following page). Hierarchical cluster analysis of MHV-68 expression profiles.
Data in the form of log2 normalised means (duplicates, n = 2-6) was converted into a 
percentage of each gene’s maximum. These percentages were imported into Cluster 
software and hierarchical clustering performed using the average-linkage algorithm and an 
uncentred correlation similarity matrix. The data is shown as a colour matrix with columns 
representing time points pi and rows representing each gene’s expression profile. Black 
boxes represent no expression and brighter shades of red correspond to increasing 
expression. The dendogram shows related expression profiles on the same branch, with 
branch lengths representing the degree of similarity between individual profiles. Line graphs 
of clustered genes are shown to the left, with the colour of each line graph corresponding to 
the dendogram branch of the same hue.
175
I
CN 00
O  H  ro  LD 00 H  rH
ORF4 6 U-DNA GLYCOS 
ORF7 TRANSPORT 
M4
ORF 3 4 
M5
ORF50 REACTIV 
ORF4 9 
Ml
ORF3 5 TEGUMENT 
ORF 6 9
ORF36 KINASE 
ORF42 TEGUMENT 
ORF3 7 ALK EXONUC 
ORF 5 5 
ORF8 GP B 
ORF3 0
ORF43 CAPSID 
ORF2 9 PACKAGING 
ORF4 7 GP L 
ORF22 GP H 
ORF54 UTPase 
ORF23
ORF32 TEGUMENT 
ORF62 ASSEMBLY 
Mil 
M12
ORF73 IE PROT 
ORF63 TEGUMENT 
ORF26 CAPSID 
ORF27
ORF17 CAPSID 
M3
OR31 
M2
ORF21 THYM KIN 
ORF64 TEGUMENT 
ORF56 DNA REP PROT 
ORF4 0 HELICASE 
ORF72 CYC D HOM 
ORF 18 
ORF24
ORF44 HELICASE 
ORFIO
ORF9 DNA POL 
ORF61 RNR, LARGE 
ORF4 8 
K3
ORF57 IE PROT 
M8
ORF59 DNA REP PROT 
ORF58 MEMBRANE 
ORF60 RNR, SMALL 
ORF6 ssDNA BIND PROT 
M6
ORF66 CAPSID 
M9
ORF19 TEGUMENT 
ORF6 8 GP 
ORF67 TEGUMENT 
ORF75C TEGUMENT 
ORF74 IL-8 R HOM 
ORF45 
ORF 5 2 
ORF20
ORF53 MEMBRANE 
ORF3 3 TEGUMENT 
M7 GP 150 
ORF3 8 TEGUMENT 
ORF75b TEGUMENT 
ORF25 MCP 
ORF 4
176
The remaining 2 clusters are shown in light and dark blue in Figure 5.8. The genes 
in these 2 clusters (those with predicted functions) are homologous to herpesvirus 
structural genes. The light blue cluster contains ORFs 25 (major capsid protein), 33 
(tegument protein), 38 (membrane protein), M7 (glycoprotein 150; Stewart, 1996) 
and 53 (membrane protein). It also contains ORFs 20, 45 and 52, which have no 
characterised homologues. The dark blue cluster includes ORFs 19 (tegument), 66 
(capsid) and 68 (glycoprotein). ORF M9 is one of the genes in this cluster and was 
originally designated as unique to MHV-68 (Virgin, 1997). However, it has since 
been found to be homologous to a capsid protein (ORF 65) of other 
gammaherpesviruses (Milligan, 1998).
The key difference between the expression patterns of these 2 clusters is the time 
at which they reach their peak abundance. The light blue cluster reaches and 
maintains a peak of expression at around 8h pi. The dark blue cluster tends to peak 
around 12h pi and are the last set of genes to reach peak levels of expression. It 
would be interesting to characterise the genes further to see if the 2 clusters 
correlate to the y1 and y2 kinetic classes.
These results highlight the ability of cluster analysis to produce functionally-related 
groups of genes. However, there are some drawbacks to this technique. In 
particular the potential of cluster analysis is somewhat limited by the nature of 
herpesvirus gene expression, as herpesviruses characteristically transcribe their 
genes in a tightly regulated cascade. Therefore, genes of the same kinetic class are 
likely to have similar expression profiles. This can be seen in the green cluster, 
which includes many functional classes of genes. They include the putative genes 
for thymidine kinase (ORF 21), glycoprotein H (ORF 22) and a cyclin D homologue 
(ORF 72). These functionally diverse genes cluster together, although within the 
cluster there are more related groups of genes. Perhaps, a more rigorous algorithm 
to group expression profiles could be useful to further divide this group. Viral genes 
tend to all be expressed with similar kinetics and so an algorithm specifically 
designed for analysis of viral transcription could prove useful in this case. The 
development of further analytical techniques for array data remains a priority for 
genomic studies.
Cluster analysis of MHV-68 gene expression has shown that different functional 
groups can be temporally related. Therefore, while it is possible to hypothesise that 
genes without characterised homologues in the red cluster (ORFs 10, 48 and M6) 
could be involved in DNA replication or a  genes, like the other cluster members, 
further study is required before more robust predictions can be made. M6 is
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particularly interesting as it is a gene unique to MHV-68, with no homologues 
currently in the gene databases.
5.2 Gene Expression in the Presence of Viral Protein 
Synthesis Inhibition
5.2.1 Inhibition of Protein Synthesis with Cvcloheximide
To dissect the transcriptional behaviour of MHV-68 further, a  genes were 
characterised by blocking de novo protein synthesis with CX. Initial studies using 
100|jg/ml and 50|jg/ml concentrations of CX resulted in cell death of NIH 3T3 cell 
monolayers, although these concentrations were often used in similar studies 
(Nicholas, 1990; Haque, 2000). However, other studies have shown that these 
levels of CX can result in apoptosis for a variety of cell types (Martin, 1995). 
Therefore, to define the concentration required for 95% inhibition of protein 
synthesis, the metabolism of radiolabelled methionine by NIH 3T3 cells was 
measured in the presence of 100|ig/ml -  0.1ng/ml CX.
NIH 3T3 cell monolayers were incubated in the presence of radiolabelled 
methionine and a range of CX concentrations. After 6h, the incorporation of 
methionine was quantified. Figure 5.9 shows that in the presence of 50pg/ml and 
100jug/ml, the NIH 3T3 cells were unable to metabolise any methionine. In fact, 
95% inhibition of protein synthesis was obtained with only 2pg/ml CX, and therefore 
this dose was used in all subsequent experiments. As the CX was solublised in 
DMSO, control monolayers were incubated with equivalent concentrations of 
DMSO alone. These cells showed no inhibition of methionine uptake.
5.2.2 Characterisation of MHV-68 a Genes
An array experiment was set up to investigate gene expression in the presence of 
95% protein synthesis inhibition. NIH 3T3 cell monolayers were both pre-treated 
with, and then infected in the presence of CX. Negative controls (uninfected cells in 
the presence of CX) and positive controls (cells infected in the absence of CX) were 
also included. Cells were harvested at 5h and 8h pi and RNA was isolated for 
subsequent array hybridisations. The results of these hybridisations are shown in 
Figure 5.10.
At both 5h and 8h pi, ORF 73 transcript levels were higher when protein synthesis 
was inhibited, than when it was not. This suggested that ORF 73 continued to be 
transcribed, and accumulated, in the absence of a switch to (3-class gene
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expression, and that ORF 73 transcription did not require de novo viral protein 
synthesis. Therefore, ORF 73 was characterised as an a  gene.
At 5h pi, ORFs 29b and 35 showed slightly higher transcript abundances when (3 
gene transcription was inhibited by CX than when it was not. However, at 8h pi, the 
levels of these genes had decreased compared to their levels at 5h pi when de 
novo protein synthesis was inhibited. Furthermore their transcript levels increased 
between 5h and 8h pi if CX was not used. This suggests that these genes are not a  
genes as the opposite trend in their levels would be expected if this was the case. 
Indeed, examining the results for uninfected samples hybridised to the array show 
that the signals for these 2 ORFs were similar to background levels, which again 
suggests that these are not a  genes (data not shown).
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Figure 5.9. Incorporation of radiolabelled methionine by NIH 3T3 cells in the presence of 
CX.
NIH 3T3 cell monolayers were incubated in the presence of varying concentrations of CX. 
The cells were then infected with MHV-68 and radiolabelled methionine introduced into the 
medium. Cells were harvested after 6h and the level of methionine incorporation measured. 
The y-axis shows percentage incorporation of labelled methionine relative to uninhibited 
controls. The x-axis shows the concentration of CX in the cell medium.
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Figure 5.10 (preceding pages). DNA array analysis of MHV-68 gene expression in the 
absence of de novo protein synthesis.
NIH 3T3 cells were infected in the presence of CX to produce a 95% protein synthesis 
block, or without inhibition. RNA was isolated from cells harvested at 5h and 8h pi, and used 
to produce radiolabelled target for hybridisation to arrays. Signals from a single 
representative experiment were quantified, normalised and plotted as bar charts. A. Array 
analysis of cells infected in the presence of CX 5h pi. B. Array analysis of uninhibited cells 
5h pi. C. Array analysis of cells infected in the presence of CX 8h pi. D. Array analysis of 
uninhibited cells 8h pi.
5.3 Gene Expression in the Presence of Viral DNA 
Replication Inhibition
Having characterised a  gene expression, y genes were also studied. 4 ’-S-EtdU is a 
thionucleoside analogue and has been shown to be a potent inhibitor of MHV-68 
DNA replication (Barnes, 1999). Therefore, NIH 3T3 cells were pre-treated and 
infected in the presence of 200ng/ml 4-S-EtdU, which has been shown to 
completely inhibit MHV-68 replication as determined by plaque assay (Barnes, 
1999). Negative (uninfected with 4-S-EtdU) and positive (infected without inhibition) 
controls were also set up. Cells were harvested at 5h and 18h pi.
The results of hybridisations with samples taken at 18h pi (n = 4) are shown in 
Figure 5.11. The transcription profile of an infection where viral DNA replication has 
been inhibited by the antiviral 4 ’-S-EtdU is shown in Figure 5 .11A, and that of an 
uninhibited infection in Figure 5.11B. It is clear that there is reduced viral 
transcription globally in the presence of 4 ’-S ’EtdU.
Figure 5.11C quantifies the difference between these 2 profiles, as the uninhibited 
dataset has been subtracted from the inhibited dataset and the results plotted. 
Negative values (represented as bars below the x-axis) indicate reduced transcript 
abundances when viral DNA replication is blocked, while positive values 
(represented by bars rising above the x-axis) represent transcripts that accumulate 
when the block is in place. This shows that the presence of 4 ’-S-EtdU has 
effectively reduced the transcription of some transcripts, e.g. ORF 52 and the 
cluster of structural genes (ORF M9 -  68) that are abundant at this time point. Its 
presence has also resulted in some transcripts increasing in abundance relative to 
uninhibited infections, indicating that blocking viral DNA replication has resulted in 
continued transcription and accumulation of some transcripts.
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infections
Figure 5.11 (preceding pages). Expression of MHV-68 genes in the absence of viral DNA 
replication.
NIH 3T3 cells were infected with or without inhibition of viral DNA replication. RNA was 
isolated from cells harvested 18h pi and used to produce radiolabelled target that were 
hybridised to arrays. Array data was quantified using a phosphoimager and the results 
plotted as bar charts (n = 4). A. Array analysis of cell infected for 18h in the presence of 4’- 
S-EdtU. B. Array analysis of uninhibited cells 18h pi. C. Difference in signal ratios due to 
inhibition of viral DNA replication. The dataset from the uninhibited infection was subtracted 
from the inhibited infection dataset. The results were plotted on a bar chart so that an 
increase in transcript abundance following inhibition is represented by bars above the x- 
axis. Bars below the x-axis represent decreased transcript abundance following inhibition. 
D. The relative difference in signal ratios due to inhibition of viral DNA replication. The 
differences between the uninhibited and inhibited datasets was transformed onto a relative 
scale so that the change in signal for each probe was represented as a percentage of its 
signal when infection was uninhibited. Y-axis values of +1 correspond to a 100% increase in 
transcript abundance, and -1 to a 100% reduction in transcript abundance.
As different transcripts are present at different levels, the results of Figure 5.11C  
were transformed onto a relative scale to further analyse the impact of the viral 
DNA replication block on each transcript’s levels relative to itself. These results are 
shown in Figure 5.11D. Again bars below the x-axis show reduced levels and bars 
above the axis, increased levels of transcripts. However, a value of -1  on the y-axis 
indicates that the transcript’s abundance was reduced to zero by the presence of 4 ’- 
S-EtdU. A value of +1 on the y-axis indicates that the abundance of the transcript 
has doubled in the presence of 4 ’-S-EtdU. The absence of a bar, or a value of 0 on 
the y-axis, indicates that there was no difference in expression between uninhibited 
and inhibited infections.
Complete inhibition of viral DNA replication has been observed with 200ng/ml 4 ’-S- 
EtdU (Barnes, 1999), but Figure 5 .11D shows a less than complete shutoff of many 
potential y genes occurring under the same conditions. While most probes showed 
close to 100% reduction in signal when viral DNA replication was inhibited, several 
probes showed a range of reductions in transcript abundance. Forty-two probes 
showed a reduction in transcript abundance of 50% or more, and 15 probes 
showed less than 50% signal reduction. The remaining 29 probes showed an 
increase in signal, and were therefore designated (3 genes.
To ascertain which transcripts were significantly reduced in abundance, in the 
presence of 4 ’-S-EtdU, the standard deviation for probe signals was calculated from
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4 replicate arrays. Only signals that became reduced by more than 2 measures of 
standard deviation were characterised as those of y genes. Forty-nine probes met 
these criteria, as listed in Table 5.7, and included predicted ORFs as well as inter- 
genic regions.
The inclusion of inter-genic probes in this group is interesting, as this suggested 
that these probes are detecting transcripts whose abundance are affected by the 
inhibition of viral transcription. However, as the analysis shown in Figure 5.11D is a 
relative one, it is useful to refer back to Figure 5.11B and Figure 5.11C to see the 
actual levels of signal detected by these probes and also the quantitative effects of 
4 ’-S-EtdU inhibition.
Figure 5 .11B shows that the level of signal detected by the inter-genic probes in an 
uninhibited infection are low (signal ratios ranging from 0.014 -  0.048). Figure 
5.11C shows that the reduction in signal when viral DNA replication is inhibited is 
also low (reductions range from 0.008 -  0.033). These results indicate that the 
change in signal for these inter-genic probes is high relative to themselves, but very 
small quantitatively. Therefore, further studies are required to determine whether 
these inter-genic regions do encode transcripts.
One inter-genic probe did however show clear relative and absolute changes in 
signal when viral DNA replication was inhibited. This was the probe for ORF 27- 
29A, which showed an 82% reduction in signal, or a change of -0 .0 7  in absolute 
terms. This suggested that this inter-genic probe could be detecting a transcript.
Further analysis showed that a number of genic probes also showed very small 
absolute changes, but which corresponded to large relative changes. Therefore, 
ORFs 21, 36, 40, 56 and 73 were designated non-y genes and are shown in a grey 
font in Table 5.7. The remaining 38 genes were designated y genes and are shown 
in a black font.
Interestingly, even at 5h pi, there was a difference in signal detected for some of the 
y genes between inhibited and uninhibited infections (data not shown). Similar to 
the inter-genic probes at 18h pi, while the relative differences were high, the 
quantitative analyses show that the actual signals were small and the difference in 
signals smaller. Therefore, further study is required before this difference can be 
confirmed.
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Table 5.7. Probes showing reduced signal following inhibition of viral DNA replication.
Probe Putative Function Change in Transcript Levels
M1-M2 Unknown -59%
M2 Unknown -50%
M3-M4 Unknown -73%
M4-M3 Unknown -81%
4 Complement regulatory protein -74%
8 Glycoprotein B -77%
K3-M5 Unknown -62%
M5-K3 Unknown -69%
17 Capsid protein -38%
18 Unknown -61%
19 Minor capsid protein -89%
20 Unknown -86%
21 Thymidine kinase -77%
22 Glycoprotein H -56%
23 Unknown -78%
24 Unknown -51%
25 Major capsid protein -86%
26 Capsid protein -72%
27 Unknown -83%
27A-29 Unknown -82%
29 DNA packaging protein -76%
30 Unknown -68%
31 Unknown -69%
33 Tegument protein -77%
34 Unknown -50%
35 Tegument protein -43%
36 Serine-threonine protein kinase -61%
39 Glycoprotein M -70%
40 Component of helicase-primase complex -69%
42 Tegument protein -32%
43 Minor capsid protein -84%
45 Unknown -80%
M7 Glycoprotein 150 -62%
52 Unknown -86%
53 Membrane protein -85%
56 Component of helicase-primase complex -73%
63 Tegument protein -71%
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Probe Putative Function Change in Transcript Levels
64 Tegument protein -38%
M9 Capsid protein -93%
66 Capsid protein -93%
67 Tegument protein -94%
68 DNA packaging protein -93%
69 None -42%
73 None -72%
74 G-protein coupled receptor -85%
75c Formylglycinamide ribotide amidotransferase -89%
75b Formylglycinamide ribotide amidotransferase -85%
M12 None -50%
M13 None -66%
5.4 Verification of Array Data
Some of the array data presented here is reflected and confirmed in previous work 
using alternate methods, such as northern blot analysis and RNAse protection 
assay, to examine MHV-68 transcription (Mackett, 1997; Husain, 1999; Simas, 
1999; Wu, 2000b; Rochford, 2001). However, northern blot analysis was also 
employed here to further confirm the data presented. Northern blots were prepared 
with RNA isolated from MHV-68 infected NIH 3T3 cells at various times pi, along 
with mock-infected controls. Additional northern blots were prepared using RNA 
isolated from cells infected in the presence of CX to represent a  gene expression, 
and also 4 ’-S-EtdU to show y gene expression.
Ten pg of total RNA, which had been spiked with 10ng luciferase mRNA, was 
loaded into each well of a denaturing agarose gel. Once RNA samples had been 
size separated by electrophoresis, they were blotted onto membranes. All probes 
were sequence verified before hybridisation to blots.
5.4.1 Northern Blot Analysis of ORF M3
When northern blots were probed for ORF M3 (chemokine binding protein), a single 
transcript of approximately 1.2kb was detected. M3 was expressed at 5h pi and 
showed continued high levels of mRNA up to 18h pi, as shown in Figure 5.12A. 
This confirmed the results obtained from array analyses (Figure 5.2 - Figure 5.7).
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ORF M3 transcripts could not be detected when cells were infected in the presence 
of CX, as shown in Figure 5.13A. This confirmed that M3 was not an a  gene as 
concluded from the array analyses shown in Figure 5.10.
A. ORF M3
Time pi: Oh 5h 8h 12h 18h
B. (3-actin
Time pi: Oh 5h 8h 12h 18h
Figure 5.12. Northern blot analysis of ORF M3 transcription.
NIH 3T3 cells were infected and harvested for isolation of RNA at various time points pi. The 
RNA was size separated on a denaturing gel and blotted onto nylon membranes. 
Radiolabelled probes were then hybridised to the membranes. The results were visualised 
using a phosphoimager. A. Hybridisation with ORF M3 specific probe. B. A control 
hybridisation for p-actin. The time pi when cells were taken for RNA isolation is indicated 
above each panel. Approximate sizes of transcripts are indicated to the right.
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A. ORF M3
Time pi: Oh 3h 5h 3h 5h
B. (3-actin
Time pi: Oh 3h 5h 3h 5h
Figure 5.13. Northern blot analysis of ORF M3 transcripts in the presence of CX.
NIH 3T3 cells were infected and harvested for isolation of RNA at various time points pi. The 
RNA was size separated on a denaturing gel and blotted onto nylon membranes. 
Radiolabelled probes were then hybridised to the membranes. The results were visualised 
using a phosphoimager. A. Hybridisation with ORF M3 specific probe. B. Control 
hybridisation for p-actin. The time pi when cells were taken for RNA isolation is indicated 
above each panel. Underlined time points indicate presence of CX. Approximate sizes of 
transcripts are indicated to the right.
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5.4.2 Northern Blot Analysis of ORF 67
A probe for ORF 67 (tegument protein) was found to hybridise to RNA isolated 18h 
pi, predominantly to a band of around 4.5kb. This hybridisation is shown in Figure 
5.14A. There were also a number of faint bands at 18h pi. This was expected as 
ORF 67 has been predicted to be part of a nested set of co-terminal genes with 
ORF 65 and 66 (Milligan, 1998). Very faint bands were also visible at 5h pi. 
Transcription of ORF 67, 66 and 65 were detected by the array from 5h to 18h pi, 
as shown in Figure 5.4 - Figure 5.7.
ORF 67 probe was also hybridised to RNA isolated from cells infected in the 
presence of 4 ’-S-EtdU, also shown in Figure 5.14A. At 18h pi, the predominant 
band was found to be greatly reduced in intensity, suggesting that the transcript 
showed y  kinetics. Fainter bands also appeared reduced in intensity. 
Characterisation of y  genes with the array had concluded that ORF 67, 66 and 65 
were all y  genes, as shown in Figure 5.11.
A. ORF 67
Time pi: 0 5 5 0 18 18
I
~4.5kb
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B. (3-actin
Time pi: 0 5 5 0 18 18
~1.9kb
Figure 5.14 (preceding and current page). Northern blot analysis of ORF 67 transcripts in 
the presence of 4 ’-S-EtdU.
NIH 3T3 cells were infected and harvested for isolation of RNA at various time points pi. The 
RNA was size separated on a denaturing gel and blotted onto nylon membranes. 
Radiolabelled probes were then hybridised to the membranes. The results were visualised 
using a phosphoimager. A. ORF 67 specific probe B. p-actin. The time pi when cells were 
taken for RNA isolation is indicated above each panel. Underlined time points indicate 
presence of 4’-S-EtdU. Approximate sizes of transcripts are indicated to the right.
5.4.3 Northern Blot Analysis of ORF 52 and 53
ORF 52 and 53 are also predicted to share a poly-adenylation signal (Milligan, 
1998). An ORF 52 probe was found to hybridise predominantly to a band of around 
400bp, and also to a band of around 700bp, as shown in Figure 5.15A. The 400bp  
band was visible at 5h pi, but was much stronger between 8h and 18h pi. The 
700bp band was fainter than the smaller one, and present between 8h and 18h pi. 
The array showed that ORF 52 was expressed from 5h pi, and was heavily 
expressed between 5h and 18h pi (Figure 5.4 - Figure 5.7).
A probe for ORF 53 was also hybridised to the same blot. This hybridised to a 
single band of around 700bp, as shown in Figure 5.15B. A faint band was seen at 
8h, 12h and 18h pi. Array analysis of ORF 53 transcription suggested that ORF 53 
was expressed at lower levels than ORF 52. The array showed that ORF 53 started 
to be expressed at 5h pi and was then expressed at higher levels up to 18h pi 
(Figure 5.4 - Figure 5.7).
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A. ORF 53
Time pi: Oh 5h 8h 12h 18h
B. ORF 52
Time pi: Oh 5h 8h 12h 18h
Figure 5.15. Northern blot analysis of ORF 52 and 53 transcripts.
NIH 3T3 cells were infected and harvested for isolation of RNA at various time points pi. The 
RNA was run out on a denaturing gel and blotted onto nylon membranes. Radiolabelled 
probes were then hybridised to the membranes. The results were visualised using a 
phosphoimager. A. ORF 53 probe. B. ORF 52 probe. It should be noted that the same blots 
were stripped and reprobed in Figure 5.12 and Figure 5.15. The time pi when cells were 
taken for RNA isolation is indicated above each panel. Approximate sizes of transcripts are 
indicated to the right.
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5.4.4 Northern Blot Analysis of P-actin
Each of the northern blots probed for viral transcripts, were stripped and probed for 
p-actin. These control hybridisations showed that the abundance of p-actin 
transcripts reduced over the course of infection with MHV-68. By 18h pi, p-actin 
transcripts were hardly detectable, as shown in Figure 5.12B. This result confirmed 
the observation made from initial array analyses that showed housekeeping gene 
transcripts were down-regulated following infection. This also reconfirmed the need 
for a control, additional to the housekeeping genes, for normalisation of array 
datasets allowing their cross-comparison.
Luciferase mRNA was also probed for, as shown in Figure 5.16. This showed a 
band of equal intensity in all lanes, which suggested that equal quantities of 
luciferase mRNA was present in each lane. Therefore, equal quantities of luciferase 
mRNA had been spiked into each RNA sample.
p-actin transcript levels were reduced in cells infected in the presence of CX, 
relative to levels in mock-infected cells, as shown in Figure 5.13B. However, the 
levels of p-actin appeared less affected when the infection was inhibited by CX, 
relative to uninhibited infections. This suggested that while host protein synthesis 
shut off occurred in the absence of viral protein synthesis, it was most efficient 
when MHV-68 a  proteins were produced. Finally, the relative abundance of p-actin 
in the uninfected lanes suggested that any toxicity to the cells caused by CX was 
minimal.
Figure 5.16 (on following page). Northern blot analysis to confirm internal luciferase control. 
NIH 3T3 cells were infected and harvested for isolation of RNA at various time points pi. Ten 
ng luciferase RNA spiked into each sample. RNA was then size separated on a denaturing 
gel and blotted onto nylon membranes. Radiolabelled probes were then hybridised to the 
membranes. The results were visualised using a phosphoimager. It should be noted that 
this blot is the same blot used in Figure 5.12 and Figure 5.16 (after stripping). The time pi 
when cells were taken for RNA isolation is indicated above each panel.
198
Time pi: Oh 5h 8h 12h 18h
5.5 Summary of MHV-68 Lytic Gene Expression
The data from the experiments presented here can be summarised as a map of 
MHV-68 transcriptional profiles (Fig. 8). Red arrows correspond to a-genes, defined 
as genes that are transcribed when de novo protein synthesis is blocked. Blue 
arrows show y-genes, defined as genes whose expression is reduced if viral DNA  
replication is inhibited. The remaining genes are shown with green arrows and most 
likely show p-class kinetics, although this is as yet not a defined group. It should be 
noted that the signals generated for ORF 11 and 39 (Figure 5.2 - Figure 5.7) are 
very low and most likely at the threshold of sensitivity for the array. Therefore, 
further studies will be required to fully characterise the transcriptional profiles of 
these genes. Interestingly, with the exception of these two genes, it seems unlikely 
that any strictly latent genes are represented on the array as all the other genes 
show expression during a lytic infection.
It is clear that genes with similar kinetics tend to cluster on the genome. The 
expression of y-genes tends to follow one of two profiles. These are a relatively late 
initiation of transcription followed by a sustained or a reduced expression. However, 
there is a continuous range of profiles between these two extremes suggesting that 
there is a range of regulatory mechanisms controlling the expression of these 
genes.
The remaining set of genes all show early peaks followed by reduced expression, 
which is characteristic of p-genes. However, it has been shown here that this is also
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a feature of a-genes. Although the time course data shows genes to have distinct 
transcriptional profiles, there is an overlap between genes of different kinetic 
classes. This demonstrates the need to block f3- or y-transcription to elucidate the 
kinetic organisation of the genome.
Figure 5.17 (on following pages). Transcriptional Map of MHV-68.
Expression profiles for the genes of MHV-68 were placed onto a physical map of the viral 
genome. Each expression profile is shown as a bar chart indicating transcript levels at Oh, 
1 h, 3h, 5h, 8h, 12h and 18h pi. Each gene’s expression profile is plotted on a relative 
scaled, normalised to its own maximal expression. Each gene is colour coded with respect 
to its expression kinetics. Red arrows represent a genes, blue arrows represent y genes and 
green arrows represent the remaining set of genes, predicted to be p genes. White arrows 
represent genes not included on the MHV-68 array.
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5.6 Discussion
The aim of the work in this chapter was to use the cDNA membrane-based array 
(developed as described in Chapter 4) to perform a global study of MHV-68 gene 
expression. The work presented here includes the first comprehensive analysis of 
gammaherpesvirus transcription throughout a de novo productive infection cycle.
5.6.1 Effects of MHV-68 Infection on Host Gene Expression
Similar to other herpesviruses (Nishioka, 1977; Fenwick, 1990), MHV-68 appears to 
effect a rapid shutoff of host protein synthesis. Results of the differential display 
analysis of MHV-68 infection of BHK cells (3.4.3) showed that the poly-A RNA 
population of infected cells was far less complex compared to mock-infected 
controls. This suggested that the range of mRNA species being produced by 
infected cells was less than in uninfected cells. Array analysis of MHV-68 infection 
has confirmed this initial observation, as the abundance of host gene transcripts 
was observed to fall following infection of NIH 3T3 cells by MHV-68. This reduction 
in host RNA levels was observed as early as 1h pi (5.1.2), and continued up to 18h 
pi (5.1.7). This was conclusively confirmed by northern blot analysis of p-actin 
transcript levels following infection (5.4.4).
5.6.2 Kinetics of MHV-68 Gene Expression
The kinetics of MHV-68 gene transcription were examined by inhibiting infections 
with CX or 4 ’-S-Etdll. Only 1 viral transcript was found to exhibit a  kinetics: ORF 73 
transcript levels increased when de novo protein synthesis was blocked, relative to 
uninhibited infections. ORF 73 is the only herpesvirus a  gene to have homologues 
in every sequenced mammalian and avian herpesvirus (UL54 in HSV-1). The 
gamma-2 herpesvirus ORF 73 homologues only conserve the C-terminal domain of 
ORF 73 (Albrecht, 1992; Russo, 1996; Virgin, 1997). This conserved C-terminal 
domain also shares secondary structure homology with the DNA binding domain of 
EBV nuclear antigen 1 (EBNA-1) (Grundhoff, 2003), which suggests that the gene 
could have shared functions across both gamma-1 and gamma-2 herpesvirus 
subgroups.
HHV-8 ORF 73 or latency-associated nuclear antigen (LANA) is expressed during 
latency (Gao, 1996a; Gao, 1996b; Rainbow, 1997) and known to interact with P-53 
(Friborg, Jr., 1999) and RING3 (Platt, 1999), but it not known whether these 
functions map to the conserved or HHV-8 specific regions of ORF 73. As LANA is 
much larger than ORF 73 of MHV-68, bovine herpesvirus-4, HVS and macaque 
rhadinovirus, these functions could be specific to HHV-8. Therefore, the exact
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function of ORF 73 in MHV-68 is unclear, but has been confirmed to be an a  gene 
in this study.
Although only 1 a  gene was identified by the array, it is possible that other genes 
were expressed in the absence of de novo protein synthesis, but below the 
detection sensitivity of the array. Therefore, RT-PCR was also employed to 
examine a-gene expression (data not shown). ORF 73 was readily detected by RT 
PCR in the presence of CX, which confirmed the results of the array. However, faint 
bands corresponding to ORFs 50, 57 and K3 could also be detected indicating that 
these too could be a-genes (data not shown).
Other studies of MHV-68 a-gene expression using different techniques and 
experimental conditions to those used here, have suggested that ORFs 57, 50 and 
K3 are expressed in the absence of protein synthesis (Liu, 2000; Rochford, 2001). 
Furthermore HSV-1 is known to express 5 a  genes (Roizman, 2001a) and HHV-8 
encodes more than 1 (Talbot, 1999; Zhu, 1999) so it seems likely that MHV-68 also 
encodes more than 1 a  gene. Therefore, a more sensitive, dedicated study of a - 
transcription may be required to fully elucidate a  gene transcription in MHV-68. 
Interesting there have been problems elucidating a  transcription in HHV-8 (Renne, 
1998; Sun, 1999). However, this could be due to having to rely on a chemically 
induced reactivation of the virus from latently-infected cell, instead of following a de 
novo infection.
The genes designated as p genes in this study are not a defined group, but rather 
classified by a process of elimination. They consist of those genes that did not 
qualify as a  or y genes (5.5). MHV-68’s p genes are typical in that they consist 
primarily of genes involved in viral genome replication. The genes designated as y 
genes, however, were defined, as those transcripts showing reduced abundances 
when viral DNA replication was inhibited by 4-S-EtdU (5.3). Typically again, these y 
genes consist mainly of genes for structural components of the virus.
Hierarchical cluster analysis of the transcriptome through an uninhibited productive 
infection resulted in 4 groups of transcription profiles (5.1.8). The first cluster 
consisted of genes whose expression peaked quickly by 5h pi and then fell quickly 
again. They consisted mainly of genes involved in DNA replication (e.g. ORF 9 
DNA polymerase, ORF 60 & 61 ribonucleotide reductase subunits), as well as 
candidate a  genes (ORF K3, ORF 57). The majority of MHV-68’s genes were 
represented in cluster 2. Their expression also peaked by 5h pi, but then remained 
at higher levels. They included an a  gene (ORF 73), DNA replication genes (e.g.
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ORF 54 UTPase, ORF 56 primase protein) as well as structural proteins (e.g. ORF  
8 glycoprotein B, ORF 43 capsid protein).
The transcription profiles in clusters 3 and 4 were similar as all these profiles 
showed a late peak in transcript abundance, followed by a maintained high level. 
However, cluster 3 profiles peaked by 8h pi, whereas cluster 4 profiles peaked by 
12h pi. The genes in these clusters consisted of structural components of the virus 
(e.g. ORF 25 major capsid protein, ORF 67 tegument protein).
5.6.3 Individual Transcription Profiles
As has been touched on earlier, most of the results from the array analyses are 
reflected in the expression kinetics of the small subset of MHV-68 genes which 
have been studied by various northern blots and RNAse protection assay 
experiments (Mackett, 1997; Husain, 1999; Simas, 1999; Wu, 2000b; Rochford, 
2001). Many of the remaining genes have homologues in other herpesviruses 
which have been better characterised and which allow useful comparison with the 
data presented here. For example herpes simplex virus 1 (HSV-1) genes UL24, 
UL37 and UL49a have been shown to be y-genes (Roizman, 2001a) and their 
predicted homologues in MHV-68, ORFs 20, 53 and 63 have been shown here to 
have y-kinetics as well. Similarly, HSV-1 genes UL2, UL12 and UL50 are (3-genes 
and in MHV-68, ORFs 46, 37 and 54 have been shown here to be (3-genes as well. 
This demonstrates that the array is a reliable global tool for rapid analysis of MHV- 
68 transcript levels under a variety of conditions during infection.
The majority of MHV-68 genes have not been characterised but most do have 
primary sequence homologues in other herpesviruses, of which some have been 
studied. It is interesting to compare the transcription patterns of MHV-68 genes with 
those of better characterised MHV-68 genes, and also to characterised homologues 
of other herpesviruses.
MHV-68 ORFs 9 and 59 share very similar transcription profiles (5.1); their 2 
profiles cluster with a correlation coefficient of 0.993 (5.1.8). This suggests that the 
2 genes are transcribed together (they peak in transcript abundance by 5h pi after 
which their levels fall, and they form part of the first cluster of genes to peak during 
MHV-68 infection). These genes are homologous to ORFs 9 and 59 of other 
gammaherpesviruses, and are therefore predicted to encode MHV-68 DNA 
polymerase and a replication protein, respectively (Virgin, 1997). The homologues 
of MHV-68 ORF 9 and 59 in HSV-1 are UL30 (DNA polymerase) and UL42 
(processivity factor), respectively. These 2 genes form the HSV-1 DNA polymerase
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heterodimer and are transcribed together (Crute, 1989a). The array data suggests 
that MHV-68 DNA polymerase also consists of an ORF 9 and 59 heterodimer, as it 
shows that these 2 genes are likely to be transcribed together. ORFs 9 and 59 of 
HHV-8 also encode the DNA polymerase and processivity factor, respectively 
(Chan, 2000). However, HHV-8 array analysis suggests that these genes are not 
transcribed together by HHV-8 (Paulose-Murphy, 2001; Jenner, 2001), although 
these studies model reactivating virus as opposed to de novo infection. Further 
studies of MHV-68 DNA polymerase are now required to elucidate transcription of 
these genes by MHV-68.
Another gene, ORF 28, is found in other gammaherpesviruses, but missing from 
the MHV-68 genome. A probe for the inter-genic region between ORFs 27 and 29 
(probe 27/29b) had been included on the array, as were all undesignated 
sequences of more than 100bp (4.2.2). Analysis of the array data suggested that 
this region encoded a gene, as a distinct transcription profile was observed for 
probe 27/29b. This suggested that a gene had been overlooked by Virgin et a/.'s 
analysis of the genome (1997). MHV-68 was subsequently resequenced and the 
genome reanalysed by Milligan et al. (1998), and this analysis predicted an ORF 28 
between ORFs 27 and 29 corresponding to probe 27/29b. The array data suggests 
that Milligan et a/.'s analysis (1998) is correct.
HSV-1 is the best-studied herpesvirus and therefore provides many useful 
comparisons for the array data. Just 7 of HSV-1 's genes are sufficient to replicate 
origin-containing plasmids and these genes are essential for HSV-1 replication: 
UL5, UL8, UL9, UL29, UL30, UL42, UL52 (Schaffer, 1973; Weller, 1983; Wu, 1988; 
Marchetti, 1988). Homologues of these genes are found in most herpesviruses 
including HHV-8 (ORFs 6, 9, 40, 41, 44, 56, 59) (Russo, 1996). However, MHV-68 
has only been found to encode 6 of these and lacks an ORF 41 homologue (Virgin, 
1997). It remains to be seen whether this gene has been overlooked in the analysis 
of the MHV-68 genome. The MHV-68 array shows that ORFs 6, 9 and 59 cluster 
closely together, as do ORFs 40, 44 and 56. Also clustering with ORFs 6, 9 and 59 
is one gene that has no predicted function, ORF M6. It would be interesting to study 
MHV-68 ORF M6 further to see whether it could encode an ORF 41 homologue. 
Although ORF M6 was predicted to be unique to MHV-68 (Virgin, 1997), so too was 
ORF M7. ORF M7 has been shown to the homologous to glycoprotein 150, which is 
well-conserved amongst herpesviruses (glycoprotein 150; Stewart, 1996). 
Interestingly, the second sequence analysis of MHV-68's genome suggests that M6 
is not an ORF (Milligan et al., 1998).
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MHV-68 ORF M3 has been characterised experimentally and has been shown to 
encode an abundantly secreted chemokine-binding protein (van Berkel, 1999; van 
Berkel, 2000; Parry, 2000; Bridgeman, 2001). The 1.4kb M3 transcript has been 
shown to be expressed abundantly at both 12h and 24h pi (van Berkel, 1999), but 
not in the presence of CX. These observations have been confirmed by the MHV- 
68 array data presented here, and also expanded on as the array detected M3 
transcripts by 3h pi. The initial study suggested that ORF M3 was transcribed with 
early-late or y-1 kinetics, as reduced transcript levels were seen on northern blots 
when the infection was inhibited by phosphonoacetic acid (PAA). The antiviral drug 
4 ’-S-EtdU has been shown to be a more potent inhibitor of MHV-68 DNA replication 
than PAA (Barnes, 1999), and array analysis of 4 ’-S-EtdU inhibited infections 
showed that M3 transcript levels were the same as in uninhibited infections. The 
array data also shows that M3 is expressed by 3h pi, its transcript abundance 
peaks at 5h pi and then remains high until late periods of infection. The data 
presented here suggests that M3 is likely to be a p gene.
5.6.4 Advantages and Limitations of Genome-Level Transcription 
Profiling
The array-based system has many advantages over the differential display system 
for type of study attempted here. Most significant of these is that by using a defined 
probeset, there is no redundancy in the data produced. Also, an array-based 
system is guaranteed to provide data for each probe, which allows comprehensive 
datasets to be collected per experiment. These features make the array-based 
analysis more appropriate for the study attempted here.
Although an array-based system was much better suited for the analysis of MHV- 
68’s transcriptome, there are a number of intrinsic limitations to this technology. 
Essentially, arrays function via specific hybridisations between target and probe 
DNA sequences. However, there is always some degree of non-specific 
hybridisation and therefore inter-probe competition. This particularly becomes a 
problem when the target sequences share homology to each other. In the case of 
array analysis of MHV-68 transcription, this becomes manifest with the nested sets 
of co-terminal RNAs. The transcripts for these genes are typically encoded one 
after another on the genome and share a poly-adenylation signal. Therefore, each 
gene’s transcript will have a region of shared sequence. Any probe that is 
homologous to a shared region will obviously bind to more than one target 
transcript.
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For example, ORFs 52 and 53 are predicted to be co-terminal transcripts encoded 
on the right-hand strand of the genome, i.e. the ORF 53 transcript also contains the 
sequence encoding ORF 52. Resolving individual transcription profiles from such 
gene structures can be problematic for methods of transcription analysis. On the 
array, the ORF 52 probe detects both the ORF 52 and 53 transcripts, and therefore 
is not specific for ORF 52 alone. In fact three labelled cDNA species result from 
reverse transcription of these two transcripts, one deriving from the ORF 52 
transcript and two from the ORF 53 transcript. Of these latter two cDNAs (primed by 
the ORF 52 and 53 specific primers, respectively), one will be an artefact that binds 
to both the ORF 52 and 53 probes. It will also be longer than the approximately 
300bp of specific cDNAs and therefore will incorporate more label as well. These 
factors can combine to make the signals observed on the array for such gene 
structures unreliable indicators of transcript abundance. In nested sets of many 
genes, these artefact cDNAs will add unequal background signals to the array 
probes and therefore an alternate method of transcription analysis must be used to 
elucidate the levels of transcription occurring in such sets of genes.
In fact, as there are only two members in this nested set, the transcription levels for 
ORF 52 and 53 on the array were still representative of actual transcription, albeit 
with a higher background, and this was confirmed by northern analysis in this study. 
Northern analysis, which resolves transcription by abundance and size, allowed 
differentiation between the transcripts for ORF 52 and 53 as, although it suffers the 
same redundancy in probe specificity, multiple analyses with individual probes can 
resolve this issue. Therefore, northern blot analysis can be very useful for 
elucidating features (such as co-terminal gene sets) that are beyond the capacity of 
array technology. Furthermore, the potential occurrence of such genomic features 
requires that one is aware of the genomic and particularly, the transcriptional 
organisation of the study subject, both when designing arrays and interpreting the 
resulting data.
Bearing these limitations in mind, the MHV-68 array has been successfully used to 
characterise the virus’ transcriptome through a productive, de novo infection in vitro.
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6 Design and Development of a Oligonucleotide-Based 
MHV-68 Array
6.1 Oligonucleotide-Based Array Systems
Oligonucleotide-based arrays (oligo arrays) have various differing characteristics to 
DNA-based arrays. Typically they employ a larger number of probes permitting 
more detailed studies of transcription, and therefore may be a more powerful tool 
for the study of viral transcription. The aim of this study was to design and develop 
a MHV-68 oligo array, and assess the potential advantages and disadvantages of 
such an oligonucleotide-based system for the analysis of MHV-68 transcription. 
This work was performed in collaboration with the array group at Arrow 
Therapeutics (UK).
The main differences between the MHV-68 DNA array and the MHV-68 oligo array 
systems are presented in Table 6.1. The MHV-68 oligo array was designed to be 
comparable to the DNA array, but also to realise the potential of the oligo array 
technology.
Table 6.1. Main features of DNA- and oligonucleotide-based arrays
DNA Array Oligonucleotide array
1 probe per gene 1 probe per 100bp
dsDNA probes, around 300bp Oligonucleotide probes, 60 bp
2 replicates of each probe 5 replicates of each probe
Probes synthesised by PCR Probes synthesised by phosphoramidite chemistry
Probes spotted onto nylon membrane Probes synthesised in situ on glass slides
Radiolabelled target Fluorescently labelled target
Single labelling only Single or dual labelling possible
Signals quantified using phosphoimager Signals quantified by high resolution laser scanner
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6.2 Oligo Array Probe Design and Synthesis
The probeset for the oligo array was designed at the genome level, in comparison 
to the DNA array, which was designed from an ORF level. One 60-mer 
oligonucleotide probe was designed for each 100bp of MHV-68’s genome, using 
Hotspots software (Arrow Therapeutics). Where possible, the oligonucleotide 
probes were designed to match up with the DNA probes used for the DNA array so 
that comparisons between the 2 platforms could be made at a later stage. Control 
probes for housekeeping genes, luciferase and negative controls were also 
designed. This step was performed by the array group at Arrow Therapeutics. As 
the oligonucleotide probes were designed at the genome level, the probeset 
included multiple probes for each predicted ORF, and also probes for the inter- 
genic regions. Furthermore, probes to the tRNA-like sequences at the left-hand end 
of the MHV-68 genome were also included.
To check the validity of probes designed by Hotspots software, all probes were 
aligned against the whole MHV-68 genome sequence using the FastA algorithm. A 
few probes were found to align to more than 1 region of the genome and were 
therefore discarded. Any probes that extended beyond the limits of an ORF were 
also discarded. Finally any probes that had complementarity to more than one ORF  
were also discarded. All probes that matched with the DNA array probe sequences 
were highlighted for later comparison to DNA array data. Probes that were 
incomplete matches to the DNA array probes were also noted.
In total 1696 probes were designed against the MHV-68 genome. Of these, 1438 
probes were complementary to ORF or tRNA sequences, while 258 probes were 
complementary to inter-genic sequences. Following the FastA alignments, 125 
probes were discarded (equivalent to 7.3%). Seventy six of the discarded probes 
were complementary to the repeat regions of MHV-68. Twenty two probes matched 
more than 1 region of the genome, and the remaining 27 probes corresponded to a 
human error when running the probe design software.
The probeset was replicated 5 times and each probe positioned randomly on the 
array. The finalised probe layout was used as a template for automated in situ 
synthesis of the oligomer probes onto glass slides. It should be noted that the 
resulting MHV-68 oligo arrays are physically much smaller than the DNA arrays, as 
the oligonucleotide probes are present at much higher spatial densities than the 
DNA probes. Unlike other oligo array systems, which tend to use soft-lithography or 
optical deproteination to synthesis the oligonucleotide probes on the arrays, this 
system uses phosphoramidite chemistry to synthesis the probes directly in situ on
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the glass slides that support the array. Importantly this system is more flexible than 
other systems as the reagents are delivered via an inkjet system and there is no 
hard template that requires to be manufactured for each probeset. This flexibility 
allows for rapid modification of probesets, as the array can be altered as quickly as 
new probe sequences can be designed.
As a further control for the oligo arrays, an internal control probe was included. This 
control probe was used to form a grid on the array to aid the orientation of the 
probes, and to show that hybridisation had occurred successfully. A pre-labelled 
oligonucleotide target (incorporating a green fluorescent tag) complementary to the 
control probe was added to the pool of cDNA target prior to hybridisation. The 
target cDNAs were labelled with a Cy5 fluorescent tag, allowing simple 
differentiation between the internal control probes and MHV-68 probes.
6.3 Oligo Array Analysis of MHV-68 Transcription
6.3.1 RNA Template
RNA samples that had previously been used for analysis with the DNA array were 
used again for analysis with the oligo array. The RNA was isolated from NIH 3T3 
cells infected at moi 10, as well as from mock-infected controls. Although RNA 
samples were stored at -80°C, they were checked again to ensure that no 
degradation had occurred using a Bioanalyser 2001 (Agilent Technologies).
Each RNA sample was analysed at 2 concentrations. The electropherogram for 
every sample showed sharp, well defined peaks, with a higher peak for the 28S  
rRNA than for the 18S rRNA. These features indicated that there was minimal 
degradation of the RNA samples. Furthermore, the electropherograms also showed 
that equivalent quantities of RNA were present in each sample, confirming the 
spectrophotometry-based quantification made previously. The electropherograms of 
RNA samples isolated at various times pi are shown overlaid in Figure 6.1. This 
analysis showed that the RNA samples were suitable for use as template in the 
oligo array experiments.
6.3.2 Target cDNA Synthesis
The RNA samples were used to synthesis fluorescently-labelled cDNA target in the 
same way as has been employed for the DNA array system, except that the 
incubation time was increased to 16h (a shorter incubation time is used in the DNA 
array system as RT is denatured over time by the radioactive decay of the labelling 
isotope).
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The probes on the DNA array corresponded to 300bp fragments at the 5 ’ end of 
each ORF. The specific primers used to prime the cDNA target labelling reaction 
were designed to only reverse transcribe the region of mRNA complementary to the 
DNA probe sequences. However, the probes on the oligo array corresponded to the 
entire genome. Therefore, oligo d(T) or random nonomers would need to be used in 
order to make use of all the probes on the array. As some of the probes on the 
array corresponded to tRNA-like sequences, which were unlikely to posses a polyA 
tail, random nonomers were chosen to prime the oligo array target synthesis 
reaction.
28S rRNA peak 18S rRNA peak
Low molecular 
weight marker
Migration Time
Figure 6.1. Analysis of RNA integrity.
RNA samples isolated at 5, 8, 12 and 18h pi, as well as from mock-infected samples, were 
fluorescently labelled and electrophoresed through a RNA LabChip (Bioanalyser, Agilent). 
The resulting electropherograms are shown overlaid to allow simple comparison of the 
profiles. The y-axes show the fluorescence and the x-axes show the migration time of RNA 
through the gel matrix of the RNA LabChip. Each sample consisted of 200ng of RNA.
However, for the purposes of this initial study, specific primers were used to allow 
better comparison to the DNA array system. Hybridisations performed with 
specifically primed target synthesis were found to produce weaker signals overall 
compared to random nonomer primed target synthesis (Figure 6.2). However, the 
dynamic range of signals was similar, whichever primers were used.
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\6.3.3 Oligo Array Hybridisation
The target cDNA was hybridised to the glass oligo arrays for 16h, following 
standardised protocols (Arrow Therapeutics). After hybridisation, the arrays were 
washed and then dipped in ether to dehydrate the array, before being air dried.
6.3.4 Quantification of Oligo Array Data
After scanning the arrays, it became obvious that the several signals on the array 
were beyond the range of the scanner. Therefore, a series of calibration scans were 
performed using varying laser strengths (10% - 100% of maximum, in 10% steps). 
Repetitive scanning of arrays had previously been found to have no effect on the 
strength of fluorescently-labelled target up to 20 consecutive scans (Dr Pete Corish, 
personal communication). RNA isolated at 12h pi was used for these calibrations as 
the DNA array had shown maximal signal strengths at this time point. All signals on 
the array were found to be within the range of the scanner when the laser strength 
was reduced to 20%. Therefore, all subsequent arrays were scanned in this way.
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Figure 6.2. Range of signals on the oligo array.
The probe signals on the oligo array were ordered by magnitude and plotted on a scatter 
graph. The signals from 2 array hybridisations, identical except for the method of priming 
cDNA target synthesis, are shown. cDNA synthesis was either primed by random nonomers 
or viral mRNA specific primers (listed in Appendix I) as indicated in the key.
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To estimate the range of the scanner, all probe signals were plotted in order of 
intensity (Figure 6.2). The plot shows that there is a linear distribution of signals 
over 7 x 102 fluorescence units, which was similar to the dynamic range of the DNA 
array. The lower limit of the scanner was set as 100 units, based on this analysis.
In addition to the signal intensity for each probe, various other criteria were also 
calculated and recorded. In total 50 properties were calculated for each probe, 
including: Position on the array (to aid identification of each probe), error 
measurements for each signal, local background for each probe, uniformity of 
signal across a spot, and whether the signal was saturated. As there were 5 
randomly placed replicates of each probe and many probes per gene, the dataset 
was considerable in size and allowed increased confidence in the data from a 
single array, in comparison to the DNA array. The dataset from each hybridisation 
was imported into Excel software for further analysis.
An example of a scanned array image is shown in Figure 6.3. This test array 
consisted of 2 probes only. These 2 probes were positioned on the array in a 
repeating series so that any inconsistencies would be obvious following 
hybridisation. The target mix consisted of Cy3-labelled 25mer oligomer, Cy5- 
labelled pyrimidine-only control oligomer, Cy5-labelled 60mer 'long' oligomer target 
(all oligomer targets at 0.2nM), a Cy5-labelled bacterial gene cDNA target and a 
Cy3-labelled GFP cDNA target (both cDNA targets at 10ng). The Cy3-labelled 
25mer oligomer and the Cy5-labelled 60mer 'long' oligomer were complementary to 
the probes on the array, and the other target species were used to simulate non­
specific background hybridisation to probes. This test array showed that there was 
little inconsistency in the hybridisation of the control oligomers.
Figure 6.3 (following page). Scanned image of hybridisation to a test array.
The test array consisted of a repeated series of 2 probes. The target pool consisted of 
fluorescently labelled oligomers complementary to the probes and various background 
species. A. Close up image of a small section of the array. Individual spots are shown which 
bound the Cy3-labelled target (green), the Cy5-labelled target (red), or no target. B. Zoomed 
out image to show the entire array. The effect of the repeated series of probes on the array 
can be seen. Also probes used to orientate the array can also be seen, such as those 
marking the borders of the array.
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V6.4 Interpretation of Oligo Array Data
6.4.1 Comparison of Data from Oligo Arrays and DNA Arrays
A time course experiment was set up using RNA was isolated from NIH 3T3 cells, 
infected with MHV-68 at moi 10, for 5h, 8h, 12h and 18h pi. Mock-infected controls 
were also taken. The same specific primers used for the DNA array, were used to 
produce fluorescently-labelled cDNA target for the oligo array. The oligo array 
hybridisation was performed, and the results compared against similar data from 
the DNA array system.
Only those probes on the oligo array that matched the probes used on the DNA 
array were considered. Each probe on the oligo array was replicated 5 times and in 
addition, each ORF of M HV-68 was represented by up to 4 different probes. For the 
purposes of this comparison, the mean signal for all probes corresponding to a 
given ORF on the oligo array was compared to the mean signal for all probes 
corresponding to a given ORF on the DNA array.
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The mean signal for each ORF was plotted as a bar chart as shown in Figure 6.4. 
For comparison purposes, the equivalent data from experiments with DNA arrays 
are also shown. While still preliminary data, there is good general concordance 
between the data from the DNA array and oligo array platforms. In particular the 
relative abundances of one transcript relative to another at any time point are well 
replicated by the 2 array systems. Also when 2 DNA array hybridisations show 
similar profiles (e.g. at the 12h and 18h time points), so do the oligo array 
hybridisations. It should be noted that the DNA array data shown in Figure 6.4 
represents the mean of several experiments (n = 4-6), whereas the oligo array data 
summarises the 5 replicate probesets on a single array.
Figure 6.4 (on following pages). Results of hybridisations to oligo arrays.
RNA was isolated from NIH 3T3 cells at various periods pi with MHV-68 at moi 10 (C., E., 
G., I.) and also from mock-infected controls (A.). Labelled target was synthesised from the 
RNA samples and hybridised to the oligo arrays. The mean signal for each ORF was 
calculated and plotted as a bar chart, for each time point (the results show the mean signal 
from 5 replicate probesets on a single array). For comparative purposes, the equivalent data 
produced by the MHV-68 DNA arrays, as shown previously in Figure 5.3 - Figure 5.7, was 
also plotted (B., D., F., H., J.).
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6.4.2 Cluster Analysis of Oliqo Array Data
As well as the quantitative expression profiles, a relative cluster analysis was 
performed on the oligo array data. As explained previously, cluster analysis takes a 
gene’s transcription profile, relative to itself, and compares it to all others. 
Therefore, it will highlight genes with similar patterns of expression, although not 
necessarily at similar levels.
Hierarchical clustering of the oligo array data was compared to the same analysis of 
the DNA array data (Figure 6.5). The overall picture of MHV-68 gene expression, as 
presented by the oligo array data, appears to have a higher resolution than that 
produced by the DNA array. This is visualised in Figure 6.5 as an increased number 
of shades of red. It seems likely that this increased resolution is related to the use 
of 60bp and 300bp probes in the oligo and DNA array systems, respectively. 
Presumably a physically smaller probe is able to differentiate better between similar 
quantities of target cDNA than larger ones.
The cluster analysis data for the oligo and DNA arrays data showed that the 
expression profiles of MHV-68’s genes are closely related, as demonstrated by the 
short branches in the respective dendograms. Both analyses also show a group of 
genes that peak in transcript abundance at 5h pi, shown in Figure 6.6. The oligo 
and DNA arrays found 22 and 16 transcripts that peaked in abundance at 5h pi, 
respectively, of which 11 were identified by both. Interestingly, the transcripts 
identified by the oligo array clustered into 2 separate groups: one cluster showing 
much reduced transcript abundance from 8h pi, and the other cluster showing 
sustained transcript abundances up to 18h pi. Furthermore, the genes identified by 
the DNA array also consisted of these two profiles. Therefore, it seems likely that 
these 2 groups of genes represent 2 different programmes of expression.
An interesting difference between the two arrays is that the oligo arrays shows 
some transcripts are not detected at all (ORFs M1, 62, M13, M14), whereas the 
DNA array detected some signal for every probe. This difference could be 
explained if the oligo array system produces less background, or that it’s calculation 
of background is more efficient, than that for the DNA array. If so, this suggests that 
the oligo array is the more sensitive system of the 2. In fact on average, 
background levels were 19% of the mean signal on DNA arrays, and 15% of the 
mean signal on oligo arrays, or alternatively, the DNA arrays produced 20% higher 
background levels than the oligo array.
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Figure 6.5. Hierarchical cluster analysis of MHV-68 expression profiles produced by the 
oligo and DNA array systems.
Data in the form of log2 normalised means was converted into a percentage of each gene’s 
maximum. These percentages were imported into Cluster software and hierarchical 
clustering performed using the average-linkage algorithm and an uncentred correlation 
similarity matrix. The data is shown as a colour matrix with columns representing time points
228
(h pi) and rows representing each gene’s expression profile. The order of the columns is not 
chronological but is intended to allow maximum contrast between profiles. Black boxes 
represent no expression and brighter shades of red correspond to increasing expression. 
The dendogram shows related expression profiles on the same branch, with branch lengths 
representing the degree of similarity between individual profiles.
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Figure 6.6. MHV-68 transcripts peaking in abundance at 5h pi as identified by oligo and 
DNA arrays.
Details of the analysis as are found in the legend for Figure 6.5. Only those genes that peak 
in transcript abundance at 5h pi are shown here.
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6.4.3 Transcriptional Profile of MHV-68 tRNA Sequences
One of the advantages of the oligo array system was that its 60-mer probes could 
be used to detect very small transcripts. MHV-68 encodes 8 tRNA sequences which 
are known to be expressed during lytic and latent infection (Bowden, 1997). RNA  
was isolated from MHV-68 infected NIH 3T3 cells and random nonomers used to 
prime the target synthesis reaction. Following hybridisation and washing, the arrays 
were scanned and signals quantified. To analyse the array data for these 
sequences, the mean signal strengths for each tRNA probe were plotted as a bar 
chart (Figure 6.7).
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Figure 6.7. MHV-68 tRNA transcript abundances as detected by the oligo array.
NIH 3T3 cells were infected with MHV-68 (moi 10) and RNA isolated at various times pi, as 
well as from mock-infected controls. Fluorescently-labelled target was synthesised with 
random nonomer primers and hybridised to arrays. Signals were quantified and mean 
values for each probe calculated. The results for the tRNA sequences are shown plotted 
above. The key shows the time point pi that each bar represents.
Previous studies have shown that MHV-68 tRNAs are expressed abundantly during 
lytic infection but that tRNA3 is weakly expressed, and this is confirmed here 
(Bowden, 1997; Simas, 1998a; Simas, 1999). It is unclear what role these tRNAs
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play, but their varied expression levels suggest that their transcription is regulated. 
This becomes more apparent when the organisation of the tRNAs in the genome 
are considered (Figure 6.8).
► ► ► ► ►
tRNA1 tRNA2 tRNA3 tRNA4 tRNAS M1 tRNAS M2 tRMA7 tRNAS M3
Figure 6.8. Organisation of MHV-68 tRNAs in the genome.
This representation of the left-hand end of the MHV-68 genome show the organisation of 
the 8 tRNAs and first 3 ORFs, represented by arrows. The direction of the arrows indicate 
the genomic strand on which the transcript is encoded.
tRNA7 is the most abundant tRNA, which suggests a functional role. However, 
previous analyses of MHV-68 tRNAs have omitted tRNA7 as it’s sequence 
suggests that it would not be involved in translation (Bowden, 1997). Furthermore at 
least 4 of the tRNAs are not aminoacylated by host tRNA-synthases, also 
suggesting that the role of these tRNAs is not in translation (Bowden, 1997).
6.4.4 High Resolution Analysis of Transcript Abundance
The oligo array features 1 probe per 100bp of genomic sequence, as opposed to 1 
per ORF for the DNA array. This results in a higher resolution of transcript 
abundance data. One possible application for this type of data is transcript 
mapping. Although there are several methods that are used exclusively for mapping 
transcripts, the oligo array can also be used to fulfil this role.
MHV-68 ORFs M8 and 57 have been predicted to encode 2 separate genes (Virgin, 
1997) and 2 exons of the same gene (Milligan, 1998). Both analyses agree on the 
presence of a non-coding region of around 300bp between these 2 ORFs or exons. 
To analyse transcription of mRNA from this region of the MHV-68 genome, RNA 
was isolated from infected NIH 3T3 cells 12hpi, and used to synthesise labelled 
cDNA target to hybridise to the array. Random nonomers were used to prime the 
reverse transcription reaction.
For the purposes of this analysis, the probes corresponding to ORF M8, 57 and the 
inter-genic probes in between the 2 ORFs were considered. There were 5 probes 
complementary to ORF M8, 2 for the inter-genic region and 6 for ORF 57. The
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mean signal for each probe was calculated from the 5 replicates on the array, and 
plotted as a bar chart starting with the most 5’ probe (Figure 6.9). The probes 
corresponding to the inter-genic region between ORFs M8 and 57 have hybridised 
to complementary cDNA target, which suggests that this region is transcribed. This 
adds evidence to the prediction that the 2 ORFs are in fact exons of the same gene. 
Further studies are now required to examine this further and should also examine 
the abundance of pre-spliced and post-spliced RNAs.
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Figure 6.9. Signal strengths of individual probes on the oligo array.
RNA was isolated from NIH 3T3 cells 12h pi by MHV-68. Random nonomers were used to 
prime labelling of cDNA target, which was hybridised to arrays. The mean signals for probes 
in the region of ORFs M8 and 57 are shown above.
The high signals observed for probes M8-1 and M8-2 were unexpected, as the 
remaining M8 probes show less signal. However examining the sequence data for 
this region shows that there is unlikely to be a polyA signal between M8 and ORF  
56, which lies directly upstream of it (Milligan, 1998). Therefore, it is possible that 
RNA polymerase carries on past the end of ORF 56, and continues some distance 
into ORF M8. Of course further studies are required to confirm this hypothesis.
6.5 Discussion
While the data produced by the oligonucleotide array should be considered 
preliminary and further optimisation is required for this system, several conclusions 
arose from these experiments. Firstly, oligo arrays for MHV-68 were successfully 
designed and manufactured with the aid of the array group at Arrow Therapeutics. 
To perform the actual oligo array experiments, the methods developed for the DNA
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array system were combined with the established protocols from the array group. 
Analysing the results of the oligo array experiments showed that overall there was 
good concordance between the data from the membrane- and glass-based arrays. 
This provided further confirmation of the results from the membrane array 
hybridisations, and showed the oligo array system to be functional. There were 
some differences observed between the two datasets but this was to be expected 
as different RNA templates were used for the 2 sets of array experiments.
The oligonucleotide array hybridisations produced significantly more data than the 
previous experiments with the DNA array, which allowed analysis of the viral 
transcriptome at a much higher resolution than had been possible previously. There 
are a total of 1438 viral probes, resulting in a 20-fold increase in data for viral 
transcript abundance. Furthermore each spot was replicated 5 times, which 
increased the statistical significance of the data produced.
The high resolution of the oligo array allows it to be used for drafting transcript 
maps. The example shown above examines the abundance of RNA species 
complementary to the region of the MHV-68 genome around ORFs M8 and 57, as 
they have been predicted to be exons of the same gene. The oligo array analysis 
provides experimental evidence for the region between these 2 ORFs being 
transcribed, and therefore corroborates the exon prediction. The oligo array will 
most likely not be a practical tool for transcript mapping when used alone, but in 
collaboration with other tools, the oligo array could provide a powerful method of 
scanning the entire genome in a single experiment. Furthermore, a strength of this 
oligo array system is the flexibility of its probeset. As modifying the probeset is fast 
and simple, the probes can be changed to allow higher resolution data of specific 
areas of interest on the genome. It is even possible to “walk” along the genome, 
1 bp at a time by using overlapping probes. The limits to the resolution of such an 
analysis remain to be seen as it is not clear yet how sensitive the probes on the 
array are when differentiating between very small differences in hybridisation 
efficiency. Another important factor when considering the array for transcript 
mapping, is the intrinsic limitations of array technology. Although the oligo array 
greatly improves the accuracy of array data, it does not alter the fundamentals of 
the technology. For example, it is not possible to be certain that the signal for a 
single probe results from hybridisation of a single target cDNA. If more than 1 cDNA 
is complementary to the probe sequence, then they will both bind. This can make 
interpretation of array data more complicated in cases such as overlapping 
transcripts. However interpretation of such events is only aided by the increased 
resolution of the oligo array.
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As well as increased resolution, the oligo array appears to present increased 
sensitivity, as demonstrated by the detection of the tRNA sequences that are 
expressed by MHV-68 (Bowden, 1997), and by lower levels of background. This 
represents the ability to detect smaller transcripts, and lower transcript levels 
respectively. Both these features increase the capability of the oligo array. The 
increased sensitivity in particular could prove to be crucial for analysis of samples in 
which viral RNAs are rare such as tissue samples from infected animals. Attempts 
have been made to investigate in vivo infection of mice by MHV-68 using the DNA 
array system. Infected lung and spleen samples were homogenised and RNA 
extracted for analysis with the array (data not shown). However these experiments 
proved unsuccessful as the proportion of viral RNA in the samples was below the 
sensitivity of the DNA array. It would be very interesting to use the oligo array to 
analyse infected tissue samples.
The oligo array presents a technological advance over the DNA array. The 
preliminary data presented here confirms this and presents exciting prospects for 
future applications of the array. In particular, the increased resolution and sensitivity 
greatly increase the potential of the system for further study of MHV-68 gene 
expression. While limitations are inherent to any system, this implementation of 
array technology helps lessen these restrictions, while enhancing its capabilities. 
Indeed the main hindrance to further applications may be development of tools to 
analyse and interpret the data produced.
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7 Final Discussion
As originally noted in the draft publication of the human genome, “the more we 
learn about the human genome, the more there is to explore” (Lander, 2001), and 
this applies equally to the MHV-68 genome. To begin with, the MHV-68 genome 
has been sequenced twice (Virgin, 1997; Milligan, 1998) and there are a number of 
differences in the results of the subsequent analyses, with respect to potential 
ORFs. For example, the analysis performed by Virgin et al. (1997) found 2 MHV-68 
unique genes (ORFs M5 and M6) in the region located between bp 26,000 and 
29,000 of the genome. However, the analysis performed by Milligan et al. (1998) 
did not find either of these, but instead found a separate gene (ORF 17.5) in this 
same region. ORF 17.5 is homologous to a known herpesvirus scaffolding protein 
(HSV-1 Ul26.5). One simple method of resolving this type of inconsistency between 
the 2 sequence analyses would be to use a MHV-68 array, which would provide 
experimental data for transcription from this region of the genome. Therefore, while 
sequence analysis is essential for furthering our understanding of the virus, further 
experimental studies are also required to further elucidate features of the virus.
So far, only a small number of MHV-68 genes have been characterised 
experimentally, such as the secreted chemokine binding protein encoded by ORF 
M3 (Parry, 2000; Bridgeman, 2001) and MHV-68 gp150 encoded by ORF M7 
(Stewart, 1996). Some wider analyses of gene expression have also been 
attempted, focusing on a number of genes or a specific region of the genome 
(Mackett, 1997; Husain, 1999; Rochford, 2001). However, there is much less known 
of MHV-68’s biology than that of other herpesviruses such as HSV-1, EBV and 
even the relatively recently discovered HHV-8. As MHV-68 is used as an expedient 
model for other gammaherpesviruses (Simas, 1998b), and has shown itself to be of 
interest in its own right (Parry, 2000), it is important to characterise the virus further. 
Therefore, the aim of this thesis was to characterise MHV-68 gene expression 
through the lytic stage of its life cycle, using techniques that allow comprehensive 
analysis of gene expression across the entire genome, as opposed to narrow 
analyses focused on 1 or a few genes.
Array technology (Schena, 1995) is particularly appropriate to use here as so few of 
M HV-68’s genes have been characterised; a global array analysis can provide a 
complete picture of MHV-68 gene expression, in a quick and relatively simple 
manner. Studies with similar goals had been successfully performed for other 
herpesviruses prior to this study, and following this study, there have also been
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similar studies of MHV-68 (Stingley, 2000; Paulose-Murphy, 2001; Jenner, 2001; 
Ebrahimi, 2003; Martinez-Guzman, 2003).
Arrays have also been used to examine the host response to viral infection in terms 
of gene expression by analysing infected samples with host gene arrays (Zhu, 
1998; Chambers, 1999; Simmen, 2001; Tsavachidou, 2001; Carter, 2002; Jones, 
2003). So far, host gene arrays do not represent complete gene sets, while 
producing much more complex datasets due to the larger genomes of the host 
organisms. This has not prevented their successful application, for example, to 
identify prognostic markers for various cancers (Dhanasekaran, 2001; van 't Veer, 
2002). In terms of viral infections, they have also been successful for identifying 
genes that are affected by infections. However a greater depth of insight, such as 
the underlying pathways behind these changes in single gene expressions, has 
eluded investigators so far.
As the genesets for host organisms are large and incomplete, differential display 
provides an alternative technique that can overcome these obstacles, and highlight 
changes in host gene expression (Liang, 1992). In this study, the optimisation of a 
differential display system for the analysis of changes in gene expression (Chapter 
3) has shown that this technique is most suited for highlighting small changes in 
gene expression, as the redundancy of the dataset increases with the size of the 
dataset. As such, it has been successfully applied to studies of interferon- 
responsive RNAs following HCMV infection (Zhu, 1997), changes in host gene 
expression as latent HSV-1 is stimulated to reactivate (Tal-Singer, 1998) and the 
stress responses of Salmonella (Wong, 1994). Although not attempted here, 
differential display could be a very useful technique to aid the study of the changes 
in host gene expression that occur at the very start of infection. It would be 
interesting to see if it is possible to dissect between active responses of the host 
and the effects of host protein synthesis shut-off by the virus, which appears to be 
very effective during MHV-68 infection (as shown in Chapter 5).
Relatively little is known of the early events during a primary gammaherpesvirus 
infection. Therefore, CX inhibition of de novo viral protein synthesis was used to 
identify MHV-68 a  genes. One a  gene, ORF 73, was identified with the MHV-68 
DNA array (5.2). It remains to be seen whether MHV-68 encodes more a  genes, 
which were not detected by this array. RT-PCR of RNA samples from CX-inhibited 
infections showed that faint bands for ORFs K3, 50 and 57, therefore further study 
of MHV-68 a  gene expression is required. It would be interesting to use the more 
sensitive oligonucleotide array as see if more than 1 a  gene is detected.
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There have been 2 further array analyses of MHV-68 gene expression since the 
work presented in this thesis (Ebrahimi, 2003; Martinez-Guzman, 2003). Both 
studies attempted to elucidate MHV-68 a  gene expression in a similar fashion as 
detailed here in Chapter 5. However Ebrahimi et al. (2003) and Martinez-Guzman 
et al. (2003) infected murine epithelial C127 and BHK cells, respectively (murine 
epithelial NIH 3T3 cells were used here). They also used 100pg/ml and 200pg/ml 
CX, respectively, to inhibit viral protein synthesis (compared to 2^g/ml here). This 
suggests that there is a large variability in the potency of CX stocks and/or 
sensitivity of cell lines to the drug. However, neither of the 2 studies reported that 
they had measured the efficacy of de novo protein synthesis inhibition with their 
particular cell lines and CX stocks. Ebrahimi et al. (2003) reported the detection of 6 
a  genes (ORFs M4, K3, 38, 50, 57 and 73), of which ORFs K3, 38 and 57 were 
most highly expressed. Martinez-Guzman et al. (2003) detected around 50 genes 
with CX inhibition (among these the highest were ORFs 69, 73, 74 and 75a), but 
most of these showed reduced expression relative to levels without CX inhibition. 
ORFs 38 and 75a are predicted to encode tegument proteins, which suggests that 
further optimisation of these systems could be useful. However both studies 
detected ORF 73, in agreement with this study.
These results of studies performed by these 2 MHV-68 arrays highlight some of the 
difficulties of optimising an array system. While it can be relatively simple to 
optimise conditions for a single probe for a single gene, it is far more complicated to 
achieve optimisation across and entire array of probes. Ebrahimi et al. (2003) 
detected levels of ORF 38 transcripts that were equal to or higher than putative a  
genes, when infection was inhibited by CX. ORF 38 is homologue to a tegument 
protein of other gammaherpesviruses. In MHV-68 it is predicted to be part of a co­
terminal set of genes (ORFs 34-38) sharing a poly-adenylation signal and 
transcribed together (Rudge, H., personal communication, Milligan, 1998). The 
homologue of ORF 38 in HSV-1 encodes the UL11 protein, which accumulates on 
the cytoplasmic face of host internal membranes during infection, and is thought to 
play a role in nucleocapsid envelopment and egress (Loomis, 2001). This suggests 
that ORF 38 is not an a  gene, and therefore the signal for ORF 38 observed by 
Ebrahimi et al. (2003) is likely to be noise. As this was one of the highest signals on 
the array, it brings the validity of the other signals into question. This demonstrates 
the importance of optimising the whole array so that every probe produces reliable 
data.
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Martinez-Guzman et al. (2003) developed a MHV-68 array that showed higher 
levels of background hybridisation under similar experimental conditions. In fact 
there was a range of background signals across the array, differing for each probe. 
As background levels were different for each probe, it would not be valid to 
compare the signals for one probe against the signals for another probe. For 
example, 2 probes could show the same signal strength, but this could be due to 
90% and 10% background, respectively. This reduces the value of the data from 
the array as each signal is then only relative to itself. Again this system requires 
further optimisation to allow use of the array as a single component rather than 
several individual components.
The MHV-68 DNA array developed here detects only 1 transcript under similar 
experimental conditions (5.2). Therefore, it does not appear to possess the 
problems illustrated for the 2 other MHV-68 arrays. However, this array may lack 
the sensitivity required to detect all a  genes. The MHV-68 oligo array that has also 
been developed here has increased sensitivity over the DNA array. It would 
therefore be interesting to perform the same experiments with the oligo array.
During uninhibited infection, several genes were observed to be expressed at the 
same time as ORF 73. These genes were grouped together by cluster analysis and 
included genes involved in DNA replication, such as DNA polymerase and 
ribonucleotide reductase. Similar observations have been made for other 
herpesviruses and subsequently for MHV-68 as well (Paulose-Murphy, 2001; 
Jenner, 2001; Martinez-Guzman, 2003). This indicates that MHV-68 DNA 
replication proteins are among the first genes to be expressed during infection. Also 
the transcript levels of this cluster fall sharply after they peak, which suggests that 
expression of these genes is inhibited at later stages of infection. It is unclear how 
this relates to protein levels for those genes, as the two are not necessarily 
proportional, but it seems likely that protein levels will fall as well.
Clustering the gene expression profiles from an uninhibited infection shows 4 
groups, the first being the one just discussed. The second cluster peaks around the 
same time as the first, but then shows a more sustained expression, and consists 
predominantly of p genes. The third cluster peaks at a later time point, and later still 
is the peak for the fourth cluster. The genes in these clusters generally represent y- 
1 and y-2 genes, respectively. However these are general trends and the clusters of 
transcription profiles are not equivalent to kinetic classes, which is unsurprising as 
kinetic classes were derived originally from protein abundances (Honess, 1974). 
Cluster analysis of HHV-8 gene expression following induced reactivation from
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latently-infected cell lines shows a similar pattern (Paulose-Murphy, 2001; Jenner, 
2001). The lytic gene transcription profiles fall into 3 clusters (Jenner, 2001), and 
functionally related genes also group together as shown for MHV-68 (5.1.8).
Having performed the first comprehensive analysis of gammaherpesvirus 
transcription through a de novo productive infection here, it is now necessary to 
build on this foundation to further characterise individual genes and develop the 
knowledge of MHV-68 biology.
Both the MHV-68 DNA and oligo array systems have much potential for studying 
the virus further. For example, having characterised lytic infection, latent infection 
could also be characterised using an array. There is currently only one in vitro 
model for MHV-68 latency, which is the S11E cell line (Usherwood, 1996a). This 
cell line was isolated from MHV-68 infected mice with lymphoproliferative disease, 
and found to contain episomal and linear forms of the MHV-68 genome. A 
proportion of cells in any S11E cell population are known to be lytically infected, 
making it a less than ideal model.
Preliminary experiments to examine latency in S11E cells were performed using the 
MHV-68 DNA array developed here. However the results showed that there was a 
consistent level of lytic cycle-associated transcripts, which prevented the isolation 
and observation of any potential latent transcripts (data not shown). It was possible 
to block lytic gene expression by maintaining the cells in medium containing the 
antiviral 4 -’S-EtdU, but array analysis of these genes detected no transcripts (data 
not shown). Interestingly, northern blot analysis of the S11 cell line, using restriction 
fragments of the MHV-68 genome, detected only a few transcripts during latency, of 
which only M2 was abundantly expressed (Husain, 1999). A subsequent array 
analysis of the S11E cell line detected 1 predominantly expressed gene, ORF 73 
(Martinez-Guzman, 2003). It would be interesting to examine the S 11 and S11E cell 
lines further using the sensitive oligo array system.
Studying latent gene expression was also attempted using an in vivo model. 
Preliminary studies of tissue samples from infected mice were performed with the 
DNA array. However, the MHV-68 DNA array was not sensitive enough to detect 
viral transcripts in tissue samples (data not shown). Preliminary attempts were 
made to amplify the RNA template isolated from tissue samples using antisense 
RNA amplification (Phillips, 1996) with little success (data not shown). However 
further optimisation of this signal amplification technique is required before its 
potential can be fully assessed. There are also other methods to produce an 
increased template population. For example, tissue samples could be dissociated
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into a single cell suspension and then sorted by FACS to enrich for infected cells. 
This would have the effect of increasing the proportion of infected cells in a sample, 
therefore increasing the amount of viral target in the overall target population. This 
technique could be particularly useful for enriching infected B cells from spleen 
samples, as a protocol for this procedure already exists (Marques, 2003). The 
differential display system could also prove valuable for this type of study, as it 
would be well suited to highlighting the changes in the expression of a small 
number of genes. Furthermore, differential display could also be able to highlight 
changes in host gene expression that occur during MHV-68 latent infection.
An alternative to amplifying the target for the array would be to increase the 
sensitivity of the probes on the array. The MHV-68 oligo array appears to be more 
sensitive than the DNA array. Therefore, it would be interesting to use this array to 
analyse tissue samples. Perhaps combining methods for amplifying target with the 
increased sensitivity of the oligo array would produce the best results. As well as 
latent gene expression, in vivo lytic gene expression could also be profiled using 
the oligo array.
A strength of the array system is that it provides a rapid screen of global gene 
expression. This would be useful, for example, when characterising mutant strains 
of the virus. The array would show exactly which genes were affected by the 
mutation, and would therefore be very useful if mutant strains were being created 
with the purpose of knocking out single genes. A preliminary screen of an ORF M3 
deletion mutant (a kind gift from Dr S. Efstathiou, Cambridge University, UK) was 
performed with the DNA array, which suggested that the transcription of other MHV- 
68 genes were unaffected by the deletion of ORF M3 (data not shown). The array 
proved to be a very rapid and convenient method for screening the effects of the 
mutation on the expression of MHV-68’s other genes.
In summary, 2 systems for the analysis of gene expression during MHV-68 infection 
have been developed and optimised. The differential display system, was found to 
have an advantage in highlighting changes in both viral and host gene expression. 
The array system, however, has an advantage in performing a global analysis of 
gene expression (for the virus only in this study) in a relatively simple manner. The 
array has been used to characterise the changing MHV-68 transcriptome through a 
de novo lytic infection in vitro. This was the first such characterisation for a 
gammaherpesvirus. A second array system using oligonucleotide probes based on 
a glass slide was developed and tested in collaboration with the Array Group at 
Arrow Therapeutics. This system corroborated the results gained with the DNA,
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membrane-based array. The oligonucleotide array appeared to be more sensitive 
than the DNA array and also has the advantage off a flexible design and 
manufacture stage, which allows the probeset to be modiified simply between one 
array and the next. These features make the oligonucleotiide array a more capable 
system than the DNA array. However, the DNA array technology is far more 
accessible as its costs are far less than the oligonucleotide array.
As the 2 systems have been established, it would be relatively simple to initiate 
further studies of MHV-68 biology to further exploit the power of these techniques. 
In particular the latent life cycle and profiling MHV-68 gene expression in vivo would 
make ideal subjects for continued investigations.
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9 Appendices
9.1 Appendix I
9.1.1 DNA Array Primer Sequences
Primer 5' Sequence 3' Sequence
A1 - M1 gccaaagcatagctcactgg acaccttgatgacccttcc
A 2-M 2 caaggaaagattcccaatcc caggacttggtacaggactcg
A 3-M 3 gctcattaaatgctgcatcc tctcttgacccagctcttcc
A 4 -M 4 cacccag cctag atttttag tacgcagacataatagctgc
A5 - 0RF4 gggattgtgggtgtaaatgg gggatcacagtaaaacactgc
A6 - 0RF6 ctcccaggctcctcttgg ccacgtccatgaaaaattgg
A7 - 0RF7 gattatgcatggacctcagc caccatagaagcaggcaagg
A8 - 0RF8 atgagagtcgcccacctaac tgaagatgtagggcacgatg
A9 - 0RF9 cagccttgccaagaaagagc ctgaacggaatgtcctcgc
A10-ORF10 ttaatcactggtgcgtgacc cgggagattagtttttatagcc
A11 -0RF11 acgaaggtcatctacatttgc tgtgaggacaacctggagg
A 12-K 3 aggagagttctgttggatctgc tccccatcactatcatcagc
B1 -M 5 agcatacagcgtgggaatgg aggggatttccaggtagagg
B 2-M 6 ggaccctccattctataaacc ccagctcgggagggggc
B3-ORF17 cgtgggaggatatgtggac atgtgtgcaacatctgcagc
B4-ORF18 aggtgcatcagccatgttgg tgaggtccttcgttgtcagg
B5-ORF19 tttgtttacctgaacccaaacc actccacccgactggaagg
B6 - ORF20 gaatgaattaggagccaagc cttctctggtggtactgtgc
B7 - 0RF21 aacaaccctggattccaacc gcccatatgcccctatatcc
B8 - ORF22 gttggtgcatggggtagg gctggtaatggtgggatagc
B9 - ORF23 aaagactgtgccttaacagg gtcatggtcaggatttttgc
B10-ORF24 tgtgaatatgatgagaatagcc atatcactggaacataggtgc
B11 -ORF25 tttgcctatgtcaggactgg acttggtcttcttccatcacc
B12-ORF26 ctctaacatctagattgtatgc ctaaatcatcatgctcatccc
C1 - ORF27 tggtgaggttgtgctaaatgg ggcaggataatagggatgtttg
C2 - ORF29b tgttacagaaggatgccaag agacttccgtgtgattgc
C3 - ORF30 ggatgctctgtgaataaatcaaag tgtcttggccgcgcttgc
C4 - 0RF31 ccaagacaagtgtatgatgc acaatgtcaccaaacagtgc
C5 - ORF32 ttcctttacaacaagatgagc tctaaagaagccctcatccc
C6 - ORF33 gacatttctgaataaagagtgtatatgg gtactggaatggctgacttcc
C7 - ORF29a tataccgcagcacagtttcc agcacccaactagtgttttagc
C8 - ORF34 ttttccccgaagcagatcc tatgctgtgctcactgatgg
C9 - ORF35 aattgggagtagtttaagggc ttaacagtgtcttccaactcc
C10-O RF36 tggattaccgacagttaccg tctgatgccatggtagaaacc
C11 -ORF37 ggaagggtcgattattctgg atacacggcagacacctcac
C12-O RF38 tcggatgttgcaagaaaacc cgtgtttgcctcgttcatattc
D1 - ORF39 
D2 - ORF40 
D3 - ORF42 
D4 - ORF43 
D5 - ORF44 
D6 - ORF45 
D7 - ORF46 
D8 - ORF47 
D9 - ORF48 
D10-ORF49  
D11 -ORF50  
D 12-M 7
E1 - ORF52 
E2 - ORF53 
E3 - ORF54 
E4 - ORF55 
E5 - ORF56 
E 6-M 8  
E7 - ORF57 
E8 - ORF58 
E9 - ORF59 
E10-ORF60  
E11 -ORF61 
E12-ORF62
F1 - ORF63 
F2 - ORF64 
F 3 -M 9  
F4 - ORF66 
F5 - ORF67 
F6 - ORF68 
F7 - ORF69 
F10-M10C  
F11 -ORF72 
F12-M 11
G1 -ORF73 
G2 - ORF74 
G3 - ORF75C 
G4 - ORF75b 
G5 - ORF75a 
G 6-M 12  
G 7-M 13  
G 8-M 14  
G 9-M 1-M 2  
G10 -M2-M1 
G11 - M2-M3 
G 12-M 3-M 2
aaaagttggagccgtctagg
caatggcacgatgttcagg
cttcccaggctgatgttgg
tctgtcagagagtgccatgc
acctcagatgccaaaattcg
atggacccctttaagaaacc
tggacacttggctaaaaacg
tggtccttttgtgtattaatgc
accttgaaacccgtgaagg
ccttctctggaaagcgtgg
caaagtccataacaggcatcc
tgtggcgttaaatccctagc
tggtcaaggaagtagaaagg
atcacccaagaaaccacacc
atactcctttgtgcccaagc
tgtaccttacaagaggctcg
atggccagataccacagc
accagttgaggagccaacg
cttgcctgaaacacggtagg
attgtgggaggaatgtctgc
cttccagcttgacactgagc
ctgggttccttgaactgacc
acgtggagcctgttcagacc
tcttcagtagtcacatcagc
ccatcagtgagcgatagtgg
ttcgcatcgaaggtacagc
cccagagctccataacaagc
cagtggatgagtttagaagc
ctgatagacgagctctgtgg
tccttcctctcaaatacactgg
gcgctcaacaggctctgc
aagcgaggagcagcacagc
tccaaggatttcttgacagc
tgggcaaccctgattacagc
acacaacctcaggcaaacc
cttagaaaactcatcattgtcc
agacagaaaaagaactcatcg
ggatgaggacgtctgggc
ttggacattgagggtcttcc
ggggaaaatatgcgtgatacc
tagtagggggcctcctgc
gctaccgcccgggcctgagg
ctggggaccagatgtaaagc
taacagtgaaggtgctaacg
aaaccccctccagtaaaagg
ttaaaaaagatacgagtcaggtgg
cagacggtacactgttactgc
tctccttgccagaagtaccc
ccaccatggaaatcagtgc
aagtgttgctacccaagaagc
tgtgggacaatatgacttgagc
cttgtacttgactcgctgacc
tgaacactaaaggccaaacc
tgggccacattgatattccc
gagctggcacacaaagaagg
aattgacagtgcctatggcc
aaatgcctcaacttctctgg
tggggaagttggttctgagg
ctggcacccacagtagtttc
gcgtagatcaaaaagacaccac
attggcccggttgaatctcc
gcctcatctacacttattgc
aaaactgtttggcatcatcg
tttctg g ttcca tctg tttg g
agagggtccctgattacacg
ggaacccatgtggaaagc
aagacagggaggcagattcc
cttcagcttcatcatgtcacc
gctgccagataaccattttcc
aggctcttgttgtgttttagg
tgcagcacaaagaagactgg
gccaaacatttcagcagagg
aaatgctccagaagaggaagg
agggcacagtgagtattttgg
gccatattgaccctgttgc
atgcagcacgtagaagcagagg
acccagattgtccgtgtgg
tggtatgtcaacccctgacc
atgtaggccctgacctttcc
atgatcctccgtccaactgc
ccttcaacatcaacatctgg
acacaatagcatagatcctgg
gaatcagatcgtgaagatagg
ataaaatctagccgctgggc
gctttgcaggtgagagtatgc
ccagtggtctgttctgatgg
caaagtttaaagtgaaagtaagc
agcagggcccgagcccctctt
tccatgggtgcatatttgg
caggttctcggttcaagtcc
caaggccccagagaaagc
cggtcgagaagacatatccc
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H1 - M3-M4 
H2 - M4-M3 
H3 - K3-M5 
H4 - M5-K3 
H5 - ORF27-29b 
H6 - ORF29-27 
H7-M10C-ORF72 
H8-ORF72-M10C 
H9 - GAPDH 
H10 - Myosin 1 
H11 -MOD  
H12 - Beta-actin
aaatatgctccatggtttgg
tcatctgacttgctgcatacg
ttttggccaggagaatataagc
caggagacatggcctatcg
tctggattttcatttcatgtg
Use same primers as H5
tcatggcaacagtcaaaagg
ctgtgcgagatttgcgtatg
acccagaagactgtggatgg
gaaggtcatgggtgttctgg
gcgtcactcccttttacgc
ggactcctatgtgggtgacg
tccccaaaagatacatcaagc
cttgtgagcctcaagagtgg
cgagacaggttgtggaaagc
cccctgaagcataactctcg
cacgtgacaagagtgcttgg
aaacgtgctagccaatcagg
atgtatcgatccccgtcctc
acctggtcctcagtgtagcc
gttcagcttttccaggaagg
ggaatcatcagtggcaatcc
atcacaatgcctgtggtacg
J1 - Cab45
J2 - Ribosomal protein S29
J3 - Ubiquitin
J4 - Phospholipase A2
J5 - HPRT
J6 - TMV 
J7 - Luciferase
gatcagcgctaaggagatgc
agcagctctactggagtcacc
tcttcgtgaagaccctgacc
ccagtcacagcaagcatacc
gggggctataagttctttgc
atgcatgcggccgcatctag
ggaactcgtcctcagtcagc
aaagactagcatgatcggttcc
gttctcgatggtgtcactgg
cctgcttctgcttcatctcc
ttcgagaggtccttttcacc
ccaacaccggcataaagaattg
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9.2 Appendix II
9.2.1 Layout of Vacuum-Spotted Arrays
1 2 3 4 5 6 7 8 9 10 11 12
A M1 M2 M3 M4 ORF4 ORF6 ORF7 ORF8 ORF9 ORF10 Cab45 K3
B M5 M6 ORF17 ORF18 ORF19 ORF2 ORF21 ORF22 ORF23 ORF24 ORF25 ORF26
C ORF27 ORF29b ORF30 ORF31 ORF32 ORF33 ORF29a ORF34 ORF35 ORF36 ORF37 ORF38
D ORF39 ORF40 ORF42 ORF43 ORF44 ORF45 ORF46 ORF47 ORF48 ORF49 ORF50 M7
E ORF52 ORF53 ORF54 ORF55 ORF56 M8 ORF57 ORF58 ORF59 ORF60 ORF61 ORF62
F ORF63 ORF64 M9 ORF66 ORF67 ORF68 ORF69 Ribo S29 Luc M10c ORF72 M11
G ORF73 ORF74 ORF75C ORF75b Ph A2 M12 M13 TMV M1-M2 M2-M1 M2-M3 M3-M2
H M3-M4 M4-M3 K3-M5 M5-K3 ORF27-29b HPRT M10c-ORF72
ORF72- 
M10c (1/2) GAPDH Myosin 1 MOD p-actin
9.2.2 Layout of Biomek Arrays
1 2 3 4 5 6 7 8 9 10 11 12
A M1 M2 M3 M4 ORF4 ORF6 ORF7 ORF8 ORF9 ORF10 Cab45t K3
B M5 M6 M6 ORF18 ORF19 ORF20 ORF21 ORF22 ORF23 ORF24 ORF25 M6
C ORF27 ORF29b ORF30 ORF31 ORF32 ORF33 ORF29a ORF34 ORF35 ORF36 ORF37 ORF38
D ORF39 ORF40 ORF42 ORF43 ORF44 ORF45 ORF46 ORF47 ORF48 ORF49 ORF50 M7
E ORF52 ORF53 ORF54 ORF55 ORF56 M8 ORF57 ORF58 ORF59 ORF60 ORF61 ORF62
F ORF57 ORF57 M9 ORF66 ORF67 ORF68 ORF69 Ribo S29 Luc M10c ORF72 M11
G ORF73 ORF74 ORF75C ORF75b Ph A2 M12 M13 TMV M1-M2 M2-M1 M2-M3 M3-M2
H M3-M4 M4-M3 K3-M5 M5-K3 ORF27-29b HPRT M10c-ORF72
ORF72- 
M10c (1/2) GAPDH Myosin 1 MOD p-actin
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9.2.3 Layout of Pin-Tool Arrays
1 2 3 4 5 6 7 8 9 10 11 12
A M1 M2 M3 M4 ORF4 ORF6 ORF7 ORF8 ORF9 ORF10 ORF11 K3
B M5 M6 ORF17 ORF18 ORF19 ORF2 ORF21 ORF22 ORF23 ORF24 ORF25 ORF26
C ORF27 ORF29b ORF30 ORF31 ORF32 ORF33 ORF29a ORF34 ORF35 ORF36 ORF37 ORF38
D ORF39 ORF40 ORF42 ORF43 ORF44 ORF45 ORF46 ORF47 ORF48 ORF49 ORF50 M7
E ORF52 ORF53 ORF54 ORF55 ORF56 M8 ORF57 ORF58 ORF59 ORF60 ORF61 ORF62
F ORF63 ORF64 M9 ORF66 ORF67 ORF68 ORF69 H20 Bluescript M10c ORF72 M11
G ORF73 ORF74 ORF75C ORF75b H20 M12 M13 TMV M1-M2 M2-M1 M2-M3 M3-M2
H M3-M4 M4-M3 K3-M5 M5-K3 ORF27-29b pGEM M10c-ORF72
ORF72-
M10c GAPDH Myosin 1 MOD p-actin
I Cab45 Ribo S29 Ubiquitin Ph A2 HPRT TMV Luc
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9.3 Appendix III -  The State of Knowledge of MHV-68 Genes, Predicted and Confirmed, at the Start of 
Array Development
Gene GenomeLocation
Coding
Strand
Function
(putative unless confirmed) Reference / Comments
M1 2023-3282 R Serpin Disruption enhances reactivation from latency - Clambey et al, 2000, J. Virol. 74:1973-84
M2
M3
M4
ORF4
ORF6
4031 -
4627
6060-
7277
8409-
9785
9873-
11036
11215 -
14523
L
L
R
R
R
Broad spectrum secreted 
chemokine binding protein
Complement regulatory 
protein 
Single-stranded DNA 
binding protein
Parry etal, 2000, J.Exp. Med., 191:573-8
ORF7 14526-16481 R Transport protein
ORF8 16505-19051 R Glycoprotein B
ORF9 19217 - 22297 R DNA polymerase
ORF10
ORF11
K3
22269 - 
23522 
23488 - 
24651 
24733 - 
25335
R
R
L BHV4 IE1 homolog
M5 26178-26672 R
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M6 26554 - 28308 R
0RF17 28326 - 29957 L Capsid protein
0RF18 29917-30768 R
0RF19 30726 - 32273 L
Tegument protein
ORF20 32119 - 32880 L
0RF21 32879 - 34810 R Thymidine kinase
ORF22 34833 - 37022 R Glycoprotein H
ORF23 37025 - 38167 L
ORF24 38103-40253 L
ORF25 40263 - 44381 R Major capsid protein
ORF26 44423 - 45319 R Capsid protein
ORF27 45329 - 46090 R
ORF29b 46395 - 47438 L Packaging protein
ORF30 47507 - 47746 R
0RF31 47710-48309 R
ORF32 48294 - 49625 R
ORF33 49588 - 50568 R
ORF29a 50549 - L Packaging protein
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ORF34
ORF35
ORF36
ORF37
ORF38
ORF39
ORF40
ORF42
ORF43
ORF44
ORF45
ORF46
ORF47
ORF48
ORF49
ORF50
M7
51466
51465- D
52460 I A
52423 - D
52878 I A
52847- P
54157 r \
54129- P
55586 I A
55544 - P
55768 I A
55802 - 1
56950 L.
57046 - P
58875 I A
58876 - 1
59634 L
59634 - I
61334 L
61303- P
63630 I A
63655 - 1
64272 L.
64275 - I
65021 L.
65027 - 1
65545 L
65584 - 1
66582 L.
66741 - 1
67643 L
67907 - P
69373 I A
69466 - R
Kinase
Alkaline exonuclease
Myristylated tegument 
protein
Glycoprotein M 
Helicase-primase
Capsid protein 
Helicase-primase
Uracil DNA glycosylase 
Glycoprotein L
Transcriptional activator 
Glycoprotein 150
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70914
ORF52 70960 - 71369 L
ORF53 71447-71701 L
Reactivation of complete 
lytic cycle from latency
ORF54 71806-72702 R dUTPase
ORF55 72744 - 73313 L
ORF56 73289 - 75793 R DNA replication protein
M8 76015-76485 R
ORF57 76662 - 77159 R Immediate-early protein
ORF58 77214 - 78254 L
ORF59 78258 - 79439 L DNA replication protein
ORF60 79565 - 80479 L
Ribonucleotide reductase, 
small
ORF61 80517-82865 L
Ribonucleotide reductase, 
large
ORF62 82871 - 84010 L
Assembly/DNA maturation
ORF63 83751 - 86564 R Tegument protein
ORF64 86567 - 93937 R Tegument protein
M9 93962 - 94519 L
ORF66 94515-95741 L
ORF67 95738 - L Tegument protein
Wu et al, 2000, J. Virol. 74:3659-67
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ORF68
ORF69
M10a
M10b
M10c
ORF72
M11
ORF73
ORF74
ORF75C
ORF75b
ORF75a
M12
M13
M14
M1 - M2
96415
96673 - 
98052 R
Glycoprotein
98061 - R
98936 FA
98903 - R
101224 l \
99087 - R
101204 r \
99187- R101367
102426 - 
103181 L Cyclin D homolog
103418-
103930 R
BCL-2 homolog (gene 
16?)
103927-
104868 L
Immediate-early protein
105057-
106067 R
GCR (IL-8 receptor 
homolog?)
106070-
109999 L
Tegument
protein/FGARAT
110077-
113901 L
Tegument
protein/FGARAT
114032-
117904 L
Tegument
protein/FGARAT
117992- R118681
118149- R
118784 l \
118808 - I
119125 L.
3283-
Inhibits Fas- and TNF-induced apoptosis - Wang et al, 1999, J Gen Virol, 80:2737-40. Unlike 
the Bcl-homologs of other gammaHV's, MHV-68's can be digested by caspases. But the 
products of digestion are not proapoptiotic - Bellows et al J. Virol. 74:5024-31
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M2-M3
M3-M4
K 3-M 5
ORF27 - 
29b 
M10c - 
ORF72
4030
4628-
6059
7278-
8408
25336 -
26177
46091 -
46394
101368-
102425
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